

# Enantioselective Remote *Meta*-C–H Arylation and Alkylation *via* a Chiral Transient Mediator

Hang Shi, Alastair N. Herron, Ying Shao, Qian Shao, and Jin-Quan Yu\*

*Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road. La Jolla, CA 92037, USA.*

## TABLE OF CONTENTS

GENERAL INFORMATION .....	2
EXPERIMENTAL SECTION.....	3
I. Desymmetrization of Diarylmethyl Amines .....	3
A. Preparation of Substrates.....	3
B. Optimization of the Reaction Conditions .....	7
C. Pd/(+)-NBE-CO <sub>2</sub> Me Catalyzed Desymmetrization of Diarylmethyl Amines.....	9
D. Directing Group Cleavage of Desymmetrization Product <b>2ae</b> .....	31
E. Mechanistic Studies .....	32
II. Enantioselective Remote C–H Activation of Homobenzylamines.....	39
A. Preparation of Substrates.....	39
B. Optimization of the Reaction Conditions .....	43
C. Pd/(+)-NBE-CO <sub>2</sub> Me Catalyzed Desymmetrization of Homobenzylamines .....	44
D. Pd/(+)-NBE-CO <sub>2</sub> Me Catalyzed Kinetic Resolution of Homobenzylamines.....	52
X-RAY CRYSTALLOGRAPHIC DATA .....	58
NMR SPECTRA .....	64
SFC TRACES.....	184
REFERENCES .....	269

## GENERAL INFORMATION

### Solvents

Dry chloroform, dichloromethane (DCM), tetrahydrofuran (THF), 1,4-dioxane, and *tert*-butylmethylether (TBME) were purchased from Sigma-Aldrich. Chloroform-*d*<sub>1</sub>, acetonitrile-*d*<sub>3</sub>, and acetone-*d*<sub>6</sub> were purchased from Cambridge Isotope Laboratories.

### Chromatography

Analytical thin layer chromatography was performed on 0.25 mm silica gel 60-F254. Visualization was carried out with UV light and Vogel's permanganate.

### Spectroscopy and Instruments

<sup>1</sup>H NMR was recorded on Bruker DRX-600 instrument (600 MHz). Chemical shifts were quoted in parts per million (ppm) referenced to 7.26 ppm of chloroform-*d*, the center peak of the pentet at 1.94 ppm of acetonitrile-*d*<sub>3</sub>, or the center peak of a pentet at 2.05 ppm of acetone-*d*<sub>6</sub>. <sup>13</sup>C NMR spectra were recorded on Bruker DRX-600 instrument (150 MHz), and were fully decoupled by broad band proton decoupling. Chemical shifts were reported in ppm referenced to the center peak of a triplet at 77.16 ppm of chloroform-*d*, the center peak of a septet at 1.32 ppm of acetonitrile-*d*<sub>3</sub>, or the center peak of a septet at 29.84 ppm of acetone-*d*<sub>6</sub>. <sup>19</sup>F NMR spectra were recorded on Bruker AMX-400 instrument (376 MHz), and were fully decoupled by broad band proton decoupling. The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sext = sextet, sep = septet, m = multiplet, br = broad. Coupling constants, *J*, were reported in Hertz unit (Hz). High-resolution mass spectra (HRMS) were recorded on an Agilent Mass spectrometer using ESI-TOF (electrospray ionization-time of flight). Enantiomeric ratios (er) were determined on the Agilent Technologies supercritical fluid chromatography (SFC) system using commercially available chiral columns. The single crystal X-ray diffraction studies were carried out on a Bruker Kappa APEX-II CCD diffractometer equipped with Mo K $\alpha$  radiation ( $\lambda = 0.71073$ ).


### Starting materials

All substrates were used as received from commercial suppliers, unless otherwise stated. Pd(OAc)<sub>2</sub> and AgOAc were purchased from Sigma-Aldrich. Methyl (1*S*,4*R*)-bicyclo[2.2.1]hept-2-ene-2-carboxylate ((+)-NBE-CO<sub>2</sub>Me,  $[\alpha]_D^{25.5} = +237$ . (*c* = 1.0, CHCl<sub>3</sub>)) was synthesized from (1*S*,2*R*,3*S*,4*R*)-3-(methoxycarbonyl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid<sup>34</sup> (98% ee after crystallization<sup>35</sup>) following literature procedures<sup>36</sup>.

## EXPERIMENTAL SECTION

## I. Desymmetrization of Diarylmethyl Amines


## A. Preparation of Substrates



Diarylmethyl amines (**s1**) were synthesized following the literature procedures<sup>37</sup>. 2-Bromopyridines (**S2**) are commercial available.


**General procedure for synthesis of substrates:** Amine **s1** (1 equiv.), Pd<sub>2</sub>(dba)<sub>3</sub> (2 mol%), DavePhos (4 mol%) and NaO<sup>t</sup>Bu (1.4 equiv.) were added to a flame-dried Schlenk tube. The Schlenk tube was evacuated and back-filled with nitrogen. 2-Bromopyridines **s2** (1 equiv.) and 1,4-dioxane (0.33 M) were added to the mixture. The Schlenk tube was immersed into a pre-heated oil bath at 90 °C. After 2 h, the oil bath was removed, and the Schlenk tube was allowed to cool to room temperature. Water was added to the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>. After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography to afford compound **s3**.

To a solution of compound **s3** (1 equiv.) in THF (0.2 M) was added MeMgBr (1.3 equiv.) at 0 °C, and the resulting mixture was allowed to warm up to room temperature and stirred for 30 min. Then Boc<sub>2</sub>O (3 equiv.) was added into the mixture. The resulting mixture was allowed to warm up to room temperature and stirred for 12 hours. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>. After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography to afford compound **1**.

**tert-Butyl (di-*m*-tolylmethyl)(3,5-dimethylpyridin-2-yl)carbamate (1a)**

Chromatography eluent: hexane/EtOAc = 15:1 v/v.


<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>) δ 8.13–8.02 (m, 1H), 7.58 (s, 1H), 7.44 (s, 1H), 7.25 (s, 1H), 7.21–7.15 (m, 1H), 7.08 (s, 1H), 7.02–6.76 (m, 4H), 6.40 (s, 1H), 2.32 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 1.94 (s, 3H), 1.25 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>) δ 154.74, 151.62, 146.71, 143.66, 140.22, 138.41, 137.97, 133.28, 132.72, 131.86, 129.66, 128.85, 128.63, 128.26, 126.11, 80.91, 67.70, 28.33, 21.58, 21.24, 17.71, 17.67. HRMS (ESI-TOF) *m/z* calc'd for C<sub>27</sub>H<sub>33</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 417.2537; found: 417.2550.

**tert-Butyl (di-*m*-tolylmethyl)(3-methylpyridin-2-yl)carbamate (1a')**

Chromatography eluent: hexane/EtOAc = 15:1 v/v.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>) δ 8.24 (dd, *J* = 4.8, 1.8 Hz, 1H), 7.59 (s, 1H), 7.46 (s, 1H), 7.36 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.25 (s, 1H), 7.14–6.73 (m, 6H), 6.43 (s, 1H), 2.32 (s, 3H), 2.12 (s, 3H), 2.00 (s, 3H), 1.26 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>) δ 154.47, 153.85, 146.45, 143.41, 139.97, 139.62, 138.26, 137.93,


133.45, 131.70, 129.55, 128.69, 128.52, 128.17, 126.00, 123.41, 80.91, 67.55, 28.18, 21.40, 21.15, 17.68. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{26}H_{31}N_2O_2$   $[M+H]^+$ : 403.2380; found: 403.2390.



**tert-Butyl (bis(3-methoxyphenyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1c)**

Chromatography eluent: hexane/EtOAc = 8:1 v/v.


$^1H$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.09 (d,  $J$  = 2.3 Hz, 1H), 7.54 (s, 1H), 7.30–7.09 (m, 3H), 6.99 (s, 1H), 6.82 (s, 1H), 6.76–6.52 (m, 3H), 6.43 (s, 1H), 3.79 (s, 3H), 3.57 (s, 3H), 2.18 (s, 3H), 1.97 (s, 3H), 1.26 (s, 9H);  $^{13}C$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  160.63, 159.88, 154.73, 151.48, 146.81, 145.35, 141.61, 140.34, 133.42, 132.87, 129.95, 129.47, 123.56, 121.32, 116.64, 114.91, 113.83, 112.82, 81.01, 67.48, 55.81, 55.74, 28.36, 17.74. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{27}H_{35}N_2O_4$   $[M+H]^+$ : 449.2435; found: 449.2445.



**tert-Butyl (bis(3-fluorophenyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1d)**

Chromatography eluent: hexane/EtOAc = 15:1 v/v.


$^1H$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.08 (d,  $J$  = 2.3 Hz, 1H), 7.70 (d,  $J$  = 6.4 Hz, 1H), 7.51–7.29 (m, 2H), 7.23 (d,  $J$  = 2.3 Hz, 1H), 7.12 (s, 1H), 7.04 (s, 1H), 6.96 (s, 1H), 6.91–6.73 (m, 2H), 6.51 (s, 1H), 2.19 (s, 3H), 1.99 (s, 3H), 1.27 (s, 9H);  $^{13}C$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  163.75 (d,  $J$  = 243.5 Hz), 162.95 (d,  $J$  = 245.9 Hz), 154.52, 151.08, 146.87, 145.96, 142.43, 140.54, 133.63, 132.69, 130.86, 130.36, 127.04, 125.10, 117.74 (d,  $J$  = 22.2 Hz), 115.98 (d,  $J$  = 23.7 Hz), 115.02 (d,  $J$  = 21.5 Hz), 114.57 (d,  $J$  = 22.2 Hz), 81.47, 66.55, 28.29, 17.72, 17.64;  $^{19}F$  NMR (376 MHz, Acetonitrile- $d_3$ )  $\delta$  -115.10, -115.68. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{25}H_{27}F_2N_2O_2$   $[M+H]^+$ : 425.2035; found: 425.2043.



**tert-Butyl (bis(3-chlorophenyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1e)**

Chromatography eluent: hexane/EtOAc = 20:1 v/v.

$^1H$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.08 (d,  $J$  = 2.3 Hz, 1H), 7.87 (s, 1H), 7.58 (s, 1H), 7.42–7.26 (m, 2H), 7.24 (d,  $J$  = 2.3 Hz, 1H), 7.21–6.95 (m, 4H), 6.47 (s, 1H), 2.19 (s, 3H), 1.98 (s, 3H), 1.27 (s, 9H);  $^{13}C$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  154.46, 151.06, 146.90, 145.22, 141.94, 140.57, 134.54, 133.89, 133.71, 132.64, 130.94, 130.80, 130.26, 129.53, 129.09, 128.27, 127.99, 127.70, 81.57, 66.51, 28.28, 17.72, 17.60. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{25}H_{27}Cl_2N_2O_2$   $[M+H]^+$ : 457.1444; found: 457.1452.




**tert-Butyl (bis(3-(trifluoromethyl)phenyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1f)**

Chromatography eluent: hexane/EtOAc = 15:1 v/v.

$^1H$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.17 (s, 1H), 8.06 (d,  $J$  = 2.4 Hz, 1H), 7.95 (s, 1H), 7.72–7.51 (m, 2H), 7.50–7.25 (m, 4H), 7.21 (d,  $J$  = 2.3 Hz, 1H), 6.67 (s, 1H), 2.17 (s, 3H), 1.96 (s, 3H), 1.26 (s, 9H);  $^{13}C$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  154.44, 150.91, 146.98, 143.91, 140.79, 140.60, 134.86, 133.85, 133.09, 132.62,




131.12, 130.90, 130.68, 130.33, 130.06, 129.59, 127.74, 126.42, 125.95, 125.10, 124.85, 124.62, 81.71, 66.56, 28.23, 17.66, 17.48;  $^{19}\text{F}$  NMR (376 MHz, Acetonitrile- $d_3$ )  $\delta$  -63.37, -63.65. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{27}\text{H}_{27}\text{F}_6\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 525.1971; found: 525.1972.



**tert-Butyl (bis(3-chlorophenyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1e)**

Chromatography eluent: hexane/EtOAc = 20:1 v/v.


$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.65 (s, 1H), 8.18 (dd,  $J$  = 4.9, 1.8 Hz, 1H), 7.77–6.20 (m, 10H), 2.11 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  161.10 (d,  $J$  = 245.2 Hz), 154.33, 152.63, 146.44, 140.00, 134.13, 133.46, 131.68, 130.41, 124.70, 123.63, 115.66 (d,  $J$  = 21.9 Hz), 81.67, 53.64, 28.25, 17.24;  $^{19}\text{F}$  NMR (376 MHz, Acetonitrile- $d_3$ )  $\delta$  -118.43, -119.60. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{24}\text{H}_{25}\text{F}_2\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 411.1879; found: 411.1890.



**tert-Butyl (bis(4-fluoro-3-methylphenyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1i)**

Chromatography eluent: hexane/EtOAc = 20:1 v/v.


$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.03 (d,  $J$  = 2.3 Hz, 1H), 7.59 (s, 1H), 7.46 (s, 1H), 7.16 (d,  $J$  = 2.3 Hz, 1H), 7.09–6.77 (m, 3H), 6.69 (s, 1H), 6.35 (s, 1H), 2.21 (s, 3H), 2.14 (s, 3H), 2.00 (s, 3H), 1.90 (s, 3H), 1.22 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  161.09 (d,  $J$  = 242.6 Hz), 154.60, 151.32, 146.77, 140.37, 139.23, 135.88, 134.38, 133.49, 132.72, 132.21, 130.25, 128.13, 125.00 (d,  $J$  = 15.5 Hz), 124.61 (d,  $J$  = 12.6 Hz), 115.20 (d,  $J$  = 22.8 Hz), 114.73 (d,  $J$  = 22.9 Hz), 81.13, 66.32, 28.34, 17.72, 17.62, 14.74, 14.33;  $^{19}\text{F}$  NMR (376 MHz, Acetonitrile- $d_3$ )  $\delta$  -121.40, -122.73. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{27}\text{H}_{31}\text{F}_2\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 453.2348; found: 453.2361.



**tert-Butyl (bis(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1j)**

Chromatography eluent: hexane/EtOAc = 4:1 v/v.


$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.10 (d,  $J$  = 2.3 Hz, 1H), 7.38 (s, 1H), 7.25 (d,  $J$  = 2.3 Hz, 1H), 7.07 (s, 1H), 6.82 (s, 1H), 6.55 (s, 3H), 6.27 (s, 1H), 4.26 (s, 4H), 4.13 (s, 4H), 2.23 (s, 3H), 1.98 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  154.65, 151.53, 146.71, 144.16, 143.57, 143.35, 140.33, 137.09, 133.32, 132.76, 123.97, 121.83, 119.94, 117.82, 117.42, 116.88, 80.85, 66.49, 65.28, 65.16, 28.38, 17.76, 17.74. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 457.1444; found: 457.1452.



**tert-Butyl (di(thiophen-2-yl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (1k)**


Chromatography eluent: hexane/EtOAc = 15:1 v/v.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.11 (d,  $J$  = 2.3 Hz, 1H), 7.36 (s, 1H), 7.33 (d,  $J$  = 2.3 Hz, 1H), 7.29–7.10 (m, 2H), 6.96 (s, 1H), 6.92–6.74 (m, 3H), 2.25 (s, 3H), 1.95 (s, 3H), 1.32 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  154.00, 151.57, 147.06, 145.75, 144.49, 140.60, 133.66, 132.40, 128.27, 127.02, 126.81, 126.74, 81.77, 58.94, 28.34, 17.80, 17.63. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{21}\text{H}_{25}\text{N}_2\text{O}_2\text{S}_2$   $[\text{M}+\text{H}]^+$ : 401.1352; found: 401.1360.



***tert*-Butyl (di([1,1'-biphenyl]-3-yl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (**1b**)**

Aryl chloride **1e** (0.23 g, 0.5 mmol, 1 equiv.),  $\text{Pd}(\text{OAc})_2$  (5.6 mg, 0.025 mmol, 5 mol%), SPhos (21 mg, 0.05 mmol, 10 mol%),  $\text{PhB}(\text{OH})_2$  (0.244 g, 2.0 mmol, 4.0 equiv.), and  $\text{K}_3\text{PO}_4$  (0.53 g, 2.5 mmol, 5.0 equiv.) were added to a flame-dried Schlenk tube. The Schlenk tube was evacuated and back-filled with nitrogen, and then toluene (4 mL) were added to the mixture. The Schlenk tube was immersed into a pre-heated oil bath at 100 °C. After 12 h, the oil bath was removed, and the Schlenk tube was allowed to cool to room temperature. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with  $\text{Na}_2\text{SO}_4$ . After the organic solvent was concentrated by rotatory evaporation, the residue was purified by silica gel chromatography (hexane/EtOAc = 12:1 v/v) to afford 0.19 g compound **1b** as a white solid (70% yield).  $^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ )  $\delta$  8.29–8.09 (m, 2H), 7.72–7.06 (m, 18H), 6.67 (s, 1H), 2.16 (s, 3H), 1.98 (s, 3H), 1.28 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ )  $\delta$  154.83, 151.45, 146.97, 144.28, 141.98, 141.50, 141.15, 140.68, 140.42, 133.62, 132.99, 130.45, 130.07, 129.88, 129.58, 129.16, 128.11, 127.82, 127.71, 126.81, 126.19, 81.16, 67.52, 28.38, 17.71. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{37}\text{H}_{37}\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 541.2850; found: 541.2854.



***tert*-Butyl (bis(3-((triisopropylsilyl)ethynyl)phenyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (**1g**)**


Aryl chloride **1e** (0.183 g, 0.4 mmol, 1 equiv.),  $\text{Pd}(\text{MeCN})_2\text{Cl}_2$  (10 mg, 0.04 mmol, 10 mol%), XPhos (38 mg, 0.08 mmol, 20 mol%), and  $\text{Cs}_2\text{CO}_3$  (0.65 g, 2.0 mmol, 5.0 equiv.) were added to a flame-dried Schlenk tube. The Schlenk tube was evacuated and back-filled with nitrogen. Ethynyltriisopropylsilane (0.36 mL, 1.6 mmol, 4.0 equiv.) and MeCN (3 mL) were added to the mixture. The Schlenk tube was immersed into a pre-heated oil bath at 90 °C. After 12 h, the oil bath was removed, and the Schlenk tube was allowed to cool to room temperature. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with  $\text{Na}_2\text{SO}_4$ . After the organic solvent was concentrated by rotatory evaporation, the residue was purified by silica gel chromatography (hexane/EtOAc = 20:1 v/v) to afford 0.18 g compound **1g** as a yellow liquid (60% yield).

$^1\text{H}$  NMR (600 MHz, Acetone- $d_6$ )  $\delta$  8.11 (d,  $J$  = 2.2 Hz, 1H), 7.98 (s, 1H), 7.73 (s, 1H), 7.49–7.06 (m, 7H), 6.56 (s, 1H), 2.21 (s, 3H), 2.02 (s, 3H), 1.28 (s, 9H), 1.13 (s, 42H);  $^{13}\text{C}$  NMR (150 MHz, Acetone- $d_6$ )  $\delta$  154.12, 151.67, 146.79, 143.03, 140.79, 140.34, 134.36, 132.98, 132.13, 131.26, 131.08, 129.79, 128.99, 128.69,

123.81, 123.39, 108.63, 108.12, 90.45, 80.93, 66.85, 28.29, 19.01, 17.69, 17.63, 12.02. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{47}H_{69}N_2O_2Si_2$   $[M+H]^+$ : 749.4892; found: 749.4891.


## B. Optimization of the Reaction Conditions

Table S1. Chiral transient mediator screening\*




\*The yields were determined by <sup>1</sup>H-NMR using  $CH_2Br_2$  as the standard.

Table S2. Ligand screening\*




\*The yields were determined by <sup>1</sup>H-NMR using  $CH_2Br_2$  as the standard.

Table S3. Directing group screening\*



\*The yields were determined by <sup>1</sup>H-NMR using CH<sub>2</sub>Br<sub>2</sub> as the standard. †80 °C.

Table S4. Salt screening\*



\*The yields were determined by <sup>1</sup>H-NMR using CH<sub>2</sub>Br<sub>2</sub> as the standard.

Table S5. Additive screening\*




\*The yields were determined by <sup>1</sup>H-NMR using CH<sub>2</sub>Br<sub>2</sub> as the standard.

Table S6. Additive screening\*




\*Isolated yield

C. Pd/(+)-NBE-CO<sub>2</sub>Me Catalyzed Desymmetrization of Diarylmethyl Amines

**General procedure:** Arene **1** (0.10 mmol, 1.0 equiv), Pd(OAc)<sub>2</sub> (2.2 mg, 10 μmol, 10 mol%), Ligand (3.5 mg, 15 μmol, 15 mol%), hydrogenphosphate (15 μmol, 15 mol%), aryl iodide (0.3 mmol, 3.0 equiv.), and AgOAc (50 mg, 0.30 mmol, 3.0 equiv.) were added into a 2-dram reaction vial. CHCl<sub>3</sub> (0.5 mL) and (+)-NBE-CO<sub>2</sub>Me (20 mol% or 50 mol%) were added to the mixture. The vial was flushed with N<sub>2</sub>, and then capped. The reaction mixture was then stirred at given temperature for 12 or 18 hours. After cooling to room temperature, the mixture was filtered through Celite and eluted with EtOAc (3 × 2 mL). The filtrate was evaporated under reduced pressure. Purification by preparative TLC chromatography afforded the title compound.

In NMR spectra, the carbamate motif caused a broadening of certain peaks. After removing of *tert*-butoxycarbonyl (Boc) group, the peaks became sharp and clear (see compound **2q**).




**Methyl (S)-3'-(((*tert*-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(*m*-tolyl)methyl)-5'-methyl-[1,1'-biphenyl]-2-carboxylate (**2a**)**

Substrate **1a** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (22 μL, 0.15 mmol, 1.5 equiv.), AgOAc (33 mg, 0.2 mmol, 2.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%), and CHCl<sub>3</sub> (1 mL) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2a** (39.1 mg) was obtained in 71% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.07 (s, 1H), 7.86–6.58 (m, 8H), 7.70 (d, *J* = 6.4 Hz, 1H), 7.54 (t, *J* = 7.0 Hz, 1H), 7.42 (t, *J* = 7.5 Hz, 1H), 7.19 (s, 1H), 6.44 (s, 1H), 3.54 (s, 3H), 2.47–2.10 (m, 6H), 2.19 (s, 3H), 1.95 (s, 3H), 1.27 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 169.99, 155.05, 152.02, 146.98, 143.17, 141.83, 140.46, 138.45, 133.52, 133.06, 132.66, 132.23, 131.61, 130.42, 128.67, 128.32, 127.03, 81.22, 68.10, 52.60, 28.64, 21.57, 21.55, 17.86. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>39</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 551.2904; found: 551.2906.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 4.32 min (minor), 4.83 min (major): 97:3 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-5'-([1,1'-biphenyl]-3-yl(((*tert*-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)methyl)-[1,1':3',1''-terphenyl]-2-carboxylate (**2b**)**

Substrate **1b** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2b** (43.9 mg) was obtained in 65% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.15 (br s, 1H), 8.14 (s, 1H), 7.87–6.91 (m, 18 H), 7.75 (d, *J* = 7.8 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.21 (s, 1H), 6.72 (s, 1H), 3.48 (s, 3H), 2.18 (s, 3 H), 2.00 (s, 3 H), 1.31 (s, 9 H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 169.78, 155.11, 151.86, 147.19, 142.93, 142.61, 142.08, 141.69, 141.52, 140.65, 133.81, 133.28, 132.55, 132.39, 131.74, 130.60, 130.09, 130.01, 129.50, 128.70, 128.58, 128.53, 128.04, 128.00, 126.69, 81.45, 67.97, 52.61, 28.69, 17.92, 17.88. HRMS (ESI-TOF) *m/z* calc'd for C<sub>45</sub>H<sub>43</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 675.3217; found: 675.3215.

SFC Chiralpak® IC column (20% isopropanol, 2.0 mL/min)  $t_r$  = 7.12 min (minor), 7.85 min (major): 96:4 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-3'-((((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(3-methoxyphenyl)methyl)-5'-methoxy-[1,1'-biphenyl]-2-carboxylate (2c)**

Substrate **1c** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%), and CHCl<sub>3</sub> (1.0 mL) at 60 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 7:2 v/v), compound **2c** (35.1 mg) was obtained in 60% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.09 (s, 1H), 7.76–6.50 (m, 8 H), 7.70 (d, *J* = 7.3 Hz, 1H), 7.54 (t, *J* = 7.1 Hz, 1H), 7.42 (t, *J* = 7.4 Hz, 1H), 7.22 (s, 1H), 6.46 (s, 1H), 3.72 (br s, 6H), 3.53 (s, 3H), 2.20 (s, 3H), 1.98 (s, 3H), 1.28 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 169.87, 160.60, 155.03, 151.89, 147.05, 145.27, 143.15, 142.85, 140.57, 133.65, 133.18, 132.68, 132.22, 131.54, 130.39, 129.87, 128.49, 123.68, 122.24, 115.76, 113.83, 81.32, 67.92, 56.31, 56.10, 52.63, 28.66, 17.93, 17.87. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>39</sub>N<sub>2</sub>O<sub>6</sub> [M+H]<sup>+</sup>: 583.2803; found: 583.2798.

SFC Chiralpak® AD-3 column (12% isopropanol, 2.0 mL/min)  $t_r$  = 5.42 min (major), 6.91 min (minor): 95:5 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-3'-((((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(3-fluorophenyl)methyl)-5'-fluoro-[1,1'-biphenyl]-2-carboxylate (2d)**

Substrate **1d** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2d** (30.0 mg) was obtained in 54% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.08 (s, 1H), 7.85–6.61 (m, 8 H), 7.78 (d, *J* = 7.4 Hz, 1H), 7.57 (t, *J* = 7.3 Hz, 1H), 7.47 (t, *J* = 7.5 Hz, 1H), 7.26 (s, 1H), 6.53 (s, 1H), 3.56 (s, 3H), 2.20 (s, 3H), 2.00 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 169.32, 163.61 (d, *J* = 247.5 Hz), 154.82, 151.48, 147.12, 144.33, 141.91, 140.79, 133.00, 132.55, 132.25, 131.62, 130.81, 129.02, 127.10, 126.00, 116.42, 115.01 (d, *J* = 14.6 Hz), 81.78, 67.02, 52.68, 28.59, 17.87, 17.84; <sup>19</sup>F NMR (376 MHz, Acetonitrile-*d*<sub>3</sub>) δ -115.02, -115.65, -115.77, -116.51. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>33</sub>F<sub>2</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 559.2403; found: 559.2403.

SFC Chiralpak® AD-3 column (10% isopropanol, 2.0 mL/min)  $t_r$  = 3.78 min (major), 4.77 min (minor): 90:10 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-3'-((((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(3-chlorophenyl)methyl)-5'-chloro-[1,1'-biphenyl]-2-carboxylate (2e)**

Substrate **1e** was arylated following the general procedure by using  $(\text{PhO})_2\text{PO}_2\text{H}$  (3.8 mg, 15  $\mu\text{mol}$ , 15 mol%), methyl 2-iodobenzoate (44  $\mu\text{L}$ , 0.3 mmol, 3.0 equiv.), and (+)-NBE- $\text{CO}_2\text{Me}$  (3.0 mg, 20  $\mu\text{mol}$ , 20 mol%) at 80  $^\circ\text{C}$  for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2e** (37.8 mg) was obtained in 64% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60  $^\circ\text{C}$ )  $\delta$  8.08 (s, 1H), 8.01–6.66 (m, 8 H), 7.79 (d,  $J = 7.4$  Hz, 1H), 7.57 (t,  $J = 7.3$  Hz, 1H), 7.47 (t,  $J = 7.5$  Hz, 1H), 7.26 (s, 1H), 6.50 (s, 1H), 3.57 (s, 3H), 2.20 (s, 3H), 1.99 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60  $^\circ\text{C}$ )  $\delta$  169.19, 154.75, 151.43, 147.14, 144.12, 141.77, 140.80, 134.50, 133.94, 132.95, 132.62, 132.10, 131.65, 130.89, 130.62, 129.56, 129.09, 128.37, 128.11, 81.86, 66.94, 52.72, 28.59, 17.88, 17.80. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{33}\text{H}_{33}\text{Cl}_2\text{N}_2\text{O}_4$   $[\text{M}+\text{H}]^+$ : 559.2403; found: 559.2403.

SFC Chiralpak<sup>®</sup> AD-3 column (15% isopropanol, 2.0 mL/min)  $t_r = 3.63$  min (major), 4.31 min (minor): 92:8 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-3'-((((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(3-(trifluoromethyl)phenyl)methyl)-5'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylate (2f)**

Substrate **1f** was arylated following the general procedure by using  $(\text{PhO})_2\text{PO}_2\text{H}$  (3.8 mg, 15  $\mu\text{mol}$ , 15 mol%), methyl 2-iodobenzoate (44  $\mu\text{L}$ , 0.3 mmol, 3.0 equiv.), and (+)-NBE- $\text{CO}_2\text{Me}$  (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100  $^\circ\text{C}$  for 12 hours. After purification by preparative TLC chromatography (hexane/DCM/Et<sub>2</sub>O = 3:3:1 v/v/v), compound **2f** (46.0 mg) was obtained in 70% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60  $^\circ\text{C}$ )  $\delta$  8.06 (s, 1H), 8.36–6.93 (m, 10 H), 7.84 (d,  $J = 7.6$  Hz, 1H), 7.24 (s, 1H), 6.71 (s, 1H), 3.54 (s, 3H), 2.19 (s, 3H), 1.98 (s, 3H), 1.28 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60  $^\circ\text{C}$ )  $\delta$  169.07, 154.74, 151.27, 147.21, 143.44, 141.73, 140.87, 134.94, 134.10, 133.67, 132.96, 132.80, 132.02, 131.78, 131.08, 129.98, 129.29, 126.44, 125.19, 82.01, 66.99, 52.63, 28.54, 17.82, 17.69;  $^{19}\text{F}$  NMR (376 MHz, Acetonitrile- $d_3$ )  $\delta$  -63.10, -63.28, -63.39, -63.50. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{35}\text{H}_{33}\text{F}_6\text{N}_2\text{O}_4$   $[\text{M}+\text{H}]^+$ : 659.2339; found: 659.2336.

SFC Chiralpak<sup>®</sup> OD-3 column (1% isopropanol, 3.0 mL/min)  $t_r = 7.52$  min (major), 12.33 min (minor): 90:10 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.






**Methyl (S)-3'-(((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(3-((triisopropylsilyl)ethynyl)phenyl)methyl)-5'-((triisopropylsilyl)ethynyl)-[1,1'-biphenyl]-2-carboxylate (2g)**

Substrate **1g** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 6:1 v/v), compound **2g** (35.3 mg) was obtained in 40% yield as a yellow oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.11–6.83 (m, 9H), 8.06 (s, 1H), 7.77 (d, *J* = 7.7 Hz, 1H), 7.56 (t, *J* = 7.7 Hz, 1H), 7.46 (t, *J* = 7.7 Hz, 1H), 6.49 (s, 1H), 3.56 (s, 3H), 2.20 (s, 3H), 1.98 (s, 3H), 1.28 (s, 9H), 1.14 (d, *J* = 7.2 Hz, 42H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 169.44, 154.84, 151.71, 147.12, 142.56, 142.12, 140.74, 133.79, 132.91, 132.53, 132.30, 131.61, 131.47, 131.19, 130.76, 129.27, 128.88, 123.90, 108.32, 91.87, 91.62, 81.73, 67.20, 52.67, 28.62, 19.22, 17.93, 17.81, 12.41. HRMS (ESI-TOF) *m/z* calc'd for C<sub>55</sub>H<sub>75</sub>N<sub>2</sub>O<sub>4</sub>Si<sub>2</sub> [M+H]<sup>+</sup>: 883.5260; found: 883.5265.

SFC Chiralpak<sup>®</sup> OD-3 column (10% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 18.12 min (major), 20.46 min (minor): 93:7 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.


**Methyl (S)-3'-(((tert-butoxycarbonyl)(3-methylpyridin-2-yl)amino)(2-fluorophenyl)methyl)-4'-fluoro-[1,1'-biphenyl]-2-carboxylate (2h)**

Substrate **1h** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (4.4 mg, 20 μmol, 20 mol%), Ligand (6.9 mg, 30 μmol, 30 mol%), (*R*)-BNDHP (10.4 mg, 30 μmol, 30 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2h** (22.8 mg) was obtained in 42% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.16 (d, *J* = 5.5 Hz, 1H), 7.92–6.64 (m, 10 H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.45 (t, *J* = 7.8 Hz, 1H), 7.40 (d, *J* = 7.6 Hz, 1H), 3.58 (s, 3H), 2.13 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 169.59, 161.52 (d, *J* = 245.6 Hz), 160.88 (d, *J* = 246.0 Hz), 154.60, 152.94, 146.64, 142.33, 140.24, 138.30, 134.47, 133.06, 132.50, 132.35, 131.75, 130.81, 130.72, 130.31, 128.64, 124.82, 123.82, 115.91 (d, *J* = 22.1 Hz), 115.59 (d, *J* = 22.6 Hz), 81.95, 53.89, 52.70, 28.54, 17.44; <sup>19</sup>F NMR (376 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ -118.31, -119.65, -120.95, -122.80. HRMS (ESI-TOF) *m/z* calc'd for C<sub>32</sub>H<sub>31</sub>F<sub>2</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 545.2246; found: 545.2244.

SFC Chiralpak<sup>®</sup> IC column (5% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 12.54 min (minor), 13.87 min (major): 91:9 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.

**Methyl (S)-5'-(((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(4-fluoro-3-methylphenyl)methyl)-2'-fluoro-3'-methyl-[1,1'-biphenyl]-2-carboxylate (2i)**


Substrate **1i** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%) at

100 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2i** (42.1 mg) was obtained in 72% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.07 (s, 1H), 7.87 (d, *J* = 7.8 Hz, 1H), 7.77–6.55 (m, 6H), 7.59 (t, *J* = 7.7 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 1H), 7.24 (s, 1H), 6.44 (s, 1H), 3.60 (s, 3H), 2.36–2.07 (m, 9H), 1.97 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 168.80, 161.41 (d, *J* = 242.7 Hz), 158.02 (d, *J* = 242.7 Hz), 157.22, 154.92, 151.76, 147.03, 140.64, 137.60, 134.49, 133.72, 133.09, 132.86, 132.38, 130.91, 129.13, 125.07, 124.94, 124.80, 124.72, 115.15 (d, *J* = 18.5 Hz), 81.42, 66.76, 52.59, 28.65, 17.87, 17.84, 14.70. <sup>19</sup>F NMR (376 MHz, Acetonitrile-*d*<sub>3</sub>) δ -121.40, -122.73, -124.84, -126.36. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>37</sub>F<sub>2</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 587.2716; found: 587.2715.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 2.09 min (major), 2.57 min (minor): 96:4 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-2-(7-(((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)benzoate (2j)**

Substrate **1j** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 1:1 v/v), compound **2j** (33.1 mg) was obtained in 52% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.09 (s, 1H), 7.77 (d, *J* = 7.7 Hz, 1H), 7.54 (t, *J* = 7.5 Hz, 1H), 7.47–6.35 (m, 6H), 7.41 (t, *J* = 7.6 Hz, 1H), 7.25 (s, 1H), 6.30 (s, 1H), 4.30–4.00 (m, 8H), 3.64 (s, 3H), 2.22 (s, 3H), 1.99 (s, 3H), 1.30 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 169.20, 154.98, 152.00, 147.00, 144.23, 143.81, 140.60, 138.96, 133.55, 133.16, 132.57, 132.28, 130.88, 130.29, 128.49, 123.75, 117.34, 81.15, 66.97, 65.56, 65.44, 65.37, 52.50, 28.70, 17.96, 17.92. HRMS (ESI-TOF) *m/z* calc'd for C<sub>37</sub>H<sub>39</sub>N<sub>2</sub>O<sub>8</sub> [M+H]<sup>+</sup>: 639.2701; found: 639.2698.

SFC Chiralpak<sup>®</sup> AD-3 column (15% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 8.55 min (major), 10.37 min (minor): 94:6 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-2-(5-(((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(thiophen-2-yl)methyl)thiophen-3-yl)benzoate (2k)**

Substrate **1k** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15 μmol, 15 mol%), methyl 2-iodobenzoate (22 μL, 0.15 mmol, 1.5 equiv.), AgOAc (33 mg, 0.2 mmol, 2.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2k** (23.5 mg) was obtained in 44% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.13 (s, 1H), 7.64 (d, *J* = 7.7 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 1H), 7.48–6.88 (m, 6H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.35 (s, 1H), 6.84 (s, 1H), 3.66 (s, 3H), 2.27 (s, 3H), 2.02 (s, 3H),

1.36 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  170.29, 154.34, 151.91, 147.28, 145.17, 141.16, 140.82, 137.02, 133.89, 132.76, 132.72, 132.21, 131.22, 130.12, 129.64, 128.67, 128.43, 127.22, 126.98, 123.79, 82.13, 59.31, 52.86, 28.67, 17.94, 17.90. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{29}\text{H}_{31}\text{N}_2\text{O}_2\text{S}_2$   $[\text{M}+\text{H}]^+$ : 535.1720; found: 535.1721.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r$  = 4.13 min (major), 5.24 min (minor): 70:30 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-(3,5-dimethylpyridin-2-yl)((5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)carbamate (**2l**)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), iodobenzene (33.6  $\mu\text{L}$ , 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 20:1 v/v), compound **2l** (30.6 mg) was obtained in 62% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.12 (s, 1H), 7.98–6.72 (m, 11H), 7.33 (t,  $J$  = 7.5 Hz, 1H), 7.19 (s, 1H), 6.49 (s, 1H), 2.41–2.12 (m, 6H), 2.19 (s, 3H), 1.97 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  155.10, 152.06, 147.03, 142.30, 141.58, 140.46, 139.11, 138.47, 133.56, 133.07, 129.97, 128.76, 128.65, 128.42, 127.97, 127.28, 81.23, 68.10, 28.65, 21.61, 17.86. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{33}\text{H}_{37}\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 493.2850; found: 493.2848.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min)  $t_r$  = 3.85 min (minor), 4.59 min (major): 97:3 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((2'-acetamido-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (**2m**)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (78.3 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 1:1 v/v), compound **2m** (41.3 mg) was obtained in 62% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.07 (s, 1H), 7.90 (s, 1H), 7.83–6.67 (m, 11H), 7.32 (t,  $J$  = 8.0 Hz, 1H), 6.48 (s, 1H), 2.53–2.11 (m, 6H), 2.20 (s, 3H), 1.96 (s, 3H), 1.84 (s, 3H), 1.28 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  169.63, 155.05, 151.99, 147.00, 140.49, 139.24, 138.51, 136.34, 135.56, 133.59, 133.09, 131.16, 129.31, 128.92, 128.80, 125.91, 124.89, 81.27, 68.04, 28.65, 24.29, 21.61, 17.88. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{35}\text{H}_{40}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$ : 550.3064; found: 550.3068.

SFC Chiralpak<sup>®</sup> AD-3 column (15% isopropanol, 1.0 mL/min)  $t_r$  = 11.05 min (major), 12.83 min (major): 92:8 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-(3,5-dimethylpyridin-2-yl)((5-methyl-2'-((2,2,2-trifluoroacetamido)-[1,1'-biphenyl]-3-yl)(m-tolyl)methyl)carbamate (2n)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (94.4 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2n** (27.8 mg) was obtained in 46% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.56 (br s, 1H), 8.08 (s, 1H), 7.83–6.59 (m, 8H), 7.73 (s, 1H), 7.43 (t, *J* = 7.8 Hz, 1H), 7.38 (t, *J* = 7.4 Hz, 1H), 7.20 (s, 1H), 6.47 (s, 1H), 2.47–2.11 (m, 6H), 2.20 (s, 3H), 1.94 (s, 3H), 1.28 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  156.38 (q, *J* = 36.9 Hz), 151.97, 147.01, 140.49, 139.00, 138.49, 138.15, 133.58, 133.07, 133.03, 131.62, 129.41, 128.95, 128.75, 128.59, 126.19, 118.15 (q, *J* = 288.2 Hz), 81.29, 68.00, 28.63, 21.51, 17.85, 17.83. <sup>19</sup>F NMR (376 MHz, Acetonitrile-*d*<sub>3</sub>)  $\delta$  -76.72, -76.82. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>37</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>: 604.2782; found: 604.2779.

SFC Chiralpak<sup>®</sup> IC column (10% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 5.15 min (minor), 5.89 min (major): 90:10 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




**(S)-3'-(((tert-Butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(m-tolyl)methyl)-5'-methyl-[1,1'-biphenyl]-2-yl acetate (2o)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (78.6 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2o** (23.1 mg) was obtained in 42% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.07 (s, 1H), 7.18 (s, 1H), 7.68–6.78 (m, 11H), 2.35 (d, *J* = 35.6 Hz, 3H), 2.22–2.09 (m, 6H), 1.93 (s, 3H), 1.90 (s, 3H), 1.25 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  170.31, 155.06, 152.01, 149.20, 146.98, 140.48, 138.55, 138.20, 136.03, 133.53, 133.04, 131.75, 129.59, 128.98, 128.84, 128.73, 127.45, 124.30, 81.25, 68.14, 28.65, 21.59, 21.09, 17.86. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>39</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 551.2904; found: 551.2900.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol/hexane (v/v = 1/1), 2.0 mL/min) *t*<sub>r</sub> = 3.68 min (major), 4.18 min (minor): 71:29 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Phenyl (S)-3'-(((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(m-tolyl)methyl)-5'-methyl-[1,1'-biphenyl]-2-carboxylate (2p)**

Substrate **1a** was arylated following the general procedure by using  $(\text{PhO})_2\text{PO}_2\text{H}$  (3.8 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (48.6 mg, 0.15 mmol, 1.5 equiv.), AgOAc (33 mg, 0.2 mmol, 2.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20  $\mu\text{mol}$ , 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2p** (39.9 mg) was obtained in 65% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.04 (s, 1H), 7.92 (d, *J* = 7.8 Hz, 1H), 7.79–6.66 (m, 11H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.51 (t, *J* = 7.6 Hz, 1H), 7.34 (t, *J* = 7.7 Hz, 2H), 7.23 (t, *J* = 7.5 Hz, 1H), 6.48 (s, 1H), 2.48–2.08 (m, 6H), 2.15 (s, 3H), 1.92 (s, 3H), 1.26 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  168.23, 155.04, 152.13, 151.99, 146.98, 143.65, 141.85, 140.48, 138.41, 133.47, 132.98, 132.88, 131.80, 131.00, 130.49, 128.99, 128.65, 128.54, 126.96, 122.63, 81.23, 68.04, 28.64, 21.56, 17.87. HRMS (ESI-TOF) *m/z* calc'd for C<sub>40</sub>H<sub>41</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 613.3061; found: 613.3055.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 3.53 min (major), 5.47 min (minor): 98:2 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-(3,5-dimethylpyridin-2-yl)((5-methyl-2'-nitro-[1,1'-biphenyl]-3-yl)(m-tolyl)methyl)carbamate (2q)**

Substrate **1a** was arylated following the general procedure by using  $(\text{PhO})_2\text{PO}_2\text{H}$  (3.8 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (37.4 mg, 0.15 mmol, 1.5 equiv.), AgOAc (33 mg, 0.2 mmol, 2.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20  $\mu\text{mol}$ , 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2q** (39.9 mg) was obtained in 62% yield as a yellow oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.08 (s, 1H), 7.96–6.69 (m, 8H), 7.84 (d, *J* = 8.1 Hz, 1H), 7.66 (t, *J* = 7.7 Hz, 1H), 7.53 (t, *J* = 7.8 Hz, 1H), 7.20 (s, 1H), 6.45 (s, 1H), 2.45–2.10 (m, 6H), 2.20 (s, 3H), 1.96 (s, 3H), 1.28 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  154.99, 151.89, 150.64, 147.00, 140.49, 139.00, 138.47, 138.26, 137.19, 133.58, 133.52, 132.98, 131.91, 130.17, 129.58, 128.74, 128.08, 126.63, 125.09, 81.29, 67.91, 28.64, 21.49, 17.88, 17.85. HRMS (ESI-TOF) *m/z* calc'd for C<sub>353</sub>H<sub>36</sub>N<sub>3</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 538.2700; found: 538.2694.

SFC Chiralpak<sup>®</sup> IC column (15% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 6.06 min (minor), 5.87 min (major): 96:4 er.


The absolute stereochemistry was assigned by analogy to compound **2ah**.



**(S)-3,5-Dimethyl-N-((5-methyl-2'-nitro-[1,1'-biphenyl]-3-yl)(m-tolyl)methyl)pyridin-2-amine (s4)**

To a solution of **2q** (27 mg, 0.05 mmol) was dissolved in dioxane (0.25 mL), HCl solution (4 N in dioxane) was added. The reaction mixture was stirred at room temperature for 3 hours. Aqueous NaHCO<sub>3</sub> solution was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were washed with aqueous NaCl solution, and then dried over Na<sub>2</sub>SO<sub>4</sub>. The organic solvent was concentrated by rotatory. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **s4** (19.1 mg) was obtained in 85% yield as a yellow liquid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.80–7.75 (m, 2H), 7.55 (td,  $J = 7.6, 1.3$  Hz, 1H), 7.43 (td,  $J = 7.8, 1.4$  Hz, 1H), 7.40 (dd,  $J = 7.7, 1.4$  Hz, 1H), 7.20 (t,  $J = 7.5$  Hz, 1H), 7.16 (s, 1H), 7.14–7.10 (m, 2H), 7.09–7.04 (m, 3H), 7.02 (s, 1H), 6.43 (d,  $J = 6.9$  Hz, 1H), 4.49 (d,  $J = 6.9$  Hz, 1H), 2.33 (d,  $J = 8.8$  Hz, 6H), 2.13 (d,  $J = 5.8$  Hz, 6H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  154.09, 149.73, 145.24, 144.43, 143.62, 138.78, 138.53, 138.44, 137.36, 136.67, 132.29, 132.12, 128.74, 128.70, 128.66, 128.14, 128.10, 127.46, 124.88, 124.33, 124.15, 121.99, 116.38, 58.64, 21.76, 17.59, 17.26. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{28}\text{H}_{28}\text{N}_3\text{O}_2$   $[\text{M}+\text{H}]^+$ : 468.2176; found: 468.2182.




***tert*-Butyl (S)-((3'-(acetamidomethyl)-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2r)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (82.5 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 1:6 v/v), compound **2r** (39.6 mg) was obtained in 70% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.13 (s, 1H), 8.05–6.62 (m, 9H), 7.37 (t,  $J = 7.7$  Hz, 1H), 7.25 (d,  $J = 7.2$  Hz, 1H), 7.19 (dd,  $J = 1.8$  Hz,  $J = 0.6$  Hz, 1H), 6.73 (s, 1H), 6.48 (s, 1H), 4.37 (d,  $J = 6.0$  Hz, 2H), 2.47–2.13 (m, 6H), 2.19 (s, 3H), 1.97 (s, 3H), 1.92 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  170.82, 155.11, 152.03, 147.06, 142.44, 141.48, 141.39, 140.47, 139.11, 138.48, 133.56, 133.06, 130.07, 128.81, 128.67, 127.56, 127.29, 127.14, 126.64, 81.25, 68.10, 44.03, 28.67, 23.25, 21.62, 17.88. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{36}\text{H}_{42}\text{N}_3\text{O}_3$   $[\text{M}+\text{H}]^+$ : 564.3221; found: 564.3229.

SFC Chiralpak<sup>®</sup> OJ column (20% isopropanol, 2.0 mL/min)  $t_r$  = 3.17 min (minor), 3.68 min (major): 95:5 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




***tert*-Butyl (S)-((3-(3-methoxy-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2s)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (70.2 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2s** (35.1 mg) was obtained in 67% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.12 (s, 1H), 7.75–6.59 (m, 9H), 7.34 (d,  $J = 6.3$  Hz, 1H), 7.19 (s, 1H), 6.90 (d,  $J = 7.6$  Hz, 1H), 6.49 (s, 1H), 3.84 (s, 3H), 2.45–2.07 (m, 6H), 2.19 (s, 3H), 1.97 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  161.47, 155.09, 152.07, 147.02, 143.84, 141.42, 140.47, 139.07, 138.47, 133.56, 133.07, 131.02, 128.77, 128.66, 127.31, 120.41, 114.03, 113.77, 81.21, 68.08, 56.21, 28.66, 21.60, 17.87. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{34}\text{H}_{39}\text{N}_2\text{O}_3$   $[\text{M}+\text{H}]^+$ : 523.2955; found: 523.2956. SFC Chiralpak<sup>®</sup> AD-3 column (10% isopropanol, 1.5 mL/min)  $t_r$  = 8.61 min (major), 9.37 min (minor): 97:3 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-(3,5-dimethylpyridin-2-yl)((3'-fluoro-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)carbamate (2t)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (70.2 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 20:1 v/v), compound **2t** (35.1 mg) was obtained in 67% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.13 (s, 1H), 8.07–6.67 (m, 9H), 7.43 (d, *J* = 7.5 Hz, 1H), 7.19 (s, 1H), 7.07 (t, *J* = 7.8 Hz, 1H), 6.49 (s, 1H), 2.47–2.10 (m, 6H), 2.19 (s, 3H), 1.96 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  164.40 (d, *J* = 244.4 Hz), 155.09, 152.00, 147.04, 144.82, 140.50, 140.21, 139.33, 138.49, 133.62, 133.11, 131.78, 131.72, 128.80, 127.34, 123.87, 119.02, 114.97 (d, *J* = 21.9 Hz), 114.60 (d, *J* = 21.8 Hz), 81.27, 68.01, 28.65, 21.60, 17.85. <sup>19</sup>F NMR (376 MHz, Acetonitrile-*d*<sub>3</sub>)  $\delta$  -114.97. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>36</sub>FN<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 511.2755; found: 511.2747.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 3.33 min (minor), 4.13 min (major): 97:3 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3'-chloro-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2u)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (71.8 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 20:1 v/v), compound **2u** (33.8 mg) was obtained in 64% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.13 (s, 1H), 7.80–6.66 (m, 9H), 7.40 (t, *J* = 7.4 Hz, 1H), 7.34 (d, *J* = 6.6 Hz, 1H), 7.19 (s, 1H), 6.49 (s, 1H), 2.49–2.11 (m, 6H), 2.20 (s, 3H), 1.96 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  155.08, 151.99, 147.03, 144.38, 140.50, 140.05, 139.36, 138.49, 135.45, 133.63, 133.12, 131.56, 129.98, 128.76, 128.26, 127.93, 127.31, 126.43, 81.28, 67.99, 28.65, 21.58, 17.87, 17.83. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>36</sub>ClN<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 527.2460; found: 527.2462.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 3.99 min (minor), 5.21 min (major): 95:5 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3'-bromo-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2v)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (85.0 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 20:1 v/v), compound **2v** (41.8 mg) was obtained in 73% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.13 (s, 1H), 8.05–6.64 (m, 9H), 7.49 (d, *J* = 7.9 Hz, 1H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.19 (s, 1H), 6.49 (s, 1H), 2.46–2.10 (m, 6H), 2.20 (s, 3H), 1.96 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  155.08, 151.99, 147.02, 144.64, 140.50, 139.96, 139.36, 138.49, 133.63, 133.12, 131.81, 131.24, 130.88, 128.80, 127.32, 126.85, 123.61, 81.28, 67.98, 28.66, 21.58, 17.89, 17.83. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>36</sub>BrN<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 571.1955; found: 571.1953.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 4.42 min (minor), 5.76 min (major): 96:4 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl ((S)-((3'-cyano-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3-methylpyridin-2-yl)carbamate (2w)**

Substrate **1a'** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (91.2 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2w** (34.6 mg) was obtained in 69% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.29 (d, *J* = 3.3 Hz, 1H), 8.15–6.71 (m, 9H), 7.66 (d, *J* = 7.7 Hz, 1H), 7.57 (t, *J* = 7.8 Hz, 1H), 7.38 (d, *J* = 7.3 Hz, 1H), 7.05 (dd, *J* = 7.5, 4.7 Hz, 1H), 6.53 (s, 1H), 2.28 (br d, *J* = 53.6 Hz, 6H), 2.03 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  154.92, 154.34, 146.86, 143.41, 140.02, 139.57, 139.40, 138.54, 133.94, 132.45, 131.91, 131.61, 131.02, 128.81, 127.37, 123.79, 119.80, 113.95, 81.43, 67.97, 28.63, 21.58, 18.00. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>34</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 504.2646; found: 504.2658.

SFC Chiralpak<sup>®</sup> OJ-3 column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 2.55 min (minor), 4.11 min (major): 90:10 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.



**tert-Butyl ((S)-((4'-((diethoxyphosphoryl)methyl)-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2x)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (106.2 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (toluene/THF = 3:2 v/v), compound **2x** (44.2 mg) was obtained in 69% yield as a colorless oil.


<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.12 (s, 1H), 7.76–6.68 (m, 11H), 7.19 (s, 1H), 6.48 (s, 1H), 4.02 (p, *J* = 7.3 Hz, 4H), 3.17 (d, *J* = 21.5 Hz, 2H), 2.41–2.14 (m, 6H), 2.19 (s, 3H), 1.97 (s, 3H), 1.29 (s, 9H),



1.24 (t,  $J = 7.1$  Hz, 6H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  155.11, 152.07, 147.04, 141.16, 140.71, 140.47, 139.12, 138.47, 133.56, 133.08, 132.90, 132.84, 131.50, 131.45, 128.79, 128.67, 127.90, 127.14, 81.24, 68.10, 63.03, 62.99, 34.31, 33.40, 28.66, 21.61, 17.86, 16.91, 16.87. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{38}\text{H}_{48}\text{N}_2\text{O}_3\text{P}$   $[\text{M}+\text{H}]^+$ : 634.3295; found: 634.3297.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol, 2.0 mL/min)  $t_r = 3.66$  min (major), 4.71 min (minor): 95:5 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((4'-(((tert-butyl(dimethyl)silyloxy)methyl)-5-methyl-[1,1'-biphenyl]-3-yl)(m-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2y)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (104 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE- $\text{CO}_2\text{Me}$  (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 15:1 v/v), compound **2y** (36.2 mg) was obtained in 57% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.12 (s, 1H), 7.72–6.78 (m, 11H), 7.19 (s, 1H), 6.48 (s, 1H), 4.77 (s, 2H), 2.44–2.14 (m, 6H), 2.19 (s, 3H), 1.96 (s, 3H), 1.29 (s, 9H), 0.97 (s, 9H), 0.13 (s, 6H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  155.09, 152.08, 147.03, 142.01, 141.38, 140.98, 140.46, 139.07, 138.46, 133.55, 133.07, 128.78, 128.64, 128.00, 127.81, 127.20, 81.22, 68.11, 65.76, 28.66, 26.55, 21.62, 19.20, 17.86, -4.81. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{40}\text{H}_{53}\text{N}_2\text{O}_3\text{Si}$   $[\text{M}+\text{H}]^+$ : 637.3820; found: 637.3820.

SFC Chiralpak<sup>®</sup> AD-3 column (10% isopropanol, 2.0 mL/min)  $t_r = 4.67$  min (major), 5.45 min (minor): 97:3 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((4'-(2-chloroethoxy)-5-methyl-[1,1'-biphenyl]-3-yl)(m-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2z)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (85 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE- $\text{CO}_2\text{Me}$  (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2z** (38.7 mg) was obtained in 68% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.12 (s, 1H), 7.99–6.65 (m, 11H), 7.19 (s, 1H), 6.48 (s, 1H), 4.29 (t,  $J = 5.5$  Hz, 2H), 3.87 (t,  $J = 5.4$  Hz, 2H), 2.44–2.08 (m, 6H), 2.19 (s, 3H), 1.96 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  159.24, 155.09, 152.07, 147.02, 141.01, 140.45, 139.02, 138.43, 135.41, 133.55, 133.07, 130.33, 129.13, 128.79, 128.64, 126.87, 116.44, 81.21, 69.70, 68.11, 43.82, 28.66, 21.62, 17.86. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{35}\text{H}_{40}\text{ClN}_2\text{O}_3$   $[\text{M}+\text{H}]^+$ : 571.2722; found: 571.2726.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r = 3.26$  min (minor), 3.92 min (major): 96:4 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((4'-formyl-5-methyl-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3-methylpyridin-2-yl)carbamate (2aa)**

Substrate **1a'** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (69.6 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2aa** (38.4 mg) was obtained in 76% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  10.03 (s, 1H), 8.29 (d, *J* = 3.4 Hz, 1H), 7.93 (d, *J* = 7.8 Hz, 2H), 7.97–6.85 (m, 9H), 7.38 (d, *J* = 7.2 Hz, 1H), 7.04 (dd, *J* = 7.5, 4.7 Hz, 1H), 6.54 (s, 1H), 2.28 (br d, *J* = 57.8 Hz, 6H), 2.04 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  193.13, 154.92, 154.36, 148.01, 146.88, 140.22, 140.01, 139.48, 138.54, 136.80, 133.89, 131.15, 128.81, 128.60, 127.58, 123.76, 81.43, 68.00, 28.63, 21.60, 18.01. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>35</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup>: 507.2642; found: 507.2637.

SFC Chiralpak<sup>®</sup> OJ-3 column (30% isopropanol, 2.5 mL/min) *t*<sub>r</sub> = 1.74 min (minor), 2.51 min (major): 96:4 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-3'-((((tert-butoxycarbonyl)(3-methylpyridin-2-yl)amino)(*m*-tolyl)methyl)-5'-methyl-[1,1'-biphenyl]-4-carboxylate (2ab)**

Substrate **1a'** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (78 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2ab** (36.0 mg) was obtained in 67% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.31 (d, *J* = 4.7 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 2H), 7.87–6.60 (m, 9H), 7.40 (d, *J* = 7.5 Hz, 1H), 7.07 (dd, *J* = 7.5, 4.7 Hz, 1H), 6.56 (s, 1H), 3.92 (s, 3H), 2.30 (br d, *J* = 53.0 Hz, 6H), 2.06 (s, 3H), 1.32 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  167.75, 154.93, 154.38, 146.89, 146.66, 140.36, 140.01, 139.42, 138.54, 133.90, 131.01, 130.38, 128.78, 128.06, 127.47, 123.77, 81.42, 68.02, 52.76, 28.63, 21.60, 18.01. HRMS (ESI-TOF) *m/z* calc'd for C<sub>34</sub>H<sub>37</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 537.2748; found: 537.2752. SFC Chiralpak<sup>®</sup> AD-3 column (15% isopropanol/hexane (v/v = 1/1), 2.0 mL/min) *t*<sub>r</sub> = 8.76 min (minor), 9.38 min (major): 97:3 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((5-methyl-4'-(pyrrolidin-1-ylsulfonyl)-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3-methylpyridin-2-yl)carbamate (2ac)**

Substrate **1a'** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (101 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **2ac** (44.6 mg) was obtained in 73% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.29 (d, *J* = 4.7 Hz, 1H), 7.97–6.74 (m, 9H), 7.85 (d, *J* = 7.9 Hz, 2H), 7.38 (d, *J* = 7.6 Hz, 1H), 7.04 (dd, *J* = 7.5, 4.7 Hz, 1H), 6.54 (s, 1H), 3.28–3.14 (m, 4H), 2.28 (br d, *J* = 63.2 Hz, 6H), 2.03 (s, 3H), 1.82–1.65 (m, 4H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  154.91, 154.34, 146.89, 146.42, 140.02, 139.82, 139.54, 138.54, 137.19, 133.91, 130.96, 129.17, 128.82, 128.55, 127.53, 123.78, 81.44, 67.97, 49.12, 28.63, 26.09, 21.61, 21.57, 18.01. HRMS (ESI-TOF) *m/z* calc'd for C<sub>36</sub>H<sub>42</sub>N<sub>3</sub>O<sub>4</sub>S [M+H]<sup>+</sup>: 612.2891; found: 612.2892.

SFC Chiralpak<sup>®</sup> OJ-3 column (10% isopropanol, 3 min, then 40% isopropanol, 2.5 mL/min) *t*<sub>r</sub> = 3.68 min (minor), 5.06 min (major): 92:8 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-3'-(((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(*m*-tolyl)methyl)-5-chloro-5'-methyl-[1,1'-biphenyl]-2-carboxylate (2ad)**

Substrate **1a** was arylated following the general procedure by using (PhO)<sub>2</sub>PO<sub>2</sub>H (3.8 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (44.6 mg, 0.15 mmol, 1.5 equiv.), AgOAc (33 mg, 0.2 mmol, 2.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20  $\mu$ mol, 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2ad** (48.4 mg) was obtained in 83% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.07 (s, 1H), 7.85–6.55 (m, 8H), 7.71 (s, 1H), 7.53 (d, *J* = 8.2 Hz, 1H), 7.19 (s, 1H), 6.45 (s, 1H), 3.56 (s, 3H), 2.53–2.09 (m, 6H), 2.19 (s, 3H), 1.95 (s, 3H), 1.27 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  168.63, 155.01, 151.97, 146.97, 141.81, 140.47, 138.49, 138.45, 134.14, 133.86, 133.51, 133.28, 133.04, 128.72, 128.53, 126.98, 81.25, 68.04, 52.94, 28.65, 21.56, 17.86. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>38</sub>ClN<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 585.2515; found: 585.2516.

SFC Chiralpak<sup>®</sup> IC column (25% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 3.37 min (minor), 3.69 min (major): 98:2 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3,5-dimethylpyridin-2-yl)((4'-methoxy-5-methyl-2'-nitro-[1,1'-biphenyl]-3-yl)(m-tolyl)methyl)carbamate (2ae)**

Substrate **1a** was arylated following the general procedure by using  $(\text{PhO})_2\text{PO}_2\text{H}$  (3.8 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (44.6 mg, 0.15 mmol, 1.5 equiv.), AgOAc (33 mg, 0.2 mmol, 2.0 equiv.), and (+)-NBE- $\text{CO}_2\text{Me}$  (3.0 mg, 20  $\mu\text{mol}$ , 20 mol%) at 80 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **2ae** (48.4 mg) was obtained in 83% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.11 (s, 1H), 7.90–6.54 (m, 10H), 7.41 (s, 1H), 6.46 (s, 1H), 3.92 (s, 3H), 2.51–2.14 (m, 6H), 2.23 (s, 3H), 1.98 (s, 3H), 1.30 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  160.57, 155.01, 151.91, 151.12, 147.00, 140.49, 138.94, 138.47, 138.06, 133.84, 133.52, 132.99, 129.92, 128.73, 128.21, 126.79, 119.63, 110.45, 81.29, 67.94, 57.07, 28.64, 21.56, 21.48, 17.87. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{34}\text{H}_{38}\text{N}_3\text{O}_5$   $[\text{M}+\text{H}]^+$ : 568.2806; found: 568.2805.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min)  $t_r$  = 4.84 min (minor), 5.48 min (major): 96:4 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3,5-dimethylpyridin-2-yl)((3-methyl-5-(naphthalen-2-yl)phenyl)(m-tolyl)methyl)carbamate (2af)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (76.2 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE- $\text{CO}_2\text{Me}$  (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/THF = 6:1 v/v), compound **2af** (35.8 mg) was obtained in 66% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.37–6.65 (m, 12H), 8.16 (s, 1H), 7.51 (p,  $J$  = 7.0 Hz, 2H), 7.20 (s, 1H), 6.53 (s, 1H), 2.52–2.10 (m, 6H), 2.19 (s, 3H), 1.98 (s, 3H), 1.30 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  155.12, 152.09, 147.06, 141.38, 140.49, 139.65, 139.23, 138.48, 134.96, 133.89, 133.58, 133.11, 129.55, 129.25, 128.81, 128.71, 127.56, 127.18, 126.51, 126.46, 81.25, 68.13, 28.68, 21.67, 21.61, 17.88. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{37}\text{H}_{39}\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 543.3006; found: 543.3004.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol, 2.0 mL/min)  $t_r$  = 4.56 min (major), 6.43 min (minor): 95:5 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.



**tert-Butyl (S)-((5-methyl-3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)(m-tolyl)methyl)(3-**


**methylpyridin-2-yl)carbamate (2ag)**

Substrate **1a'** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (102 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 12 hours. After purification by preparative TLC chromatography (hexane/toluene/EtOAc = 4:2:1 v/v/v), compound **2ag** (40.6 mg) was obtained in 66% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.55–6.69 (m, 9H), 8.31–8.25 (m, 1H), 7.95 (s, 1H), 7.39 (d, *J* = 7.7 Hz, 1H), 7.06 (ddd, *J* = 7.4, 4.6, 2.5 Hz, 1H), 6.55 (s, 1H), 2.29 (d, *J* = 74.2 Hz, 3H), 2.03 (s, 3H), 1.29 (d, *J* = 2.5 Hz, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  154.95, 154.31, 146.83, 144.70, 140.08, 139.89, 138.58, 138.49, 134.06, 133.23, 132.90 (q, *J* = 33.1 Hz), 128.87, 128.43, 127.59, 126.42, 124.88 (q, *J* = 271.9 Hz), 122.98 (hept, *J* = 3.8 Hz), , 81.49, 67.88, 28.61, 21.54, 17.97; <sup>19</sup>F NMR (376 MHz, Acetonitrile-*d*<sub>3</sub>)  $\delta$  -63.57. HRMS (ESI-TOF) *m/z* calc'd for C<sub>34</sub>H<sub>33</sub>F<sub>6</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 615.2441; found: 615.2445.

SFC Chiralpak<sup>®</sup> IC column (5% isopropanol, 1.0 mL/min) *t*<sub>r</sub> = 6.85 min (minor), 7.71 min (major): 99:1 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((5-methyl-3',5'-bis(methylsulfonyl)-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)(3-methylpyridin-2-yl)carbamate (2ah)**

Substrate **1a'** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (108 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 12 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 1:1 v/v), compound **2ah** (51.0 mg) was obtained in 80% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.71–6.72 (m, 9H), 8.37–8.32 (m, 2H), 7.39 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.07 (dd, *J* = 7.6, 4.7 Hz, 1H), 6.57 (s, 1H), 3.18 (s, 6H), 2.30 (br d, *J* = 84.6 Hz, 6H), 2.04 (s, 3H), 1.30 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  154.93, 154.19, 146.97, 145.28, 144.38, 140.08, 140.02, 138.58, 138.13, 134.02, 131.21, 128.87, 127.62, 125.70, 123.93, 81.52, 67.85, 44.78, 28.64, 21.55, 17.99. HRMS (ESI-TOF) *m/z* calc'd for C<sub>34</sub>H<sub>39</sub>N<sub>2</sub>O<sub>6</sub>S<sub>2</sub> [M+H]<sup>+</sup>: 635.2244; found: 635.2241.

SFC Chiralpak<sup>®</sup> OJ-3 column (15% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 4.87 min (minor), 5.65 min (major): 96:4 er. The absolute stereochemistry was determined by X-ray crystallography.




**tert-Butyl (S)-((3-methylpyridin-2-yl)(*m*-tolyl)(3',4',5'-trifluoro-5-methyl-[1,1'-biphenyl]-3-yl)methyl)carbamate (2ai)**

Substrate **1a'** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (77.4 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 12 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 20:1 v/v), compound **2ai** (40.1 mg) was obtained in 75% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.28 (d, *J* = 4.7 Hz, 1H), 8.13–6.62 (m, 9H), 7.38 (d, *J* = 7.5 Hz, 1H), 7.05 (dd, *J* = 7.5, 4.7 Hz, 1H), 6.52 (s, 1H), 2.27 (br d, *J* = 50.2 Hz, 6H), 2.03 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C

NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  154.92, 154.32, 152.49 (ddd,  $J = 247.1, 9.3, 3.4$  Hz), 146.87, 140.22 (dt,  $J = 249.0, 15.6$  Hz), 140.04, 139.64, 138.94, 138.57, 138.57, 138.45, 138.45, 133.96, 131.32, 128.85, 127.20, 126.13, 123.82, 112.14 (dd,  $J = 17.5, 3.8$  Hz), 81.46, 67.93, 28.63, 21.56, 17.99;  $^{19}\text{F}$  NMR (376 MHz, Acetonitrile- $d_3$ )  $\delta$  -136.70, -136.75, -165.47, -165.51. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{32}\text{H}_{32}\text{F}_3\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 533.2410; found: 533.2407.

SFC Chiralpak<sup>®</sup> IC column (5% isopropanol, 1.0 mL/min)  $t_r = 20.03$  min (minor), 21.74 min (major): 96:4 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-methylphenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2aj)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (78.6 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **2aj** (38.9 mg) was obtained in 71% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.12 (s, 1H), 7.95–6.62 (m, 9H), 7.19–7.18 (m, 1H), 6.88 (d,  $J = 7.8$  Hz, 1H), 6.46 (s, 1H), 4.26 (s, 4H), 2.47–2.11 (m, 6H), 2.19 (s, 3H), 1.96 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  155.09, 152.06, 147.02, 145.21, 144.65, 140.96, 140.46, 138.99, 138.44, 135.67, 133.58, 133.09, 130.33, 128.78, 128.63, 126.88, 120.84, 118.57, 116.50, 81.20, 68.09, 65.67, 28.67, 21.61, 17.86. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{35}\text{H}_{39}\text{N}_2\text{O}_4$   $[\text{M}+\text{H}]^+$ : 551.2904; found: 551.2909.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol, 1.0 mL/min)  $t_r = 7.61$  min (major), 8.67 min (minor): 97:3 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-methylphenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2ak)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu\text{mol}$ , 15 mol%), aryl iodide (103 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **2ak** (48.2 mg) was obtained in 76% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.49–6.63 (m, 9H), 8.18 (s, 1H), 7.63 (d,  $J = 8.7$  Hz, 1H), 7.21–7.17 (m, 1H), 6.99 (s, 1H), 6.51 (s, 1H), 4.44 (q,  $J = 7.1$  Hz, 2H), 2.45–2.09 (m, 6H), 2.19 (s, 3H), 1.97 (s, 3H), 1.41 (t,  $J = 7.1$  Hz, 3H), 1.30 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  178.98, 161.62, 156.56, 155.08, 153.99, 151.95, 147.12, 140.51, 140.07, 139.52, 138.50, 134.56, 133.68, 133.10, 131.73, 130.04, 128.78, 127.35, 125.79, 123.80, 120.44, 115.20, 81.31, 67.98, 64.05, 28.66, 21.59, 17.86, 14.51. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{39}\text{H}_{41}\text{N}_2\text{O}_6$   $[\text{M}+\text{H}]^+$ : 633.2959; found: 633.2962.

SFC Chiralpak<sup>®</sup> OD-3 column (30% isopropanol, 2.0 mL/min)  $t_r$  = 4.79 min (minor), 5.35 min (major): 96:4 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-(3,5-dimethylpyridin-2-yl)((3-methyl-5-(6-(trifluoromethyl)pyridin-3-yl)phenyl)(m-tolyl)methyl)carbamate (2al)**

Substrate **1a** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15 μmol, 15 mol%), ligand (6.9 mg, 23 μmol, 23 mol%), (*R*)-BNDHP (8.0 mg, 23 μmol, 23 mol%), aryl iodide (81.9 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2al** (34.9 mg) was obtained in 62% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 9.18–6.62 (m, 9H), 8.13 (s, 1H), 7.81 (d, *J* = 8.1 Hz, 1H), 7.19 (s, 1H), 6.52 (s, 1H), 2.53–2.10 (m, 6H), 2.19 (s, 3H), 1.97 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 155.07, 151.92, 149.44, 147.28 (q, *J* = 34.3 Hz), 147.04, 140.78, 140.52, 139.82, 138.56, 136.91, 136.79, 133.66, 133.12, 131.46, 128.84, 127.62, 123.29 (d, *J* = 272.8 Hz), 121.79, 81.35, 67.95, 28.65, 21.57, 17.85; <sup>19</sup>F NMR (376 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ -68.47. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>35</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 562.2676; found: 562.2675.

SFC Chiralpak<sup>®</sup> AD-3 column (10% isopropanol, 2.0 mL/min)  $t_r$  = 4.10 min (minor), 5.02 min (major): 5:95 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3-(2-chloropyridin-4-yl)-5-methylphenyl)(m-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2am)**

Substrate **1a** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15 μmol, 15 mol%), ligand (6.9 mg, 23 μmol, 23 mol%), (*R*)-BNDHP (8.0 mg, 23 μmol, 23 mol%), aryl iodide (71.7 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 7:2 v/v), compound **2am** (34.9 mg) was obtained in 65% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 8.37 (s, 1H), 8.28–6.72 (m, 9H), 8.13 (s, 1H), 7.19 (s, 1H), 6.51 (s, 1H), 2.49–2.10 (m, 6H), 2.19 (s, 3H), 1.95 (s, 3H), 1.29 (d, *J* = 1.1 Hz, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C) δ 155.04, 153.02, 152.80, 151.89, 151.32, 147.03, 140.53, 139.82, 138.55, 137.25, 133.69, 133.13, 131.74, 128.84, 127.33, 122.74, 121.67, 81.36, 67.87, 28.65, 21.56, 17.87, 17.82. HRMS (ESI-TOF) *m/z* calc'd for C<sub>32</sub>H<sub>35</sub>ClN<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 528.2412; found: 528.2411.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol, 2.0 mL/min)  $t_r$  = 2.67 min (minor), 3.18 min (major): 89:11 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3-(2-chloroquinolin-6-yl)-5-methylphenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2an)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (87 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2an** (29.5 mg) was obtained in 51% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.38–6.84 (m, 9H), 8.26 (d, *J* = 8.6 Hz, 1H), 8.15 (s, 1H), 7.98 (d, *J* = 8.1 Hz, 1H), 7.45 (d, *J* = 8.6 Hz, 1H), 7.20 (s, 1H), 6.53 (s, 1H), 2.51–2.13 (m, 6H), 2.19 (s, 3H), 1.98 (s, 3H), 1.30 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  155.11, 152.02, 151.49, 148.36, 147.06, 140.88, 140.71, 140.51, 140.31, 139.45, 138.51, 133.62, 133.12, 131.12, 129.83, 128.81, 128.45, 127.66, 126.43, 123.85, 81.30, 68.07, 28.67, 21.63, 17.87. HRMS (ESI-TOF) *m/z* calc'd for C<sub>36</sub>H<sub>37</sub>ClN<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 578.2569; found: 578.2567.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 7.76 min (minor), 8.79 min (major): 90:10 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-((3-methyl-5-(quinoxalin-6-yl)phenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2ao)**

Substrate **1a** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15  $\mu$ mol, 15 mol%), Ligand (6.9 mg, 23  $\mu$ mol, 23 mol%), (*R*)-BNDHP (8.0 mg, 23  $\mu$ mol, 23 mol%), aryl iodide (76.8 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 1:1 v/v), compound **2ao** (25.5 mg) was obtained in 47% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.86 (d, *J* = 1.8 Hz, 1H), 8.83 (d, *J* = 1.8 Hz, 1H), 8.50–6.68 (m, 11H), 7.22–7.18 (m, 1H), 6.54 (s, 1H), 2.54–2.11 (m, 6H), 2.20 (s, 3H), 1.98 (s, 3H), 1.30 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  155.12, 152.02, 147.15, 147.08, 146.50, 144.41, 143.78, 143.52, 140.53, 140.06, 139.56, 138.54, 133.69, 133.15, 131.99, 130.99, 130.46, 128.83, 128.78, 127.81, 127.69, 81.31, 68.04, 28.66, 21.61, 17.87, 17.86. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>37</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 545.2911; found: 545.2919. SFC Chiralpak<sup>®</sup> IC column (25% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 7.87 min (minor), 9.29 min (major): 84:16 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.






**tert-Butyl (S)-((3-(benzo[b]thiophen-2-yl)-5-methylphenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2ap)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (78 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 10:1 v/v), compound **2ap** (33.4 mg) was obtained in 61% yield as a yellow solid.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.35–6.64 (m, 8H), 8.15 (s, 1H), 7.87 (d, *J* = 7.9 Hz, 1H), 7.81 (d, *J* = 7.9 Hz, 1H), 7.37 (t, *J* = 7.5 Hz, 1H), 7.33 (t, *J* = 7.5 Hz, 1H), 7.20 (s, 1H), 6.49 (s, 1H), 2.45–2.13 (m, 6H), 2.19 (s, 3H), 1.99 (s, 3H), 1.30 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  155.06, 151.98, 147.11, 145.43, 142.04, 140.51, 140.47, 139.54, 138.54, 134.72, 133.60, 133.02, 131.82, 130.50, 128.82, 126.51, 125.87, 125.69, 124.81, 123.39, 120.73, 81.35, 67.91, 28.66, 21.54, 17.87. HRMS (ESI-TOF) *m/z* calc'd for C<sub>35</sub>H<sub>37</sub>N<sub>2</sub>O<sub>2</sub>S [M+H]<sup>+</sup>: 549.2570; found: 549.2577.

SFC Chiralpak<sup>®</sup> AD-3 column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 5.01 min (major), 6.48 min (major): 97:3 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**tert-Butyl (S)-(3,5-dimethylpyridin-2-yl)((3-methyl-5-(5-methylthiophen-2-yl)phenyl)(*m*-tolyl)methyl)carbamate (2aq)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (67.2 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 20:1 v/v), compound **2aq** (33.4 mg) was obtained in 65% yield as a yellow solid.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.12 (d, *J* = 2.3 Hz, 1H), 8.03–6.57 (m, 8H), 7.19 (d, *J* = 2.3 Hz, 1H), 6.73 (s, 1H), 6.43 (s, 1H), 2.47 (s, 3H), 2.38–2.10 (m, 6H), 2.19 (s, 3H), 1.97 (s, 3H), 1.29 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  155.05, 152.03, 147.06, 143.14, 140.72, 140.47, 139.25, 138.47, 135.21, 133.53, 132.99, 130.61, 128.72, 127.56, 125.51, 124.22, 81.26, 67.96, 28.66, 21.58, 21.52, 17.86, 15.51. HRMS (ESI-TOF) *m/z* calc'd for C<sub>32</sub>H<sub>37</sub>N<sub>2</sub>O<sub>2</sub>S [M+H]<sup>+</sup>: 513.2570; found: 513.2566.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 4.61 min (minor), 5.44 min (major): 96:4 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.




**Methyl (S)-3-(3-(((tert-butoxycarbonyl)(3,5-dimethylpyridin-2-yl)amino)(*m*-tolyl)methyl)-5-(5-methylthiophen-2-yl)phenyl)carbamate (2ar)**

**methylphenyl)thiophene-2-carboxylate (2ar)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (80.4 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2ar** (36.8 mg) was obtained in 66% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.07 (s, 1H), 7.85–6.52 (m, 8H), 7.61 (d, *J* = 5.4 Hz, 1H), 7.19 (s, 1H), 6.44 (s, 1H), 3.67 (s, 3H), 2.40–2.13 (m, 6H), 2.19 (s, 3H), 1.95 (s, 3H), 1.27 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  163.45, 155.06, 152.04, 149.34, 146.97, 140.48, 138.46, 138.04, 136.48, 133.53, 133.08, 132.57, 131.72, 129.93, 129.51, 128.72, 128.23, 81.23, 68.08, 52.57, 28.64, 21.54, 17.86. HRMS (ESI-TOF) *m/z* calc'd for C<sub>33</sub>H<sub>37</sub>N<sub>2</sub>O<sub>4</sub>S [M+H]<sup>+</sup>: 557.2469; found: 557.2467.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 6.26 min (minor), 7.39 min (major): 89:11 er. The absolute stereochemistry was assigned by analogy to compound **2ah**.


**tert-Butyl (S)-((3-(5-formylfuran-2-yl)-5-methylphenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2as)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (66.6 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **2as** (20.4 mg) was obtained in 40% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  9.59 (s, 1H), 8.11 (s, 1H), 7.81–6.67 (m, 8H), 7.38 (s, 1H), 7.19 (s, 1H), 6.48 (s, 1H), 2.41–2.12 (m, 6H), 2.19 (s, 3H), 1.97 (d, *J* = 3.7 Hz, 3H), 1.29 (s, 5H); <sup>13</sup>C NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  178.42, 160.35, 155.04, 153.50, 151.92, 147.06, 140.52, 139.70, 138.58, 133.63, 133.01, 131.83, 129.91, 128.87, 125.37, 125.25, 123.64, 109.16, 81.43, 67.86, 28.64, 21.54, 17.85, 17.82. HRMS (ESI-TOF) *m/z* calc'd for C<sub>32</sub>H<sub>35</sub>N<sub>2</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 511.2591; found: 511.2586.

SFC Chiralpak<sup>®</sup> OJ-3 column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 2.56 min (minor), 2.99 min (major): 99.8:0.2 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.

**tert-Butyl (S)-((3-methyl-5-(1-tosyl-1H-indol-6-yl)phenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2at)**


Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (119 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2at** (58.1 mg) was obtained in 70% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.39–6.80 (m, 9H), 8.17 (s, 1H), 7.78 (d, *J* = 8.0 Hz, 2H), 7.64 (d, *J* = 3.7 Hz, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.23 (d, *J* = 8.1 Hz, 2H), 7.20 (d, *J* = 2.3 Hz, 1H), 6.74 (d, *J* = 3.7 Hz, 1H), 6.54 (s, 1H), 2.45–2.11 (m, 6H), 2.30 (s, 3H), 2.17 (s, 3H), 2.01 (s, 3H), 1.31 (s, 9H); <sup>13</sup>C NMR

(150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  155.10, 152.12, 147.17, 146.98, 141.59, 140.50, 139.21, 138.48, 136.61, 136.03, 133.51, 133.00, 131.40, 131.26, 128.78, 128.48, 127.95, 127.53, 124.06, 122.98, 112.67, 110.32, 81.30, 68.12, 28.70, 21.72, 21.65, 17.92, 17.89. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{42}H_{44}N_3O_4S$   $[M+H]^+$ : 686.3047; found: 686.3050.

SFC Chiralpak® OJ-3 column (15% isopropanol, 1.0 mL/min)  $t_r$  = 23.56 min (minor), 25.77 min (major): 92:8 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.



**tert-Butyl (S)-((3-methyl-5-(1-tosyl-1H-indol-6-yl)phenyl)(*m*-tolyl)methyl)(3,5-dimethylpyridin-2-yl)carbamate (2au)**

Substrate **1a** was arylated following the general procedure by using (*R*)-BNDHP (5.2 mg, 15  $\mu$ mol, 15 mol%), aryl iodide (119 mg, 0.3 mmol, 3.0 equiv.), and (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%) at 100 °C for 18 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **2au** (40.3 mg) was obtained in 59% yield as a colorless oil.


<sup>1</sup>H NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.39–6.69 (m, 9H), 8.12 (s, 1H), 7.99 (d,  $J$  = 8.6 Hz, 1H), 7.80 (d,  $J$  = 8.0 Hz, 2H), 7.63 (d,  $J$  = 3.7 Hz, 1H), 7.29 (d,  $J$  = 8.1 Hz, 2H), 7.17 (s, 1H), 6.76 (d,  $J$  = 3.7 Hz, 1H), 6.48 (s, 1H), 2.52–2.09 (m, 6H), 2.31 (s, 3H), 2.17 (s, 3H), 1.96 (s, 3H), 1.28 (s, 9H); <sup>13</sup>C NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  155.09, 152.05, 147.03, 141.50, 140.46, 139.10, 138.44, 138.06, 136.17, 135.38, 133.54, 133.07, 132.76, 131.23, 128.76, 128.60, 127.91, 127.51, 125.07, 120.80, 114.88, 110.72, 81.23, 68.08, 28.66, 21.71, 21.61, 17.86. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{42}H_{44}N_3O_4S$   $[M+H]^+$ : 686.3047; found: 686.3048.

SFC Chiralpak® AD-3 column (30% isopropanol, 3.0 mL/min)  $t_r$  = 2.70 min (major), 3.32 min (minor): 94:6 er.

The absolute stereochemistry was assigned by analogy to compound **2ah**.

#### D. Directing Group Cleavage of Desymmetrization Product **2ae**

The directing group was removed following a modified known procedure<sup>38</sup>.



**tert-Butyl (S)-((4'-methoxy-5-methyl-2'-nitro-[1,1'-biphenyl]-3-yl)(*m*-tolyl)methyl)carbamate (s5)**

To a solution of compound **2ae** (28.4 mg, 50  $\mu$ mol, 1 equiv.) in dry DCM (0.5 mL), NaHCO<sub>3</sub> (6.3 mg, 75  $\mu$ mol, 1.5 equiv.) and MeOTf (7.9  $\mu$ L, 70  $\mu$ mol, 1.4 equiv.) were added at 0 °C. The reaction mixture was stirred at room temperature for 5 hours, and then filtered through cotton. The filtrate was evaporated under reduced pressure. The residue was dissolved in MeOH (0.5 mL). Aqueous NaOH solution (6 N, 0.25 mL) was added. The reaction mixture was stirred at 40 °C for 3 hours. Aqueous NH<sub>4</sub>Cl solution was added and extracted with EtOAc. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>. After the organic solvent was


concentrated by rotary evaporation, the residue was purified by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v) to afford 20.9 mg compound **s5** as a colorless oil (90 % yield).

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.33 (d,  $J$  = 2.7 Hz, 1H), 7.29 (d,  $J$  = 8.5 Hz, 1H), 7.22 (t,  $J$  = 7.7 Hz, 1H), 7.11 (dd,  $J$  = 8.5, 2.6 Hz, 1H), 7.08–7.01 (m, 4H), 6.97 (d,  $J$  = 14.0 Hz, 2H), 5.85 (s, 1H), 5.13 (s, 1H), 3.88 (s, 3H), 2.33 (d,  $J$  = 2.8 Hz, 6H), 1.44 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  159.18, 155.19, 149.80, 142.65, 141.88, 138.77, 138.51, 137.55, 132.89, 128.77, 128.68, 128.32, 128.26, 127.85, 124.49, 124.09, 118.71, 109.10, 79.94, 58.41, 56.06, 28.52, 21.60, 21.59. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{27}\text{H}_{30}\text{NaN}_2\text{O}_5$   $[\text{M}+\text{Na}]^+$ : 485.2047; found: 485.2044.

SFC Chiralpak<sup>®</sup> AD-3 column (15% isopropanol, 1.5 mL/min)  $t_r$  = 9.12 min (minor), 9.74 min (major): 94:6 er.

## E. Mechanistic Studies

### 1. Preparation of substrates




Benzylamine (**s6**) was synthesized following the literature procedures<sup>28</sup>.

#### *tert*-Butyl 3-fluoro-6-D-benzyl(3-methylpyridin-2-yl)carbamate (*o*-D-s7)

Aryl bromide **s6** (1.90 g, 4.8 mmol, 1.0 equiv),  $\text{Pd}_2(\text{dba})_3$  (88 mg, 96  $\mu\text{mol}$ , 2 mol%), XPhos (92 mg, 0.19 mmol, 10 mol%), and  $\text{K}_2\text{CO}_3$  (1.66 g, 12 mmol, 2.5 equiv.) were added into a flame-dried Schlenk tube. The Schlenk tube was evacuated and back-filled with nitrogen. Isopropanol-*d*<sub>8</sub> (5 mL) was added to the mixture. The Schlenk tube was immersed into a pre-heated oil bath at 80 °C. After 12 hours, the reaction mixture was filtered through Celite and eluted with EtOAc. After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography (hexanes/EtOAc = 8:1 v/v) to afford 0.456 g compound ***o*-D-s7** as a white solid (30% yield).

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.34 (d,  $J$  = 5.7 Hz, 1H), 7.46 (d,  $J$  = 8.0 Hz, 1H), 7.19 (t,  $J$  = 7.4 Hz, 1H), 7.09 (t,  $J$  = 6.9 Hz, 1H), 6.99 (d,  $J$  = 10.4 Hz, 1H), 6.90 (t,  $J$  = 8.5 Hz, 1H), 5.31–4.52 (m, 2H), 2.00 (s, 3H), 1.41 (d,  $J$  = 15.4 Hz, 9H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  162.81 (d,  $J$  = 245.9 Hz), 153.91, 153.57, 146.53, 140.87, 139.44, 131.50, 129.68 (d,  $J$  = 8.3 Hz), 123.87, 122.41, 115.46, 114.18 (d,  $J$  = 20.9 Hz), 81.03, 51.84, 28.37, 17.62;  $^{19}\text{F}$  NMR (376 MHz, Chloroform-*d*)  $\delta$  -113.72. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{18}\text{H}_{21}\text{DFN}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 318.1723; found: 318.1731.




Benzylamine (**s8**) was synthesized following the literature procedures<sup>28</sup>.

#### *tert*-Butyl 3-fluoro-5-D-benzyl(3-methylpyridin-2-yl)carbamate (*m*-D-s7)

Aryl bromide **s8** (1.19 g, 3.0 mmol, 1.0 equiv),  $\text{Pd}_2(\text{dba})_3$  (55 mg, 60  $\mu\text{mol}$ , 2 mol%), XPhos (57 mg, 0.12 mmol, 10 mol%), and  $\text{K}_2\text{CO}_3$  (1.04 g, 7.5 mmol, 2.5 equiv.) were added into a flame-dried Schlenk tube. The Schlenk tube was evacuated and back-filled with nitrogen. Isopropanol-*d*<sub>8</sub> (5 mL) was added to the mixture. The Schlenk tube was immersed into a pre-heated oil bath at 80 °C. After 12 hours, the reaction mixture was filtered through Celite and eluted with EtOAc. After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography (hexanes/EtOAc = 8:1 v/v) to afford 0.59 g compound ***m*-D-s7** as a white solid (62% yield).

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.34 (dd,  $J = 4.8, 2.1$  Hz, 1H), 7.47 (d,  $J = 7.7$  Hz, 1H), 7.09 (dd,  $J = 7.6, 4.8$  Hz, 1H), 7.05–6.94 (m, 2H), 6.90 (dd,  $J = 8.7, 2.6$  Hz, 1H), 5.26–4.48 (m, 2H), 2.00 (s, 3H), 1.40 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  162.83 (d,  $J = 245.4$  Hz), 153.94, 153.58, 146.54, 141.05, 139.45, 131.52, 129.53 (td,  $J = 24.8, 9.1$  Hz), 124.10, 122.42, 115.51, 114.10 (d,  $J = 20.9$  Hz), 81.04, 51.87, 28.38, 17.64;  $^{19}\text{F}$  NMR (376 MHz, Chloroform-*d*)  $\delta$  -113.72. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{18}\text{H}_{21}\text{DFN}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 318.1723; found: 318.1733.



Diarylmethyl amines (**s1**) was synthesized following the literature procedures<sup>37</sup>.

### **tert-Butyl ((3,5-dimethylphenyl)(*m*-tolyl)methyl)(3-methylpyridin-2-yl)carbamate (**s9**)**

Amine **s1** (0.675 g, 3.0 mmol, 1 equiv.),  $\text{Pd}_2(\text{dba})_3$  (83 mg, 90  $\mu\text{mol}$ , 3 mol%), DavePhos (72 mg, 0.18 mmol, 6 mol%) and  $\text{NaO}^t\text{Bu}$  (0.4 g, 4.2 mmol, 1.4 equiv.) were added to a flame-dried Schlenk tube. The Schlenk tube was evacuated and back-filled with nitrogen. 2-Bromopyridines **s2** (0.52 g, 3 mmol, 1 equiv.) and 1,4-dioxane (9 mL) were added to the mixture. The Schlenk tube was immersed into a pre-heated oil bath at 90 °C. After 2 h, the oil bath was removed, and the Schlenk tube was allowed to cool to room temperature. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with  $\text{Na}_2\text{SO}_4$ . After the organic solvent was concentrated by rotatory evaporation, the residue was purified by silica gel chromatography (hexanes/EtOAc = 20:1 v/v) to afford compound **s3**.


To a solution of compound **s3** in dry THF (30 mL) was added MeMgBr (3.0 M, 1.3 mL, 3.9 mmol, 1.3 equiv.) at 0 °C, and the resulting mixture was allowed to warm up to room temperature and stirred for 30 min. Then  $\text{Boc}_2\text{O}$  (1.96 g, 9 mmol, 3 equiv.) was added into the mixture. The resulting mixture was allowed to warm up to room temperature and stirred for another 12 hours. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with  $\text{Na}_2\text{SO}_4$ . After the organic solvent was concentrated by rotatory evaporation, the residue was purified by silica gel chromatography (hexanes/EtOAc = 20:1 v/v) to afford 0.456 g compound **s9** as a white solid (45% yield).

$^1\text{H}$  NMR (600 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  8.25 (dd,  $J = 4.8, 2.2$  Hz, 1H), 7.69–6.55 (m, 7H), 7.36 (dd,  $J = 7.6, 2.2$  Hz, 1H), 7.03 (dd,  $J = 7.4, 4.8$  Hz, 1H), 6.38 (s, 1H), 2.39–2.02 (m, 9H), 2.00 (s, 3H), 1.26 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile-*d*<sub>3</sub>, 60 °C)  $\delta$  154.61, 154.04, 146.56, 143.55, 140.18, 139.73, 138.31, 137.95, 133.57, 131.73, 129.66, 129.33, 128.98, 128.58, 128.26, 126.80, 126.11, 123.53, 81.00, 67.69, 28.33, 21.50, 21.25, 17.82. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{27}\text{H}_{33}\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : 417.2537; found: 417.2545.

## 2. Measurement of the kinetic isotope effect

Kinetic studies on the *meta*-arylation of **s7**, ***o*-D-s7**, and ***m*-D-s7** were conducted in separate vessels.



Arene (0.05 mmol, 1.0 equiv),  $\text{Pd}(\text{OAc})_2$  (1.1 mg, 5  $\mu\text{mol}$ , 10 mol%), 3,5-diCF<sub>3</sub>-pyridone (1.7 mg, 7.5  $\mu\text{mol}$ , 15 mol%), 4-iodobenzotrifluoride (14.7  $\mu\text{L}$ , 0.1 mmol, 2.0 equiv.), and AgOAc (25 mg, 0.15 mmol, 3.0 equiv.) were added into a 2-dram reaction vial.  $\text{CHCl}_3$  (0.5 mL) and NBE-CO<sub>2</sub>Me (11.4 mg, 75  $\mu\text{mol}$ , 1.5 equiv.) were added to the mixture. The reaction mixture was then stirred at 100 °C for given times. After cooling to room temperature, the mixture was filtered through Celite and eluted with EtOAc (3  $\times$  2 mL). The filtrate was evaporated under reduced pressure. The yield was determined by  $^{19}\text{F}$  NMR analysis of the crude mixture using 1,2-difluorobenzene as an internal standard. All measurements were repeated once.





**Fig. S1.** Determination of the kinetic isotope effect.

### 3. Measurement of reaction rate dependence



Arene, Pd(OAc)<sub>2</sub>, ligand (1.5 equiv. to Pd(OAc)<sub>2</sub>), 4-iodobenzotrifluoride, and AgOAc were added into a 2-dram reaction vial. CHCl<sub>3</sub> and NBE-CO<sub>2</sub>Me were added to the mixture. The reaction mixture was then stirred at 100 °C for given times. After cooling to room temperature, the mixture was filtered through Celite and eluted with EtOAc. The filtrate was evaporated under reduced pressure. The yield was determined by <sup>19</sup>F NMR analysis of the crude mixture using 1,2-difluorobenzene as an internal standard. All measurements were repeated once.



**Fig. S2.** Reaction rate dependence of arene **s7** on aryl iodide using super-stoichiometric NBE-CO<sub>2</sub>Me.



**Fig. S3.** Reaction rate dependence of arene **s7** on aryl iodide using catalytic NBE-CO<sub>2</sub>Me.



**Fig. S4.** Reaction rate dependence of arene **s7** on NBE-CO<sub>2</sub>Me.





Fig. S5. Reaction rate dependence on arene **s7**.





Fig. S6. Reaction rate dependence of arene **s7** on catalyst.







Fig. S7. Reaction rate dependence of arene **s9** on aryl iodide using super-stoichiometric NBE-CO<sub>2</sub>Me.






**Fig. S8.** Reaction rate dependence of arene **s9** on NBE-CO<sub>2</sub>Me.




**Fig. S9.** Proposed catalytic cycle



**tert-Butyl (3,5-dimethylpyridin-2-yl)((5-fluoro-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methyl)carbamate (**s10**)**

Preparative TLC chromatography eluent: hexane/EtOAc = 10:1 v/v.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 8.36 (d, *J* = 5.1 Hz, 1H), 7.67 (d, *J* = 8.1 Hz, 2H), 7.59 (d, *J* = 8.1 Hz, 2H), 7.50 (d, *J* = 7.7 Hz, 1H), 7.30 (s, 1H), 7.15 (d, *J* = 9.5 Hz, 1H), 7.14–7.05 (m, 2H), 4.99 (br d, *J* = 106.1 Hz, 2H), 2.07 (s, 3H), 1.41 (s, 9H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 163.21 (d, *J* = 246.5 Hz), 153.97, 153.59, 146.61, 143.43, 141.71 (d, *J* = 7.9 Hz), 139.53, 130.02 (q, *J* = 32.5 Hz), 129.70, 127.46, 125.96, 124.28 (q, *J* = 272.0 Hz), 122.51, 115.13, 113.09 (d, *J* = 22.6 Hz), 81.22, 51.93, 28.38, 17.73. <sup>19</sup>F NMR (376 MHz, Chloroform-*d*) δ -62.80, -113.10. HRMS (ESI-TOF) *m/z* calc'd for C<sub>25</sub>H<sub>25</sub>F<sub>4</sub>N<sub>2</sub>O<sub>2</sub>[M+H]<sup>+</sup>: 461.1847; found: 461.1853.





***tert*-Butyl ((3,5-dimethylphenyl)(5-methyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methyl)(3-methylpyridin-2-yl)carbamate (s11)**

Preparative TLC chromatography eluent: hexane/EtOAc = 20:1 v/v.

$^1\text{H}$  NMR (600 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  8.29 (dd,  $J$  = 4.9, 1.7 Hz, 1H), 8.14–6.95 (m, 9H), 7.38 (dd,  $J$  = 7.5, 2.0 Hz, 1H), 7.04 (dd,  $J$  = 7.5, 4.7 Hz, 1H), 6.82 (br s, 1H), 6.48 (s, 1H), 2.33 (br s, 3H), 2.18 (br s, 6H), 2.03 (s, 3H), 1.29 (s, 9H);  $^{13}\text{C}$  NMR (150 MHz, Acetonitrile- $d_3$ , 60 °C)  $\delta$  154.99, 154.41, 146.87, 146.18, 140.01, 139.48, 138.44, 133.93, 129.88 (q,  $J$  = 32.1 Hz), 129.58, 128.77, 128.58, 127.46, 126.87, 126.84, 125.83 (q,  $J$  = 271.1 Hz), 123.78, 81.43, 68.01, 28.63, 21.62, 21.47, 17.99;  $^{19}\text{F}$  NMR (376 MHz, Acetonitrile- $d_3$ )  $\delta$  -63.15. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{34}\text{H}_{36}\text{F}_3\text{N}_2\text{O}_2[\text{M}+\text{H}]^+$ : 561.2723; found: 561.2720.

**Hydrogen/deuterium exchange experiment**


Arene (0.05 mmol, 1.0 equiv),  $\text{Pd}(\text{OAc})_2$  (1.1 mg, 5  $\mu\text{mol}$ , 10 mol%), 3,5-di $\text{CF}_3$ -pyridone (1.7 mg, 7.5  $\mu\text{mol}$ , 15 mol%), 4-iodobenzotrifluoride (14.7  $\mu\text{L}$ , 0.1 mmol, 2.0 equiv.), and  $\text{AgOAc}$  (25 mg, 0.15 mmol, 3.0 equiv.) were added into a 2-dram reaction vial.  $\text{CHCl}_3$  (0.5 mL), additive, and  $\text{NBE-CO}_2\text{Me}$  were added to the mixture. The reaction mixture was then stirred at 100 °C for 2 hours. After cooling to room temperature, the mixture was filtered through Celite and eluted with EtOAc (3  $\times$  2 mL). The filtrate was evaporated under reduced pressure. The yield was determined by  $^{19}\text{F}$  NMR and  $^1\text{H}$  NMR analysis of the crude product.



additive	s10	m-D-s7	s7
none	17%	73%	9%
$\text{H}_2\text{O}$ (2 equiv.)	18%	68%	9%

## II. Enantioselective Remote C–H Activation of Homobenzylamines


### A. Preparation of Substrates



Ketones (**s12**) were synthesized following the literature procedures<sup>39</sup>.

**General procedure for synthesis of substrates:** to a solution of ketone **s12** (1 equiv.) in MeOH/DCM (0.15 M, v/v = 5/1), NaBH<sub>3</sub>CN (1 equiv.) and NH<sub>4</sub>OAc (10 equiv.) were added. The reaction flask was stirred at 40 °C overnight. Aqueous NaOH solution (10 wt%) was added into the reaction mixture, which was then extracted with DCM. The combined organic layers were washed with aqueous NaCl solution, and then dried over Na<sub>2</sub>SO<sub>4</sub>. The organic solvent was concentrated by rotary evaporation to afford compound **s13**.

To a solution of crude amine **s13** (1 equiv.) in DCM (0.15 M), NsCl (1.1 equiv.) was added. Then Et<sub>3</sub>N (2.0 equiv.) was added at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred overnight. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>. After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography to afford compound **3**.




**3a**

#### *N*-(1,3-Di-*o*-tolylpropan-2-yl)-4-nitrobenzenesulfonamide (**3a**)

Chromatography eluent: hexane/EtOAc = 8:1 v/v.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 7.99 (d, *J* = 8.9 Hz, 2H), 7.51 (d, *J* = 8.8 Hz, 2H), 7.10 (td, *J* = 7.4, 1.6 Hz, 2H), 7.04 (t, *J* = 7.1 Hz, 2H), 7.02–6.96 (m, 4H), 4.86 (d, *J* = 7.6 Hz, 1H), 3.57 (q, *J* = 7.2 Hz, 1H), 2.88 (d, *J* = 7.2 Hz, 4H), 2.10 (s, 6H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 149.47, 145.41, 136.26, 135.53, 130.82, 130.58, 127.59, 127.20, 126.19, 123.98, 55.50, 39.70, 19.25. HRMS (ESI-TOF) *m/z* calc'd for C<sub>23</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>S[M-H]<sup>-</sup>: 423.1384; found: 423.1383.




**3b**

#### *N*-(1,3-Bis(2-methoxyphenyl)propan-2-yl)-4-nitrobenzenesulfonamide (**3b**)

Chromatography eluent: hexane/EtOAc = 8:1 v/v.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 7.97 (d, *J* = 8.8 Hz, 2H), 7.53 (d, *J* = 8.9 Hz, 2H), 7.17 (ddd, *J* = 8.2, 7.4, 1.8 Hz, 2H), 6.95 (dd, *J* = 7.4, 1.8 Hz, 2H), 6.81–6.74 (m, 4H), 5.37 (d, *J* = 6.6 Hz, 1H), 3.82 (s, 6H), 3.67 (dddd, *J* = 7.8, 6.5, 5.3, 2.4 Hz, 1H), 2.93 (dd, *J* = 13.7, 7.9 Hz, 2H), 2.77 (dd, *J* = 13.7, 5.9 Hz, 2H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 157.42, 149.37, 145.68, 131.44, 128.19, 127.67, 126.25, 123.78, 120.95, 110.64, 56.90, 55.54, 36.25. HRMS (ESI-TOF) *m/z* calc'd for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>6</sub>S[M+H]<sup>+</sup>: 457.1428; found: 457.1435.




**3c**

#### *N*-(1,3-Bis(2-fluorophenyl)propan-2-yl)-4-nitrobenzenesulfonamide (**3c**)

Chromatography eluent: hexane/EtOAc = 8:1 v/v.


$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.00 (d,  $J$  = 8.9 Hz, 2H), 7.59 (d,  $J$  = 8.9 Hz, 2H), 7.15 (tdd,  $J$  = 7.6, 5.3, 1.9 Hz, 2H), 7.06 (td,  $J$  = 7.6, 1.8 Hz, 2H), 6.98 (td,  $J$  = 7.5, 1.2 Hz, 2H), 6.87 (ddd,  $J$  = 9.7, 8.2, 1.2 Hz, 2H), 4.65 (d,  $J$  = 8.5 Hz, 1H), 3.77 (dtd,  $J$  = 13.9, 7.8, 5.9 Hz, 1H), 2.93–2.77 (m, 4H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  161.23 (d,  $J$  = 244.9 Hz, 1H), 149.61, 145.74, 131.87 (d,  $J$  = 4.0 Hz, 1H), 128.98 (d,  $J$  = 8.2 Hz, 1H), 127.73, 124.26 (d,  $J$  = 3.5 Hz, 1H), 124.07, 124.05 (d,  $J$  = 15.5 Hz, 1H), 115.56 (d,  $J$  = 22.1 Hz, 1H), 56.14, 35.28;  $^{19}\text{F}$  NMR (376 MHz, Chloroform-*d*)  $\delta$  -117.50. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{21}\text{H}_{17}\text{F}_2\text{N}_2\text{O}_4\text{S}[\text{M-H}]^-$ : 431.0883; found: 431.0884.



### ***N*-(1,3-Bis(2-chlorophenyl)propan-2-yl)-4-nitrobenzenesulfonamide (3d)**

Chromatography eluent: hexane/EtOAc = 8:1 v/v.


$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.00 (d,  $J$  = 8.8 Hz, 2H), 7.60 (d,  $J$  = 8.9 Hz, 2H), 7.23–7.18 (m, 2H), 7.15–7.09 (m, 6H), 4.89 (d,  $J$  = 8.4 Hz, 1H), 3.96 (dt,  $J$  = 8.3, 7.2 Hz, 1H), 3.01 (d,  $J$  = 7.1 Hz, 4H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  149.54, 145.53, 135.07, 134.28, 131.88, 129.83, 128.55, 127.68, 127.09, 124.02, 55.54, 39.64. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{21}\text{H}_{19}\text{Cl}_2\text{N}_2\text{O}_4\text{S}[\text{M-H}]^-$ : 463.0292; found: 463.0285.



### ***N*-(1,3-Di-*m*-tolylpropan-2-yl)-4-nitrobenzenesulfonamide (3e)**

Chromatography eluent: hexane/EtOAc = 8:1 v/v.


$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.01 (d,  $J$  = 8.9 Hz, 2H), 7.52 (d,  $J$  = 9.0 Hz, 2H), 7.08 (t,  $J$  = 7.5 Hz, 2H), 6.99 (d,  $J$  = 7.7 Hz, 3H), 6.84 (d,  $J$  = 7.6 Hz, 2H), 6.81 (s, 2H), 4.52 (d,  $J$  = 8.0 Hz, 1H), 3.61 (dt,  $J$  = 7.7, 5.7 Hz, 1H), 2.86 (dd,  $J$  = 13.8, 5.8 Hz, 2H), 2.69 (dd,  $J$  = 13.7, 7.3 Hz, 2H), 2.23 (s, 6H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  149.50, 145.73, 138.41, 136.97, 130.29, 128.70, 127.80, 127.70, 126.59, 123.90, 57.66, 41.67, 21.42. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_4\text{S}[\text{M-H}]^-$ : 423.1384; found: 423.1386.



### ***N*-(1,3-Bis(3-(trifluoromethoxy)phenyl)propan-2-yl)-4-nitrobenzenesulfonamide (3f)**

Chromatography eluent: hexane/EtOAc = 8:1 v/v.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.06 (d,  $J$  = 8.9 Hz, 2H), 7.60 (d,  $J$  = 8.9 Hz, 2H), 7.22 (t,  $J$  = 7.9 Hz, 2H), 7.05 (d,  $J$  = 8.3 Hz, 2H), 6.98 (d,  $J$  = 7.6 Hz, 2H), 6.87 (s, 2H), 4.62 (d,  $J$  = 8.4 Hz, 1H), 3.68 (dtd,  $J$  = 13.5, 7.6, 5.7 Hz, 1H), 2.92 (dd,  $J$  = 13.9, 5.7 Hz, 2H), 2.76 (dd,  $J$  = 13.9, 7.4 Hz, 2H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  149.81 (q,  $J$  = 1.7 Hz), 149.46, 145.51, 139.06, 130.21, 127.84, 127.71, 123.02, 121.32, 120.46 (d,  $J$  = 257.6 Hz), 119.57, 57.23, 41.42;  $^{19}\text{F}$  NMR (376 MHz, Chloroform-*d*)  $\delta$  -58.05. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{23}\text{H}_{17}\text{F}_6\text{N}_2\text{O}_6\text{S}[\text{M-H}]^-$ : 563.0717; found: 563.0719.




### ***N*-(1,3-Di(naphthalen-1-yl)propan-2-yl)-4-nitrobenzenesulfonamide (3g)**

Chromatography eluent: hexane/EtOAc = 6:1 v/v.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.70 (d,  $J$  = 8.2 Hz, 3H), 7.68 (d,  $J$  = 8.2 Hz, 3H), 7.44 (d,  $J$  = 8.9 Hz, 1H), 7.41 (d,  $J$  = 8.5 Hz, 2H), 7.38 (ddd,  $J$  = 8.1, 6.8, 1.1 Hz, 2H), 7.33 (dd,  $J$  = 8.2, 6.9 Hz, 2H), 7.24 (dd,  $J$  = 7.0, 1.2 Hz, 2H), 7.21 (ddd,  $J$  = 8.6, 7.0, 1.5 Hz, 2H), 7.18 (d,  $J$  = 9.0 Hz, 1H), 4.66 (d,  $J$  = 6.4 Hz, 1H), 3.90 (h,  $J$  = 7.0 Hz, 1H), 3.34 (dd,  $J$  = 14.1, 7.5 Hz, 2H), 3.27 (dd,  $J$  = 14.1, 6.7 Hz, 2H);  $^{13}\text{C}$  NMR (150 MHz,

Chloroform-*d*)  $\delta$  148.74, 143.66, 134.07, 133.29, 131.44, 128.88, 128.14, 128.10, 126.90, 126.31, 126.05, 125.44, 123.45, 123.09, 54.78, 39.89. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{29}H_{23}N_2O_4S[M-H]^-$ : 495.1384; found: 495.1379.




### ***N*-(1,3-Bis(2-bromo-4-fluorophenyl)propan-2-yl)-4-nitrobenzenesulfonamide (3h)**

Chromatography eluent: hexane/EtOAc = 8:1 v/v.

$^1H$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.08 (d,  $J$  = 8.8 Hz, 1H), 7.62 (d,  $J$  = 8.8 Hz, 2H), 7.12 (dd,  $J$  = 8.1, 2.6 Hz, 2H), 7.09 (dd,  $J$  = 8.5, 5.9 Hz, 2H), 6.87 (td,  $J$  = 8.1, 2.6 Hz, 2H), 4.76 (d,  $J$  = 8.9 Hz, 1H), 3.94 (qt,  $J$  = 8.6, 5.8 Hz, 1H), 2.99 (dd,  $J$  = 14.0, 5.8 Hz, 2H), 2.93 (dd,  $J$  = 14.1, 8.6 Hz, 2H);  $^{13}C$  NMR (150 MHz, Chloroform-*d*)  $\delta$  162.32 (d,  $J$  = 251.4 Hz), 149.66, 145.77, 132.61 (d,  $J$  = 3.8 Hz), 132.57 (d,  $J$  = 8.3 Hz), 127.81, 124.72 (d,  $J$  = 9.4 Hz), 124.03, 120.33 (d,  $J$  = 24.3 Hz), 114.93 (d,  $J$  = 20.9 Hz), 55.73, 41.25;  $^{19}F$  NMR (376 MHz, Chloroform-*d*)  $\delta$  -112.74. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{21}H_{15}Br_2F_2N_2O_4S[M-H]^-$ : 586.9093; found: 586.9088.


Substrates **3i**, **3j**, **3k** and **3l** were synthesized following the literature procedures<sup>29</sup>.



### **Methyl 2-((4-nitrophenyl)sulfonamido)-3-(*o*-tolyl)propanoate (3i)**

Chromatography eluent: hexane/EtOAc = 5:1 v/v.


$^1H$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.16 (d,  $J$  = 8.8 Hz, 2H), 7.75 (d,  $J$  = 8.9 Hz, 2H), 7.10 (td,  $J$  = 7.4, 1.4 Hz, 1H), 7.06–6.98 (m, 2H), 6.94 (dd,  $J$  = 7.6, 1.3 Hz, 1H), 5.41 (d,  $J$  = 7.9 Hz, 1H), 4.22 (td,  $J$  = 8.4, 5.3 Hz, 1H), 3.63 (s, 3H), 3.13 (dd,  $J$  = 14.2, 5.5 Hz, 1H), 2.89 (dd,  $J$  = 14.1, 8.8 Hz, 1H), 2.24 (s, 3H);  $^{13}C$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.79, 149.97, 145.58, 136.58, 133.49, 130.84, 130.31, 128.19, 127.68, 126.31, 124.20, 56.53, 52.95, 36.81, 19.43. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{17}H_{19}N_2O_6S[M+H]^+$ : 379.0958; found: 379.0957.



### **Methyl 3-(naphthalen-1-yl)-2-((4-nitrophenyl)sulfonamido)propanoate (3j)**

Chromatography eluent: hexane/EtOAc = 5:1 v/v.


$^1H$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.80 (d,  $J$  = 8.4 Hz, 1H), 7.77 (d,  $J$  = 8.8 Hz, 2H), 7.70 (dd,  $J$  = 8.1, 1.4 Hz, 1H), 7.65 (d,  $J$  = 8.2 Hz, 1H), 7.47 (ddd,  $J$  = 8.4, 6.8, 1.5 Hz, 1H), 7.43 (ddd,  $J$  = 8.0, 6.8, 1.2 Hz, 1H), 7.38 (d,  $J$  = 8.8 Hz, 2H), 7.27 (dd,  $J$  = 8.2, 7.0 Hz, 1H), 7.27 (d,  $J$  = 6.6 Hz, 1H), 5.35 (d,  $J$  = 9.3 Hz, 1H), 4.33 (td,  $J$  = 9.8, 4.5 Hz, 1H), 3.76 (s, 3H), 3.65 (dd,  $J$  = 14.4, 4.5 Hz, 1H), 3.12 (dd,  $J$  = 14.3, 10.3 Hz, 1H);  $^{13}C$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.86, 149.43, 144.48, 133.95, 131.31, 131.12, 129.06, 128.46, 128.44, 127.54, 126.76, 126.17, 125.44, 123.58, 122.85, 56.42, 53.18, 36.61. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{20}H_{19}N_2O_6S[M+H]^+$ : 415.0958; found: 415.0952.



### **4-Nitro-*N*-(1-(*o*-tolyl)propan-2-yl)benzenesulfonamide (3k)**

Chromatography eluent: hexane/EtOAc = 8:1 v/v.


$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.13 (d,  $J$  = 8.9 Hz, 2H), 7.72 (d,  $J$  = 8.8 Hz, 2H), 7.07 (td,  $J$  = 7.5, 1.4 Hz, 1H), 7.00 (t,  $J$  = 7.4 Hz, 1H), 6.95 (d,  $J$  = 7.5 Hz, 1H), 6.91 (dd,  $J$  = 7.5, 1.4 Hz, 1H), 4.73 (d,  $J$  = 7.7 Hz, 1H), 3.61–3.46 (m, 1H), 2.74 (dd,  $J$  = 14.1, 5.8 Hz, 1H), 2.64 (dd,  $J$  = 14.1, 8.7 Hz, 1H), 2.12 (s, 3H), 1.28 (d,  $J$  = 6.5 Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  149.75, 146.21, 136.21, 135.49, 130.77, 130.31, 127.95, 127.21, 126.25, 124.19, 51.01, 41.19, 22.92, 19.41. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_4\text{S}[\text{M}+\text{H}]^+$ : 335.1060; found: 335.1055.



### Methyl 3-(2-bromophenyl)-2-((4-nitrophenyl)sulfonamido)propanoate (**3i**)

Chromatography eluent: hexane/EtOAc = 5:1 v/v.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.15 (d,  $J$  = 8.8 Hz, 2H), 7.78 (d,  $J$  = 8.8 Hz, 2H), 7.38 (dd,  $J$  = 8.0, 1.2 Hz, 1H), 7.14 (td,  $J$  = 7.4, 1.3 Hz, 1H), 7.10 (dd,  $J$  = 7.6, 1.9 Hz, 1H), 7.04 (td,  $J$  = 7.7, 1.8 Hz, 1H), 5.50 (d,  $J$  = 9.8 Hz, 1H), 4.37 (td,  $J$  = 9.8, 5.2 Hz, 1H), 3.68 (s, 3H), 3.23 (dd,  $J$  = 14.0, 5.3 Hz, 1H), 2.98 (dd,  $J$  = 13.9, 9.8 Hz, 1H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.56, 149.98, 145.49, 134.95, 133.17, 131.95, 129.20, 128.24, 127.76, 124.80, 124.20, 55.93, 53.13, 39.36. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{16}\text{H}_{16}\text{BrN}_2\text{O}_6\text{S}[\text{M}+\text{H}]^+$ : 442.9907; found: 442.9911.




### *N*-(1-((*tert*-Butyldimethylsilyl)oxy)-3-(naphthalen-1-yl)propan-2-yl)-4-nitrobenzenesulfonamide (**3m**)

To a solution of ester **3j** (1.24 g, 3 mmol, 1.0 equiv.) in EtOH/THF (15 mL/15 mL),  $\text{NaBH}_4$  (0.34 g, 9.0 mmol, 3.0 equiv.) was added. The reaction mixture was stirred at room temperature overnight. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were washed with aqueous NaCl solution, and then dried over  $\text{Na}_2\text{SO}_4$ . The organic solvent was concentrated by rotary evaporation to afford compound **s14**.

To a solution of crude alcohol **s14** in THF (20 mL),  $\text{Et}_3\text{N}$  (0.83 mL, 6.0 mmol, 2.0 equiv.), imidazole (0.204 g, 3.0 mmol, 1.0 equiv.) and TBSCl (0.45 g, 3.0 mmol, 1.0 equiv.) were added at 0 °C. The reaction mixture was stirred at room temperature overnight. Aqueous  $\text{NH}_4\text{Cl}$  solution was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with  $\text{Na}_2\text{SO}_4$ . After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography (hexane/EtOAc = 8:1 v/v) to afford 0.92 g compound **3m** as a white solid (61% yield for two steps).

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.73 (d,  $J$  = 7.7 Hz, 1H), 7.66 (d,  $J$  = 8.9 Hz, 2H), 7.63 (dd,  $J$  = 7.5, 1.9 Hz, 1H), 7.59 (d,  $J$  = 8.2 Hz, 1H), 7.39 (dtd,  $J$  = 13.7, 6.8, 1.6 Hz, 2H), 7.32 (d,  $J$  = 8.8 Hz, 2H), 7.25 (dd,  $J$  = 8.0, 6.9 Hz, 1H), 7.11 (d,  $J$  = 6.8 Hz, 1H), 5.02–4.73 (m, 1H), 3.92 (dd,  $J$  = 9.7, 2.9 Hz, 1H), 3.68 (dd,  $J$  = 9.7, 6.3 Hz, 1H), 3.60 (dtt,  $J$  = 13.7, 7.1, 3.8 Hz, 1H), 3.54 (dd,  $J$  = 14.3, 4.6 Hz, 1H), 2.84 (dd,  $J$  = 14.3, 10.1 Hz, 1H), 0.98 (s, 9H), 0.16 (s, 3H), 0.14 (s, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  149.05, 144.59, 133.95, 133.24, 131.39, 128.83, 127.93, 127.88, 127.18, 126.31, 126.03, 125.42, 123.36, 123.30, 66.08, 55.79, 35.83, 26.06, 18.45, -5.19, -5.25. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{25}\text{H}_{33}\text{N}_2\text{O}_5\text{SSi}[\text{M}+\text{H}]^+$ : 501.1874; found: 501.1864.



### *N*-(1-(3,5-Dimethylphenyl)-2-(*o*-tolyl)ethyl)-4-nitrobenzenesulfonamide (**3n**)

To a solution of sulfinyl imine **s15** (3.43 g, 10 mmol, 1.0 equiv.) in dry THF (30 mL), a solution of (2-methylbenzyl)magnesium chloride solution (1 M in Et<sub>2</sub>O, 15 mL, 15 mmol, 1.5 equiv.) was added at 0 °C. The reaction mixture was stirred at room temperature overnight. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>. After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography (hexane/EtOAc = 4:1 v/v) to afford 2.72 g compound **s16** as a colorless liquid (79% yield).


To a solution of compound **s16** (2.72 g, 7.9 mmol, 1 equiv.) in MeOH (30 mL), hydrochloric acid solution (4 M in dioxane, 7.9 mL) was added. The reaction mixture was stirred at room temperature overnight. Aqueous Na<sub>2</sub>CO<sub>3</sub> solution was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>. The organic solvent was concentrated by rotary evaporation to afford compound **s17**.

To a solution of crude amine **s17** in DCM (60 mL), NsCl (1.75 g, 7.9 mmol, 1.0 equiv.) was added. Then Et<sub>3</sub>N (2.2 mL, 15.8 mmol, 2.0 equiv.) was added at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred overnight. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>. After the organic solvent was concentrated by rotary evaporation, the residue was purified by silica gel chromatography (hexane/EtOAc = 6:1 v/v.) to afford 2.71 g compound **3n** as a white solid (81% yield for two steps).

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 8.00 (d, *J* = 8.8 Hz, 2H), 7.56 (d, *J* = 8.8 Hz, 2H), 7.11 (td, *J* = 7.4, 1.3 Hz, 1H), 7.06–7.00 (m, 2H), 6.96 (d, *J* = 7.4 Hz, 1H), 6.80 (s, 1H), 6.66 (s, 2H), 5.20 (d, *J* = 4.0 Hz, 1H), 4.51 (dt, *J* = 9.6, 4.9 Hz, 1H), 3.01 (dd, *J* = 14.4, 5.5 Hz, 1H), 2.90 (dd, *J* = 14.4, 9.3 Hz, 1H), 2.17 (s, 9H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 149.57, 146.05, 140.15, 138.30, 136.51, 134.80, 130.84, 130.13, 129.53, 128.12, 127.39, 126.35, 124.48, 123.64, 58.56, 41.60, 21.27, 19.49. HRMS (ESI-TOF) *m/z* calc'd for C<sub>23</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>SNa[M+Na]<sup>+</sup>: 447.1349; found: 447.1350.

## B. Optimization of the Reaction Conditions

Table S7. Chiral transient mediator screening\*



\*The yields were determined by <sup>1</sup>H-NMR using Cl<sub>2</sub>HC-CHCl<sub>2</sub> as the standard.

Table S8. Additive screening\*

Reaction scheme for Table S8: A chiral homobenzylamine derivative reacts with an iodide-substituted methyl benzoate derivative (1 equiv.) in the presence of 10 mol% Pd(OAc)<sub>2</sub>, 20 mol% pyridine, 15 mol% additive, 50 mol% (+)-NBE-CO<sub>2</sub>Me, AgOAc (3 equiv.), and CHCl<sub>3</sub> at 100 °C to form a desymmetrized product.

additive	yield (%)	er
none	50%	72:28 er
(R)-BNDHP	43%	62:38 er
(S)-BNDHP	46%	62:38 er
Me	45%	66:34
CF <sub>3</sub>	42%	69:31 er
Me	42%	69:31 er
HDQ	26%	64:36 er
(DHQD) <sub>2</sub> PHAL	24%	67:33 er

\*The yields were determined by <sup>1</sup>H-NMR using Cl<sub>2</sub>HC-CHCl<sub>2</sub> as the standard.

Table S9. Ligand and solvent screening\*

Reaction scheme for Table S9: A chiral homobenzylamine derivative reacts with an iodide-substituted methyl benzoate derivative (3 equiv.) in the presence of 10 mol% Pd(OAc)<sub>2</sub>, 20 mol% ligand, 50 mol% (+)-NBE-CO<sub>2</sub>Me, AgOAc (3 equiv.), and solvent at 100 °C to form a desymmetrized product.

ligand	yield (%)	er
pyridine	55%	92:8 er
Me	35%	82:18
Ac	54%	91:9 er
Ph	55%	93:7 er
Me	45%	92:8 er
OH	20%	86:14 er

solvent	yield (%)	er
CHCl <sub>3</sub>	55%	93:7 er
DCE	54%	92:8 er
toluene	46%	90:10 er
TBME	63%	99:1 er
TBME	72%	97:3 er <sup>†</sup>

\*The yields were determined by <sup>1</sup>H-NMR using Cl<sub>2</sub>HC-CHCl<sub>2</sub> as the standard. <sup>†</sup>20 mol% (+)-NBE-CO<sub>2</sub>Me, 90 °C.


Table S10. Additive screening\*

Reaction scheme for Table S10: A chiral homobenzylamine derivative reacts with an iodide-substituted methyl benzoate derivative (3 equiv.) in the presence of x mol% Pd(OAc)<sub>2</sub>, 2x mol% 3-Me-5-Ph-pyridine, 20 mol% (+)-NBE-CO<sub>2</sub>Me, AgOAc (3 equiv.), TBME, 90 °C, N<sub>2</sub>, 24 h to form a desymmetrized product.

loading of Pd(OAc) <sub>2</sub>	result*
10 mol%	71% yield, 97:3 er
5 mol%	70% yield, 97:3 er
2.5 mol%	65% yield, 97:3 er


\*Isolated yield

### C. Pd/(+)-NBE-CO<sub>2</sub>Me Catalyzed Desymmetrization of Homobenzylamines



**General procedure:** Arene **3** (0.10 mmol, 1.0 equiv), Pd(OAc)<sub>2</sub> (2.2 mg, 10 μmol, 10 mol%), 3-methyl-5-phenylpyridine (3.4 mg, 20 μmol, 20 mol%), iodide (0.3 mmol, 3.0 equiv.), and AgOAc (50 mg, 0.30 mmol, 3.0 equiv.) were added into a 2-dram reaction vial. TBME (1 mL) and (+)-NBE-CO<sub>2</sub>Me (20 mol% or 50 mol%) were added to the mixture. The vial was flushed with N<sub>2</sub>, and then capped. The reaction mixture was then stirred at 90 °C for 24 hours. After cooling to room temperature, the mixture was filtered through Celite and eluted with EtOAc (3 × 2 mL). The filtrate was evaporated under reduced pressure. Purification by preparative TLC chromatography afforded the title compound.






**Methyl (R)-4'-methyl-3'-(2-((4-nitrophenyl)sulfonamido)-3-(*o*-tolyl)propyl)-[1,1'-biphenyl]-2-carboxylate (4a)**

Substrate **3a** was arylated following the general procedure by using methyl 2-iodobenzoate (44  $\mu$ L, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20  $\mu$ mol, 20 mol%), and TBME (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 3:1 v/v), compound **4a** (39.7 mg) was obtained in 71% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  7.99 (d,  $J$  = 8.8 Hz, 2H), 7.87 (dd,  $J$  = 7.8, 1.4 Hz, 1H), 7.57 (d,  $J$  = 8.8 Hz, 2H), 7.53 (td,  $J$  = 7.6, 1.4 Hz, 1H), 7.41 (td,  $J$  = 7.6, 1.3 Hz, 1H), 7.30 (dd,  $J$  = 7.7, 1.2 Hz, 1H), 7.11–7.03 (m, 3H), 7.03–6.95 (m, 4H), 4.91 (d,  $J$  = 6.7 Hz, 1H), 3.72 (s, 3H), 3.56 (q,  $J$  = 7.0 Hz, 1H), 3.02–2.82 (m, 4H), 2.11 (s, 3H), 2.04 (s, 3H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*)  $\delta$  168.77, 149.51, 145.49, 142.39, 139.12, 136.29, 135.68, 135.39, 134.76, 131.71, 131.23, 130.96, 130.80, 130.70, 130.59, 130.28, 130.20, 127.98, 127.40, 127.24, 127.15, 126.17, 124.01, 54.83, 52.35, 39.76, 39.52, 19.33, 18.96. HRMS (ESI-TOF)  $m/z$  calc'd for C<sub>31</sub>H<sub>31</sub>N<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup>: 559.1897; found: 559.1904.

SFC Chiralpak<sup>®</sup> OJ-3 column (25% isopropanol, 2.0 mL/min)  $t_r$  = 3.09 min (minor), 4.57 min (major): 97:3 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (R)-4'-methoxy-3'-(3-(2-methoxyphenyl)-2-((4-nitrophenyl)sulfonamido)propyl)-[1,1'-biphenyl]-2-carboxylate (4b)**

Substrate **3b** was arylated following the general procedure by using methyl 2-iodobenzoate (44  $\mu$ L, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4b** (45.0 mg) was obtained in 76% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  7.98 (d,  $J$  = 8.7 Hz, 2H), 7.81 (dd,  $J$  = 7.8, 1.4 Hz, 1H), 7.58 (d,  $J$  = 8.7 Hz, 2H), 7.51 (td,  $J$  = 7.6, 1.4 Hz, 1H), 7.38 (td,  $J$  = 7.7, 1.3 Hz, 1H), 7.27 (dd,  $J$  = 7.8, 1.1 Hz, 1H), 7.16–7.09 (m, 2H), 7.01 (d,  $J$  = 2.3 Hz, 1H), 6.91 (dd,  $J$  = 7.4, 1.7 Hz, 1H), 6.77 (d,  $J$  = 8.3 Hz, 1H), 6.73 (t,  $J$  = 7.4 Hz, 1H), 6.70 (d,  $J$  = 8.1 Hz, 1H), 5.39 (d,  $J$  = 6.6 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.75–3.70 (m, 1H), 3.68 (s, 3H), 2.97 (dd,  $J$  = 13.7, 7.3 Hz, 1H), 2.89–2.81 (m, 2H), 2.76 (dd,  $J$  = 13.8, 5.5 Hz, 1H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*)  $\delta$  169.03, 157.37, 156.94, 149.38, 145.91, 142.01, 133.75, 131.78, 131.49, 131.43, 130.82, 130.53, 130.05, 128.16, 128.05, 127.88, 127.08, 126.24, 125.68, 123.78, 110.56, 110.23, 56.34, 55.54, 55.49, 52.18, 36.74, 35.77. HRMS (ESI-TOF)  $m/z$  calc'd for C<sub>31</sub>H<sub>31</sub>N<sub>2</sub>O<sub>8</sub>S [M+H]<sup>+</sup>: 591.1796; found: 591.1801.

SFC Chiralpak<sup>®</sup> AD-3 column (40% isopropanol, 3.0 mL/min)  $t_r$  = 2.84 min (minor), 4.41 min (major): 87:13 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (R)-4'-fluoro-3'-(3-(2-fluorophenyl)-2-((4-nitrophenyl)sulfonamido)propyl)-[1,1'-biphenyl]-2-carboxylate (4c)**

Substrate **3c** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15 μmol, 15 mol%), ligand (5.1 mg, 30 μmol, 30 mol%), methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4c** (33.8 mg) was obtained in 60% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 8.03 (d, *J* = 8.9 Hz, 2H), 7.91 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.66 (d, *J* = 8.8 Hz, 2H), 7.54 (td, *J* = 7.5, 1.4 Hz, 1H), 7.43 (td, *J* = 7.7, 1.3 Hz, 1H), 7.28 (d, *J* = 1.2 Hz, 1H), 7.16–7.09 (m, 3H), 7.07 (td, *J* = 7.5, 1.8 Hz, 1H), 6.95 (td, *J* = 7.4, 1.2 Hz, 1H), 6.89 (t, *J* = 9.4 Hz, 1H), 6.83 (ddd, *J* = 9.8, 8.2, 1.2 Hz, 1H), 4.96 (d, *J* = 8.3 Hz, 1H), 3.86–3.79 (m, 1H), 3.73 (s, 3H), 2.99–2.87 (m, 3H), 2.82 (dd, *J* = 14.0, 8.3 Hz, 1H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 168.41, 161.21 (d, *J* = 244.9 Hz), 160.70 (d, *J* = 245.7 Hz), 149.60, 145.91, 141.71, 137.59 (d, *J* = 3.8 Hz), 132.45 (d, *J* = 4.8 Hz), 131.92 (d, *J* = 4.7 Hz), 131.84, 130.98, 130.46, 130.05, 128.89 (d, *J* = 3.7 Hz), 128.84 (d, *J* = 3.3 Hz), 127.92, 127.70, 124.35 (d, *J* = 3.5 Hz), 124.26 (d, *J* = 15.5 Hz), 124.08, 123.21 (d, *J* = 16.4 Hz), 115.46 (d, *J* = 22.2 Hz), 115.14 (d, *J* = 22.6 Hz), 55.63, 52.28, 35.46, 34.86; <sup>19</sup>F NMR (376 MHz, Chloroform-*d*) δ -117.59, -119.70. HRMS (ESI-TOF) *m/z* calc'd for C<sub>29</sub>H<sub>25</sub>F<sub>2</sub>N<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup>: 567.1396; found: 567.1398.

SFC Chiralpak<sup>®</sup> OJ-3 column (25% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 3.27 min (minor), 3.54 min (major): 86:14 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (R)-4'-chloro-3'-(3-(2-chlorophenyl)-2-((4-nitrophenyl)sulfonamido)propyl)-[1,1'-biphenyl]-2-carboxylate (4d)**

Substrate **3d** was arylated following the general procedure by using methyl 2-iodobenzoate (44 μL, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (hexane/Et<sub>2</sub>O/DCM = 4:4:3 v/v/v), compound **4d** (41.6 mg) was obtained in 69% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 8.00 (d, *J* = 8.8 Hz, 2H), 7.93 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.64 (d, *J* = 8.8 Hz, 2H), 7.55 (td, *J* = 7.6, 1.4 Hz, 1H), 7.44 (t, *J* = 7.4 Hz, 1H), 7.29 (d, *J* = 7.6 Hz, 1H), 7.20 (d, *J* = 8.2 Hz, 1H), 7.18 (d, *J* = 2.2 Hz, 1H), 7.14 (dd, *J* = 7.2, 2.0 Hz, 1H), 7.11–7.05 (m, 4H), 5.04 (d, *J* = 7.9 Hz, 1H), 4.04–3.94 (m, 1H), 3.74 (s, 3H), 3.09–2.92 (m, 4H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 168.33, 149.56, 145.65, 141.53, 140.32, 135.25, 134.28, 134.15, 133.38, 132.46, 131.96, 131.94, 130.94, 130.57, 129.88, 129.76, 129.44, 128.55, 128.45, 127.96, 127.90, 127.00, 124.03, 54.83, 52.38, 39.71, 39.15. HRMS (ESI-TOF) *m/z* calc'd for C<sub>29</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup>: 599.0805; found: 599.0809.

SFC Chiralpak<sup>®</sup> AD-3 column (30% isopropanol, 3.0 mL/min) *t*<sub>r</sub> = 3.34 min (minor), 5.65 min (major): 95:5 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (R)-3'-methyl-5'-(2-((4-nitrophenyl)sulfonamido)-3-(*m*-tolyl)propyl)-[1,1'-biphenyl]-2-carboxylate (4e)**

Substrate **3e** was arylated following the general procedure by using methyl 2-iodobenzoate (20.5 μL, 0.14 mmol, 1.4 equiv.), (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%), and TBME (1.5 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 3:1 v/v), compound **4e** (30.5 mg) was obtained in 55% yield as a white solid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.03 (d,  $J$  = 8.8 Hz, 2H), 7.87 (dd,  $J$  = 7.8, 1.3 Hz, 1H), 7.61 (d,  $J$  = 8.8 Hz, 2H), 7.54 (td,  $J$  = 7.6, 1.4 Hz, 1H), 7.42 (td,  $J$  = 7.6, 1.2 Hz, 1H), 7.31 (dd,  $J$  = 7.7, 1.0 Hz, 1H), 7.06 (t,  $J$  = 7.5 Hz, 1H), 7.00 (s, 1H), 6.97 (d,  $J$  = 7.6 Hz, 1H), 6.88 (s, 1H), 6.85 (d,  $J$  = 7.6 Hz, 1H), 6.82 (s, 1H), 6.78 (s, 1H), 4.78 (d,  $J$  = 7.6 Hz, 1H), 3.72 (s, 3H), 3.64 (q,  $J$  = 6.7, 6.0 Hz, 1H), 2.92 (dd,  $J$  = 13.7, 5.8 Hz, 1H), 2.84 (dd,  $J$  = 13.8, 5.8 Hz, 1H), 2.76 (dd,  $J$  = 13.7, 6.7 Hz, 1H), 2.69 (dd,  $J$  = 13.8, 7.6 Hz, 1H), 2.26 (s, 3H), 2.22 (s, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  168.72, 149.50, 145.89, 142.64, 141.61, 138.32, 138.24, 137.23, 136.22, 131.66, 130.89, 130.28, 130.23, 129.13, 128.64, 128.04, 127.78, 127.60, 127.46, 127.42, 126.57, 123.92, 57.36, 52.27, 41.52, 41.31, 21.43, 21.40. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{31}\text{H}_{30}\text{NaN}_2\text{O}_6\text{S}$   $[\text{M}+\text{Na}]^+$ : 581.1717; found: 581.1725.

SFC Chiralpak<sup>®</sup> OD-3 column (30% isopropanol, 2.0 mL/min)  $t_r$  = 4.46 min (major), 5.78 min (minor): 88:12 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (R)-3'-((4-nitrophenyl)sulfonamido)-3-(3-(trifluoromethoxy)phenyl)propyl-5'-(trifluoromethoxy)-[1,1'-biphenyl]-2-carboxylate (4f)**

Substrate **3f** was arylated following the general procedure by using methyl 2-iodobenzoate (44  $\mu\text{L}$ , 0.30 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20  $\mu\text{mol}$ , 20 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (hexane/Et<sub>2</sub>O = 1:2 v/v), compound **4f** (40.0 mg) was obtained in 57% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.08 (d,  $J$  = 8.8 Hz, 2H), 7.98 (dd,  $J$  = 7.8, 1.3 Hz, 1H), 7.66 (d,  $J$  = 8.9 Hz, 2H), 7.58 (td,  $J$  = 7.5, 1.4 Hz, 1H), 7.48 (td,  $J$  = 7.7, 1.3 Hz, 1H), 7.30 (dd,  $J$  = 7.6, 1.3 Hz, 1H), 7.19 (t,  $J$  = 7.9 Hz, 1H), 7.07 (d,  $J$  = 1.6 Hz, 1H), 7.05–7.00 (m, 2H), 6.99 (d,  $J$  = 7.8 Hz, 1H), 6.89 (s, 1H), 6.82 (s, 1H), 4.94 (d,  $J$  = 8.1 Hz, 1H), 3.76 (s, 3H), 3.73 (td,  $J$  = 8.1, 4.1 Hz, 1H), 3.02 (dd,  $J$  = 13.8, 5.5 Hz, 1H), 2.90 (dd,  $J$  = 13.9, 5.6 Hz, 1H), 2.80 (dd,  $J$  = 13.9, 6.6 Hz, 1H), 2.70 (dd,  $J$  = 13.9, 8.0 Hz, 1H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  167.99, 149.81, 149.38, 149.11, 145.68, 143.63, 141.31, 139.45, 137.73, 132.14, 130.90, 130.80, 130.09, 129.70, 128.98, 128.29, 127.88, 127.82, 124.15, 122.05, 120.48 (q,  $J$  = 258.1 Hz), 120.25 (q,  $J$  = 256.0 Hz), 120.44, 119.74, 119.42, 56.76, 52.38, 41.33, 40.91;  $^{19}\text{F}$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -58.07, -58.10. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{31}\text{H}_{25}\text{F}_6\text{N}_2\text{O}_8\text{S}$   $[\text{M}+\text{H}]^+$ : 699.1230; found: 699.1214.

SFC Chiralpak<sup>®</sup> AD-3 column (10% isopropanol, 2.0 mL/min)  $t_r$  = 4.84 min (minor), 6.02 min (major): 90:10 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.



**Methyl (R)-4'-chloro-3'-(3-(2-chlorophenyl)-2-((4-nitrophenyl)sulfonamido)propyl)-[1,1'-biphenyl]-2-carboxylate (4g)**


Substrate **3g** was arylated following the general procedure by using methyl 2-iodobenzoate (44  $\mu\text{L}$ , 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20  $\mu\text{mol}$ , 20 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (toluene/DCM/Et<sub>2</sub>O = 2:1:1 v/v/v), compound **4g** (44.5 mg) was obtained in 71% yield as a yellow liquid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.99 (dd,  $J$  = 7.8, 1.4 Hz, 1H), 7.77 (d,  $J$  = 8.3 Hz, 2H), 7.71 (d,  $J$  = 8.1 Hz, 1H), 7.68 (d,  $J$  = 8.2 Hz, 1H), 7.65 (d,  $J$  = 1.7 Hz, 1H), 7.60 (td,  $J$  = 7.5, 1.4 Hz, 1H), 7.51–7.41 (m, 5H), 7.36 (dd,  $J$  = 12.5, 8.4 Hz, 4H), 7.30 (dt,  $J$  = 7.5, 4.2 Hz, 2H), 7.25 (d,  $J$  = 1.8 Hz, 1H), 7.17 (d,  $J$  = 8.4 Hz,

1H), 7.08 (t,  $J = 7.6$  Hz, 1H), 4.99 (d,  $J = 5.1$  Hz, 1H), 3.90 (q,  $J = 7.1$  Hz, 1H), 3.75 (s, 3H), 3.66–3.57 (m, 1H), 3.32–3.24 (m, 2H), 3.16 (dd,  $J = 14.3, 8.6$  Hz, 1H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform- $d$ )  $\delta$  168.49, 148.80, 143.77, 142.62, 138.57, 134.11, 134.04, 133.69, 132.12, 131.94, 131.67, 131.42, 130.68, 130.34, 130.06, 129.84, 128.99, 128.91, 128.20, 128.03, 127.79, 127.38, 126.85, 126.31, 126.29, 126.16, 126.03, 125.48, 123.79, 123.21, 54.50, 52.58, 40.32, 39.29. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{37}\text{H}_{30}\text{NaN}_2\text{O}_6\text{S}$   $[\text{M}+\text{Na}]^+$ : 653.1717; found: 653.1720.

SFC Chiralpak<sup>®</sup> AD-3 column (40% isopropanol, 2.0 mL/min)  $t_r = 5.37$  min (minor), 8.26 min (major): 98:2 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (*R*)-4'-bromo-5'-(3-(2-bromo-4-fluorophenyl)-2-((4-nitrophenyl)sulfonamido)propyl)-2'-fluoro-[1,1'-biphenyl]-2-carboxylate (**4h**)**

Substrate **3h** was arylated following the general procedure by using methyl 2-iodobenzoate (44  $\mu\text{L}$ , 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (toluene/EtOAc = 6:1 v/v), compound **4h** (43.5 mg) was obtained in 60% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Chloroform- $d$ )  $\delta$  8.10 (d,  $J = 8.8$  Hz, 2H), 8.02 (dd,  $J = 7.8, 1.4$  Hz, 1H), 7.68 (d,  $J = 8.8$  Hz, 2H), 7.59 (td,  $J = 7.6, 1.5$  Hz, 1H), 7.49 (td,  $J = 7.7, 1.3$  Hz, 1H), 7.28 (dd,  $J = 7.6, 1.3$  Hz, 1H), 7.16 (dd,  $J = 8.2, 2.0$  Hz, 2H), 7.10–7.04 (m, 2H), 6.83 (td,  $J = 8.2, 2.7$  Hz, 1H), 5.01 (d,  $J = 8.6$  Hz, 1H), 3.99 (dt,  $J = 8.5, 5.7$  Hz, 1H), 3.79 (s, 3H), 3.04 (ddd,  $J = 21.5, 14.0, 5.6$  Hz, 2H), 2.98–2.89 (m, 2H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform- $d$ )  $\delta$  167.52, 161.42 (d,  $J = 251.0$  Hz), 158.19 (d,  $J = 250.9$  Hz), 149.69, 145.76, 135.41, 133.47 (d,  $J = 4.0$  Hz), 132.79 (d,  $J = 3.8$  Hz), 132.62 (d,  $J = 8.1$  Hz), 132.36, 132.79 (d,  $J = 3.5$  Hz), 131.46, 130.65, 130.23, 128.88 (d,  $J = 15.9$  Hz), 128.65, 128.06, 124.70 (d,  $J = 9.1$  Hz), 124.12, 123.59 (d,  $J = 9.4$  Hz), 120.21 (d,  $J = 24.2$  Hz), 119.89 (d,  $J = 25.8$  Hz), 114.80 (d,  $J = 20.7$  Hz), 55.05, 52.42, 41.34, 40.79;  $^{19}\text{F}$  NMR (376 MHz, Chloroform- $d$ )  $\delta$  -112.99, -115.98. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{29}\text{H}_{23}\text{Br}_2\text{F}_2\text{N}_2\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$ : 722.9606; found: 722.9599.

SFC Chiralpak<sup>®</sup> OJ-3 column (30% isopropanol, 2.0 mL/min)  $t_r = 3.96$  min (minor), 4.40 min (major): 92:8 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.



**(*R*)-*N*-(1-(4-methyl-2'-nitro-[1,1'-biphenyl]-3-yl)-3-(*o*-tolyl)propan-2-yl)-4-nitrobenzenesulfonamide (**4i**)**


Substrate **3a** was arylated following the general procedure by using 1-iodo-2-nitrobenzene (74.5 mg, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20  $\mu\text{mol}$ , 20 mol%), and TBME (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4i** (35.5 mg) was obtained in 65% yield as a white solid.

$^1\text{H}$  NMR (600 MHz, Chloroform- $d$ )  $\delta$  7.99 (d,  $J = 8.9$  Hz, 2H), 7.83 (d,  $J = 8.0$  Hz, 1H), 7.61 (t,  $J = 7.4$  Hz, 1H), 7.54 (d,  $J = 8.9$  Hz, 2H), 7.48 (t,  $J = 7.7$  Hz, 1H), 7.39 (d,  $J = 7.6$  Hz, 1H), 7.11 (d,  $J = 1.1$  Hz, 2H), 7.07 (s, 1H), 7.03 (t,  $J = 7.3$  Hz, 1H), 6.96 (t,  $J = 7.3$  Hz, 1H), 6.92 (d,  $J = 7.5$  Hz, 1H), 6.89 (d,  $J = 7.4$  Hz, 1H), 4.82 (d,  $J = 7.4$  Hz, 1H), 3.55 (h,  $J = 7.2$  Hz, 1H), 3.06 (dd,  $J = 13.8, 6.4$  Hz, 1H), 2.94–2.82 (m, 2H), 2.68 (dd,  $J = 14.1, 9.1$  Hz, 1H), 2.22 (s, 3H), 1.99 (s, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform- $d$ )  $\delta$  149.55, 149.41, 145.33, 136.69, 136.25, 136.05, 135.79, 135.41, 135.32, 132.48, 131.87, 131.29, 130.79, 130.47, 130.20,

128.33, 127.78, 127.19, 126.69, 126.20, 124.22, 124.04, 55.34, 40.38, 38.76, 19.29, 19.11. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{29}H_{28}N_3O_6S$   $[M+H]^+$ : 546.1693; found: 546.1694.

SFC Chiralpak<sup>®</sup> OJ-3 column (10% isopropanol, 2.0 mL/min)  $t_r$  = 23.64 min (minor), 24.81 min (major): 99:1 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**(R)-N-(1-(4'-(2-chloroethoxy)-4-methyl-[1,1'-biphenyl]-3-yl)-3-(*o*-tolyl)propan-2-yl)-4-nitrobenzenesulfonamide (**4j**)**

Substrate **3a** was arylated following the general procedure by using  $Pd(OAc)_2$  (3.3 mg, 15  $\mu$ mol, 15 mol%), 4-acetylpyridine as ligand (3.3  $\mu$ L, 30  $\mu$ mol, 30 mol%), diethyl (4-iodobenzyl)phosphonate (106 mg, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%), and TBME (0.3 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 1:6 v/v), compound **4j** (39.0 mg) was obtained in 60% yield as a yellow solid.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  7.85 (d,  $J$  = 8.8 Hz, 2H), 7.45 (d,  $J$  = 8.8 Hz, 2H), 7.41 (d,  $J$  = 7.9 Hz, 2H), 7.35 (dd,  $J$  = 8.3, 2.5 Hz, 2H), 7.22 (dd,  $J$  = 7.9, 2.0 Hz, 1H), 7.17 (d,  $J$  = 2.0 Hz, 1H), 7.11–6.98 (m, 4H), 6.96 (d,  $J$  = 7.9 Hz, 1H), 5.57 (d,  $J$  = 8.1 Hz, 1H), 4.14–3.98 (m, 4H), 3.61 (q,  $J$  = 7.3 Hz, 1H), 3.21 (s, 1H), 3.18 (s, 1H), 2.95 (dd,  $J$  = 13.7, 7.2 Hz, 1H), 2.91–2.74 (m, 3H), 2.15 (s, 3H), 2.05 (s, 3H), 1.34–1.17 (m, 6H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  149.25, 145.88, 138.96 (d,  $J$  = 3.8 Hz), 138.24 (d,  $J$  = 1.4 Hz), 136.35, 136.28, 135.72, 135.34, 131.16, 130.79, 130.74 (d,  $J$  = 11.4 Hz), 130.73, 130.38 (d,  $J$  = 6.2 Hz), 129.08, 127.36, 127.15, 126.85, 126.83, 126.14, 125.33, 123.82, 62.40 (dd,  $J$  = 6.8, 1.6 Hz), 55.56, 40.24, 39.47, 33.41 (d,  $J$  = 138.3 Hz), 19.38, 18.80, 16.55 (d,  $J$  = 6.0 Hz). HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{34}H_{40}N_2O_7PS$   $[M+H]^+$ : 651.2288; found: 651.2285.

SFC Chiralpak<sup>®</sup> OJ-3 column (20% isopropanol, 2.0 mL/min)  $t_r$  = 6.51 min (major), 8.58 min (minor): 96:4 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**(R)-N-(1-(4'-(2-chloroethoxy)-4-methyl-[1,1'-biphenyl]-3-yl)-3-(*o*-tolyl)propan-2-yl)-4-nitrobenzenesulfonamide (**4k**)**

Substrate **3a** was arylated following the general procedure by using  $Pd(OAc)_2$  (3.3 mg, 15  $\mu$ mol, 15 mol%), 4-acetylpyridine as ligand (3.3  $\mu$ L, 30  $\mu$ mol, 30 mol%), 1-(2-chloroethoxy)-4-iodobenzene (85 mg, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **4k** (33.6 mg) was obtained in 58% yield as a yellow solid.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  7.88 (d,  $J$  = 8.8 Hz, 2H), 7.45 (d,  $J$  = 8.8 Hz, 2H), 7.41 (d,  $J$  = 8.9 Hz, 2H), 7.22 (dd,  $J$  = 7.8, 2.0 Hz, 1H), 7.15–7.08 (m, 2H), 7.08–7.01 (m, 3H), 6.95 (dd,  $J$  = 15.1, 8.4 Hz, 3H), 4.96 (d,  $J$  = 8.0 Hz, 1H), 4.26 (t,  $J$  = 5.8 Hz, 2H), 3.84 (t,  $J$  = 5.9 Hz, 2H), 3.62 (td,  $J$  = 7.9, 5.7 Hz, 1H), 2.99 (dd,  $J$  = 13.8, 7.0 Hz, 1H), 2.95–2.86 (m, 2H), 2.80 (dd,  $J$  = 14.1, 8.5 Hz, 1H), 2.18 (s, 3H), 2.04 (s, 3H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*)  $\delta$  157.88, 149.37, 145.43, 138.24, 136.36, 136.00, 135.51, 134.75, 133.45, 131.25, 130.86, 130.69, 128.61, 127.79, 127.41, 127.26, 126.23, 125.12, 123.90, 115.23, 68.25, 55.61, 42.02,

40.33, 39.48, 19.43, 18.78. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{31}H_{30}ClN_2O_5S$   $[M-H]^-$ : 577.1569; found: 577.1561.

SFC Chiralpak<sup>®</sup> OJ-3 column (40% isopropanol, 2.5 mL/min)  $t_r$  = 6.01 min (minor), 7.36 min (major): 91:9 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**(R)-N-(1-(4-methyl-3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-3-(*o*-tolyl)propan-2-yl)-4-nitrobenzenesulfonamide (**4l**)**

Substrate **3a** was arylated following the general procedure by using 1-iodo-3,5-bis(trifluoromethyl)benzene (53  $\mu$ L, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **4l** (40.0 mg) was obtained in 63% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  7.96–7.89 (m, 4H), 7.84 (s, 1H), 7.49 (d,  $J$  = 8.8 Hz, 2H), 7.36 (dd,  $J$  = 7.8, 2.1 Hz, 1H), 7.27 (d,  $J$  = 2.1 Hz, 1H), 7.19 (d,  $J$  = 7.9 Hz, 1H), 7.07 (td,  $J$  = 7.4, 1.5 Hz, 1H), 7.00 (t,  $J$  = 7.7 Hz, 1H), 6.96–6.92 (m, 2H), 4.75 (d,  $J$  = 8.1 Hz, 1H), 3.69 (td,  $J$  = 7.8, 5.8 Hz, 1H), 3.06 (dd,  $J$  = 13.9, 7.3 Hz, 1H), 2.97 (dd,  $J$  = 13.9, 6.9 Hz, 1H), 2.90 (dd,  $J$  = 14.0, 5.8 Hz, 1H), 2.77 (dd,  $J$  = 14.0, 8.6 Hz, 1H), 2.26 (s, 3H), 2.05 (s, 3H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*)  $\delta$  149.51, 145.65, 142.60, 137.54, 136.87, 136.14, 135.97, 135.23, 132.34 (q,  $J$  = 33.2 Hz), 131.83, 130.93, 130.53, 129.35, 127.50, 127.40, 126.88, 126.35, 125.83, 123.48 (q,  $J$  = 272.9 Hz), 123.97, 121.03 (hept,  $J$  = 3.7 Hz), 55.49, 40.50, 39.52, 19.23; <sup>19</sup>F NMR (376 MHz, Chloroform-*d*)  $\delta$  -63.08. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{31}H_{25}F_6N_2O_4S$   $[M-H]^-$ : 635.1445; found: 635.1439.

SFC Chiralpak<sup>®</sup> OD-3 column (20% isopropanol, 2.0 mL/min)  $t_r$  = 3.17 min (minor), 4.38 min (major): 95:5 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**(R)-N-(1-(5-(2-chloropyridin-4-yl)-2-methylphenyl)-3-(*o*-tolyl)propan-2-yl)-4-nitrobenzenesulfonamide (**4m**)**

Substrate **3a** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15  $\mu$ mol, 15 mol%), 4-acetylpyridine as ligand (3.3  $\mu$ L, 30  $\mu$ mol, 30 mol%), 2-chloro-4-iodopyridine (50 mg, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu$ mol, 50 mol%), and TBME (0.5 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4m** (24.1 mg) was obtained in 45% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  8.40 (d,  $J$  = 5.1 Hz, 1H), 7.92 (d,  $J$  = 8.8 Hz, 2H), 7.49 (d,  $J$  = 8.9 Hz, 2H), 7.45 (d,  $J$  = 1.2 Hz, 1H), 7.38–7.32 (m, 2H), 7.28 (d,  $J$  = 2.0 Hz, 1H), 7.14 (d,  $J$  = 7.8 Hz, 1H), 7.07 (t,  $J$  = 7.4 Hz, 1H), 7.01 (t,  $J$  = 7.3 Hz, 1H), 6.97 (t,  $J$  = 7.1 Hz, 2H), 5.13 (d,  $J$  = 8.2 Hz, 1H), 3.67 (h,  $J$  = 7.4 Hz, 1H), 3.03–2.92 (m, 2H), 2.89 (dd,  $J$  = 13.9, 6.2 Hz, 1H), 2.83 (dd,  $J$  = 13.9, 8.2 Hz, 1H), 2.21 (s, 3H), 2.08 (s, 3H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*)  $\delta$  152.22, 150.71, 150.08, 149.29, 145.56, 138.36, 136.74, 136.00, 135.13, 134.26, 131.59, 130.73, 130.40, 129.09, 127.27, 127.19, 126.15, 125.39, 123.80, 121.49, 119.98, 55.36, 40.02, 39.56, 19.13, 19.07. HRMS (ESI-TOF)  $m/z$  calc'd for  $C_{28}H_{27}ClN_3O_4S$   $[M+H]^+$ : 536.1405; found: 536.1408.

SFC Chiralpak® OJ-3 column (30% isopropanol, 2.0 mL/min)  $t_r$  = 4.68 min (major), 10.34 min (minor): 92:8 er.

The absolute stereochemistry was determined by X-ray crystallography.




**(R)-N-(1-(5-(5-formylfuran-2-yl)-2-methylphenyl)-3-(*o*-tolyl)propan-2-yl)-4-nitrobenzenesulfonamide (4n)**

Substrate **3a** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15 μmol, 15 mol%), 4-acetylpyridine as ligand (3.3 μL, 30 μmol, 30 mol%), 5-iodofuran-2-carbaldehyde (66.6 mg, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%), and TBME (0.3 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4n** (27.4 mg) was obtained in 53% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 9.62 (s, 1H), 7.84 (d, *J* = 8.8 Hz, 2H), 7.48 (d, *J* = 8.8 Hz, 2H), 7.41 (d, *J* = 1.9 Hz, 1H), 7.37 (dd, *J* = 7.9, 1.9 Hz, 1H), 7.30 (d, *J* = 3.7 Hz, 1H), 7.13–7.09 (m, 1H), 7.08–7.05 (m, 2H), 7.04 (d, *J* = 7.7 Hz, 2H), 6.70 (d, *J* = 3.7 Hz, 1H), 5.25 (d, *J* = 8.5 Hz, 1H), 3.73–3.65 (m, 1H), 2.99 (dd, *J* = 13.7, 7.0 Hz, 1H), 2.89 (dd, *J* = 13.8, 6.4 Hz, 2H), 2.77 (dd, *J* = 14.1, 8.9 Hz, 1H), 2.19 (s, 3H), 2.08 (s, 3H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 177.20, 159.16, 151.82, 149.23, 146.14, 138.44, 136.95, 136.40, 135.47, 131.23, 130.88, 130.74, 127.34, 127.32, 127.28, 126.68, 126.26, 123.92, 123.83, 107.43, 55.83, 40.64, 39.10, 19.45, 19.14. HRMS (ESI-TOF) *m/z* calc'd for C<sub>28</sub>H<sub>27</sub>N<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup>: 519.1584; found: 519.1590.

SFC Chiralpak® OD-3 column (30% isopropanol, 3.0 mL/min)  $t_r$  = 3.74 min (minor), 4.41 min (major): 96:4 er.

The absolute stereochemistry was determined by X-ray crystallography.




**(R)-N-(1-(2-methyl-5-(5-methylthiophen-2-yl)phenyl)-3-(*o*-tolyl)propan-2-yl)-4-nitrobenzenesulfonamide (4o)**

Substrate **3a** was arylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15 μmol, 15 mol%), 4-acetylpyridine as ligand (3.3 μL, 30 μmol, 30 mol%), 2-iodo-5-methylthiophene (67.2 mg, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%), and TBME (0.3 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4o** (22.5 mg) was obtained in 43% yield as a yellow solid.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 7.88 (d, *J* = 8.8 Hz, 2H), 7.46 (d, *J* = 8.8 Hz, 2H), 7.17 (dd, *J* = 7.8, 2.0 Hz, 1H), 7.12 (td, *J* = 7.1, 2.1 Hz, 1H), 7.10 – 7.04 (m, 3H), 7.00 (d, *J* = 2.0 Hz, 1H), 6.96 (d, *J* = 3.5 Hz, 1H), 6.89 (d, *J* = 7.9 Hz, 1H), 6.72 – 6.66 (m, 1H), 4.66 (d, *J* = 7.9 Hz, 1H), 3.65 – 3.55 (m, 1H), 3.03 (dd, *J* = 13.8, 6.7 Hz, 1H), 2.91 (dd, *J* = 13.8, 7.4 Hz, 1H), 2.86 (dd, *J* = 14.1, 5.3 Hz, 1H), 2.68 (dd, *J* = 14.1, 8.9 Hz, 1H), 2.50 (s, 3H), 2.21 (s, 3H), 2.00 (d, *J* = 2.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 149.40, 145.42, 141.19, 139.57, 136.47, 136.09, 135.44, 134.90, 132.63, 131.22, 130.93, 130.73, 127.41, 127.33, 127.26, 126.44, 126.26, 123.98, 123.84, 122.63, 55.79, 40.60, 39.04, 19.51, 18.85, 15.60. HRMS (ESI-TOF) *m/z* calc'd for C<sub>28</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [M+H]<sup>+</sup>: 521.1563; found: 521.1572.

SFC Chiralpak® IC column (30% isopropanol, 2.0 mL/min)  $t_r$  = 5.08 min (major), 5.82 min (minor): 88:12 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




#### Ethyl (*R*)-2-(4-methyl-3-(2-((4-nitrophenyl)sulfonamido)-3-(*o*-tolyl)propyl)phenyl)acetate (**4p**)

Substrate **3a** was alkylated following the general procedure by using Pd(OAc)<sub>2</sub> (3.3 mg, 15 μmol, 15 mol%), 4-acetylpyridine as ligand (3.3 μL, 30 μmol, 30 mol%), ethyl 2-iodoacetate (35 μL, 0.3 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50 μmol, 50 mol%), and DCM (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4p** (24.5 mg) was obtained in 48% yield as a colorless oil.


<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 7.96 (d, *J* = 8.9 Hz, 2H), 7.50 (d, *J* = 8.9 Hz, 2H), 7.08 (td, *J* = 7.4, 1.7 Hz, 1H), 7.04–6.95 (m, 4H), 6.93 (d, *J* = 1.9 Hz, 1H), 6.85 (d, *J* = 7.7 Hz, 1H), 4.89 (d, *J* = 7.5 Hz, 1H), 4.16 (q, *J* = 7.1 Hz, 2H), 3.55–3.41 (m, 3H), 2.91 (dd, *J* = 13.9, 7.3 Hz, 1H), 2.87–2.80 (m, 2H), 2.77 (dd, *J* = 13.9, 8.2 Hz, 1H), 2.10 (s, 3H), 1.96 (s, 3H), 1.26 (t, *J* = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 171.80, 149.44, 145.26, 136.30, 135.74, 135.54, 134.94, 131.98, 131.63, 130.96, 130.81, 130.61, 128.08, 127.70, 127.18, 126.17, 123.95, 61.12, 55.19, 40.79, 39.86, 39.52, 19.29, 18.76, 14.35. HRMS (ESI-TOF) *m/z* calc'd for C<sub>27</sub>H<sub>31</sub>N<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup>: 511.1897; found: 511.1899.

SFC Chiralpak<sup>®</sup> OJ-3 column (20% isopropanol, 2.0 mL/min) *t*<sub>r</sub> = 3.87 min (minor), 4.18 min (major): 92:8 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.

#### D. Pd/(+)-NBE-CO<sub>2</sub>Me Catalyzed Kinetic Resolution of Homobenzylamines



**General procedure:** Arene **3** (0.10 mmol, 1.0 equiv), Pd(OAc)<sub>2</sub> (2.2 mg, 10 μmol, 10 mol%), 3-methyl-5-phenylpyridine (3.4 mg, 20 μmol, 20 mol%), coupling partner, and AgOAc (33 mg, 0.20 mmol, 2.0 equiv.) were added into a 2-dram reaction vial. TBME (1 mL) and (+)-NBE-CO<sub>2</sub>Me (3.0 mg, 20 μmol, 20 mol%) were added to the mixture. The vial was flushed with N<sub>2</sub> and then capped. The reaction mixture was then stirred at 80 °C for 24 hours. After cooling to room temperature, the mixture was filtered through Celite and eluted with EtOAc (3 × 2 mL). The filtrate was evaporated under reduced pressure. Purification by preparative TLC chromatography afforded product **4**.



#### Methyl (*S*)-3'-(3-methoxy-2-((4-nitrophenyl)sulfonamido)-3-oxopropyl)-4'-methyl-[1,1'-biphenyl]-2-carboxylate (**4q**)


Substrate **3i** was arylated following the general procedure by using methyl 2-bromobenzoate (7.1 μL, 0.05 mmol, 0.5 equiv.) and TBME (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4q** (24.4 mg) was obtained in 47% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*) δ 8.17 (d, *J* = 8.8 Hz, 2H), 7.92–7.79 (m, 3H), 7.52 (td, *J* = 7.5, 1.4 Hz, 1H), 7.41 (td, *J* = 7.6, 1.3 Hz, 1H), 7.28–7.23 (m, 1H), 7.09 (dd, *J* = 7.7, 1.9 Hz, 1H), 7.06 (d, *J* = 7.8 Hz, 1H), 6.98 (d, *J* = 1.8 Hz, 1H), 5.60 (br s, 1H), 4.23 (dd, *J* = 8.4, 5.5 Hz, 1H), 3.76 (s, 3H), 3.62 (s, 3H), 3.17 (dd, *J* = 14.3, 5.5 Hz, 1H), 2.97 (dd, *J* = 14.2, 8.4 Hz, 1H), 2.20 (s, 3H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*) δ 171.68, 168.76, 149.98, 145.69, 142.25, 139.28, 135.58, 132.81, 131.68, 130.90, 130.67, 130.65, 130.25, 130.21, 128.42, 127.73, 127.44, 124.19, 56.12, 52.89, 52.41, 36.58, 19.08. HRMS (ESI-TOF) *m/z* calc'd for C<sub>25</sub>H<sub>25</sub>N<sub>2</sub>O<sub>8</sub>S [M+H]<sup>+</sup>: 513.1326; found: 513.1331.



SFC Chiralpak<sup>®</sup> AD-3 column (30% isopropanol, 2.0 mL/min)  $t_r$  = 4.31 min (minor), 6.64 min (major): 88:12 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (S)-2-(4-(3-methoxy-2-((4-nitrophenyl)sulfonamido)-3-oxopropyl)naphthalen-2-yl)benzoate (4r)**

Substrate **3j** was arylated following the general procedure by using methyl 2-bromobenzoate (7.1  $\mu$ L, 0.05 mmol, 0.5 equiv.) and TBME (1 mL). After purification by preparative TLC chromatography (toluene/EtOAc = 5:1 v/v), compound **4r** (25.8 mg) was obtained in 47% yield as a white solid.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  8.06 (dd,  $J$  = 7.9, 1.4 Hz, 1H), 7.75–7.69 (m, 3H), 7.69–7.65 (m, 2H), 7.62 (td,  $J$  = 7.5, 1.4 Hz, 1H), 7.53 (d,  $J$  = 8.8 Hz, 2H), 7.50 (td,  $J$  = 7.7, 1.3 Hz, 1H), 7.43 (dd,  $J$  = 7.6, 1.2 Hz, 1H), 7.39–7.33 (m, 2H), 7.23 (d,  $J$  = 1.7 Hz, 1H), 5.53 (d,  $J$  = 6.5 Hz, 1H), 4.21 (ddd,  $J$  = 10.8, 6.4, 4.4 Hz, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 3.71 (dd,  $J$  = 14.3, 4.4 Hz, 1H), 3.12 (dd,  $J$  = 14.4, 10.7 Hz, 1H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*)  $\delta$  171.84, 168.24, 149.35, 144.20, 142.75, 138.73, 134.04, 132.36, 131.47, 130.94, 130.56, 130.06, 129.41, 129.34, 129.20, 127.96, 127.93, 127.26, 126.71, 126.32, 123.56, 122.68, 56.01, 53.07, 52.83, 35.93. HRMS (ESI-TOF)  $m/z$  calc'd for C<sub>28</sub>H<sub>25</sub>N<sub>2</sub>O<sub>8</sub>S [M+H]<sup>+</sup>: 549.1326; found: 549.1328.

SFC Chiralpak<sup>®</sup> IC column (40% isopropanol, 2.0 mL/min)  $t_r$  = 5.86 min (major), 8.90 min (minor): 93:7 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (S)-2-(4-(3-((tert-butyldimethylsilyloxy)-2-((4-nitrophenyl)sulfonamido)propyl)naphthalen-2-yl)benzoate (4s)**

Substrate **3m** was arylated following the general procedure by using methyl 2-bromobenzoate (7.1  $\mu$ L, 0.05 mmol, 0.5 equiv.) and TBME (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **4s** (29.8 mg) was obtained in 47% yield as a colorless oil.

<sup>1</sup>H NMR (600 MHz, Chloroform-*d*)  $\delta$  8.02 (dd,  $J$  = 7.8, 1.4 Hz, 1H), 7.67–7.59 (m, 6H), 7.52–7.46 (m, 3H), 7.44 (d,  $J$  = 7.7 Hz, 1H), 7.34–7.27 (m, 2H), 7.17 (d,  $J$  = 1.7 Hz, 1H), 4.91 (d,  $J$  = 5.1 Hz, 1H), 4.08 (dd,  $J$  = 9.8, 3.2 Hz, 1H), 3.87 (s, 3H), 3.80–3.65 (m, 2H), 3.58–3.43 (m, 1H), 2.75 (dd,  $J$  = 14.5, 10.9 Hz, 1H), 0.98 (s, 9H), 0.16 (d,  $J$  = 8.3 Hz, 6H); <sup>13</sup>C NMR (150 MHz, Chloroform-*d*)  $\delta$  168.36, 149.05, 144.19, 142.69, 138.57, 134.08, 132.25, 131.74, 131.50, 130.78, 130.32, 130.17, 129.60, 129.00, 127.85, 127.79, 126.76, 126.32, 126.16, 123.41, 123.22, 66.62, 55.40, 52.72, 35.83, 26.08, 18.45, -5.12, -5.16. HRMS (ESI-TOF)  $m/z$  calc'd for C<sub>33</sub>H<sub>39</sub>N<sub>2</sub>O<sub>7</sub>SSi [M+H]<sup>+</sup>: 635.2242; found: 635.2242.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r$  = 3.05 min (major), 3.96 min (minor): 92:8 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.



**Methyl (R)-4'-methyl-3'-(2-((4-nitrophenyl)sulfonamido)propyl)-[1,1'-biphenyl]-2-carboxylate (4t)**


Substrate **3k** was arylated following the general procedure by using methyl 2-bromobenzoate (21.1  $\mu$ L, 0.15 mmol, 1.5 equiv.) and TBME (1 mL) at 80 °C for 48 hours. After purification by preparative TLC chromatography (hexane/EtOAc = 4:1 v/v), compound **4t** (17.8 mg) was obtained in 38% yield as a colorless

oil.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.15 (d,  $J$  = 8.4 Hz, 2H), 7.89 (d,  $J$  = 7.8 Hz, 1H), 7.82 (d,  $J$  = 8.4 Hz, 2H), 7.54 (t,  $J$  = 7.7 Hz, 1H), 7.42 (t,  $J$  = 7.7 Hz, 1H), 7.28 (d,  $J$  = 7.7 Hz, 1H), 7.10 (d,  $J$  = 7.7 Hz, 1H), 6.98 (d,  $J$  = 7.8 Hz, 1H), 6.95 (s, 1H), 4.82 (d,  $J$  = 6.4 Hz, 1H), 3.78 (s, 3H), 3.52 (p,  $J$  = 6.6 Hz, 1H), 2.82 (dd,  $J$  = 14.1, 5.6 Hz, 1H), 2.65 (dd,  $J$  = 14.2, 8.8 Hz, 1H), 2.06 (s, 3H), 1.31 (d,  $J$  = 6.4 Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  168.69, 149.78, 146.24, 142.41, 139.20, 135.38, 134.53, 131.78, 131.01, 130.98, 130.73, 130.35, 130.07, 128.40, 127.47, 127.27, 124.20, 52.48, 50.24, 41.20, 22.85, 19.06. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$ : 469.1428; found: 469.1426.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r$  = 5.09 min (minor), 6.50 min (major): 93:7 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




#### Methyl (*S*)-3'-((2-(3,5-dimethylphenyl)-2-((4-nitrophenyl)sulfonamido)ethyl)-4'-methyl-[1,1'-biphenyl]-2-carboxylate (**4u**)

Substrate **3n** was arylated following the general procedure by using methyl 2-bromobenzoate (14.1  $\mu\text{L}$ , 0.10 mmol, 1.0 equiv.) and TBME (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4u** (27.4 mg) was obtained in 49% yield as a colorless oil.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.00 (d,  $J$  = 8.8 Hz, 2H), 7.91 (dd,  $J$  = 7.8, 1.4 Hz, 1H), 7.65 (d,  $J$  = 8.8 Hz, 1H), 7.53 (td,  $J$  = 7.6, 1.5 Hz, 1H), 7.42 (td,  $J$  = 7.6, 1.3 Hz, 1H), 7.24 (dd,  $J$  = 7.7, 1.3 Hz, 1H), 7.09 (dd,  $J$  = 7.7, 2.0 Hz, 1H), 7.07–6.98 (m, 2H), 6.79 (s, 1H), 6.64 (d,  $J$  = 1.4 Hz, 2H), 5.48 (d,  $J$  = 6.2 Hz, 1H), 4.57–4.46 (m, 1H), 3.81 (s, 2H), 3.08 (dd,  $J$  = 14.2, 5.2 Hz, 1H), 2.91 (dd,  $J$  = 14.3, 8.9 Hz, 1H), 2.16 (s, 6H), 2.02 (s, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  168.81, 149.53, 146.17, 142.57, 140.24, 139.13, 138.12, 135.83, 133.89, 131.75, 131.08, 131.00, 130.54, 130.36, 129.98, 129.33, 128.41, 127.40, 127.39, 124.58, 123.58, 58.21, 52.50, 41.80, 21.26, 19.03. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{31}\text{H}_{30}\text{NaN}_2\text{O}_6\text{S}$   $[\text{M}+\text{Na}]^+$ : 581.1717; found: 581.1714.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r$  = 5.18 min (minor), 5.90 min (major): 90:10 er.

The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




#### Methyl (*S*)-3'-((2-(3,5-dimethylphenyl)-2-((4-nitrophenyl)sulfonamido)ethyl)-4'-methyl-[1,1'-biphenyl]-2-carboxylate (**4v**)

Substrate **3j** was arylated following the general procedure by using 1-iodo-3,5-bis(trifluoromethyl)benzene (53.1  $\mu\text{L}$ , 0.30 mmol, 3.0 equiv.), AgOAc (50 mg, 0.30 mmol, 3.0 equiv.), and TBME (0.5 mL). After purification by preparative TLC chromatography (toluene/EtOAc = 5:1 v/v), compound **4v** (26.4 mg) was obtained in 42% yield as a white solid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.07 (d,  $J$  = 1.5 Hz, 2H), 7.95–7.90 (m, 2H), 7.89 (d,  $J$  = 1.8 Hz, 1H), 7.85 (dd,  $J$  = 7.9, 1.5 Hz, 1H), 7.82 (d,  $J$  = 8.8 Hz, 2H), 7.62–7.53 (m, 2H), 7.50–7.44 (m, 3H), 4.47 (dd,  $J$  = 9.8, 4.6 Hz, 1H), 3.81–3.69 (m, 4H), 3.30 (dd,  $J$  = 14.4, 9.8 Hz, 1H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.72, 149.63, 144.96, 142.33, 134.89, 134.13, 133.04, 132.63 (q,  $J$  = 33.2 Hz), 131.34, 129.63, 127.83, 127.60, 127.25, 127.22, 127.05, 126.66, 123.45 (q,  $J$  = 272.7 Hz), 123.68, 123.05, 121.50 (hept,  $J$  = 3.6 Hz),

56.66, 53.26, 36.69;  $^{19}\text{F}$  NMR (376 MHz, Chloroform-*d*)  $\delta$  -63.00. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{28}\text{H}_{21}\text{F}_6\text{N}_2\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$ : 627.1019; found: 581.1048.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min)  $t_r$  = 3.17 min (major), 4.20 min (minor): 92:8 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**(S)-N-(1-((*tert*-butyldimethylsilyloxy)-3-(3-(5-formylfuran-2-yl)naphthalen-1-yl)propan-2-yl)-4-nitrobenzenesulfonamide (**4w**)**

Substrate **3m** was arylated following the general procedure by using 5-iodofuran-2-carbaldehyde (22.2 mg, 0.10 mmol, 1.0 equiv.) and TBME (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4w** (23.4 mg) was obtained in 39% yield as an orange solid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  9.71 (s, 1H), 7.98 (s, 1H), 7.83 (d,  $J$  = 9.1 Hz, 1H), 7.77–7.70 (m, 1H), 7.64 (d,  $J$  = 8.5 Hz, 2H), 7.55–7.44 (m, 3H), 7.38 (d,  $J$  = 3.9 Hz, 1H), 7.33 (d,  $J$  = 8.5 Hz, 2H), 6.92 (d,  $J$  = 3.9 Hz, 1H), 5.16 (d,  $J$  = 7.8 Hz, 1H), 3.92 (d,  $J$  = 6.9 Hz, 1H), 3.70 (d,  $J$  = 6.2 Hz, 2H), 3.52 (dd,  $J$  = 14.4, 4.0 Hz, 1H), 2.95 (dd,  $J$  = 14.4, 9.6 Hz, 1H), 1.00 (s, 9H), 0.16 (d,  $J$  = 12.2 Hz, 6H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  177.38, 158.76, 152.39, 149.14, 145.38, 135.00, 133.74, 131.88, 129.50, 127.67, 127.19, 127.13, 125.84, 124.44, 124.11, 123.52, 123.43, 108.36, 66.27, 56.29, 35.74, 26.09, 18.51, -5.19, -5.24. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{30}\text{H}_{35}\text{N}_2\text{O}_7\text{SSi}$   $[\text{M}+\text{H}]^+$ : 595.1929; found: 595.1927.

SFC Chiralpak<sup>®</sup> IC column (20% isopropanol, 2.0 mL/min)  $t_r$  = 9.35 min (major), 10.69 min (minor): 90:10 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (S)-3-(3-(2-ethoxy-2-oxoethyl)naphthalen-1-yl)-2-((4-nitrophenyl)sulfonamido)propanoate (**4x**)**

Substrate **3j** was alkylated following the general procedure by using 4-acetylpyridine as ligand (2.2  $\mu\text{L}$ , 20  $\mu\text{mol}$ , 20 mol%), ethyl 2-iodoacetate (35.5  $\mu\text{L}$ , 0.30 mmol, 3.0 equiv.), AgOAc (50 mg, 0.30 mmol, 3.0 equiv.), (+)-NBE-CO<sub>2</sub>Me (7.5 mg, 50  $\mu\text{mol}$ , 50 mol%), and DCM (1 mL) at 80 °C for 48 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 5:1 v/v), compound **4x** (20.1 mg) was obtained in 40% yield as a white solid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.74 (d,  $J$  = 8.3 Hz, 1H), 7.70 (d,  $J$  = 8.8 Hz, 2H), 7.59 (dd,  $J$  = 8.0, 1.4 Hz, 1H), 7.50 (s, 1H), 7.42 (ddd,  $J$  = 8.4, 6.8, 1.5 Hz, 1H), 7.38 (td,  $J$  = 7.5, 7.0, 1.6 Hz, 3H), 7.15 (d,  $J$  = 1.7 Hz, 1H), 5.53 (d,  $J$  = 9.3 Hz, 1H), 4.29 (ddd,  $J$  = 10.7, 9.2, 4.2 Hz, 1H), 4.24 (q,  $J$  = 7.1 Hz, 2H), 3.80 (s, 3H), 3.71 (s, 2H), 3.63 (dd,  $J$  = 14.3, 4.2 Hz, 1H), 3.07 (dd,  $J$  = 14.3, 10.7 Hz, 1H), 1.33 (t,  $J$  = 7.1 Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.92, 171.62, 149.25, 144.26, 133.97, 131.53, 131.38, 130.19, 130.18, 128.69, 128.47, 127.57, 126.60, 126.47, 123.43, 122.73, 61.39, 56.23, 53.23, 41.17, 36.43, 14.43. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_8\text{S}$   $[\text{M}+\text{H}]^+$ : 501.1326; found: 501.1323.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r$  = 6.10 min (major), 17.17 min (minor): 90:10 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




**Methyl (S)-3-(3-methylnaphthalen-1-yl)-2-((4-nitrophenyl)sulfonamido)propanoate (**4y**)**

Substrate **3j** was alkylated following the general procedure by using 4-acetylpyridine as ligand (2.2  $\mu\text{L}$ , 20  $\mu\text{mol}$ , 20 mol%), iodomethane (18.7  $\mu\text{L}$ , 0.30 mmol, 3.0 equiv.), AgOAc (50 mg, 0.30 mmol, 3.0 equiv.), and DCM (1 mL). After purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v), compound **4y** (15.4 mg) was obtained in 36% yield as yellow solid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  7.80–7.69 (m, 3H), 7.60 (d,  $J$  = 7.1 Hz, 1H), 7.44–7.31 (m, 5H), 6.98 (s, 1H), 5.34 (d,  $J$  = 9.3 Hz, 1H), 4.40–4.25 (m, 1H), 3.78 (s, 3H), 3.62 (d,  $J$  = 14.7 Hz, 1H), 3.12–2.98 (m, 1H), 2.40 (s, 3H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.90, 149.42, 144.55, 135.00, 134.27, 130.98, 130.69, 129.58, 128.39, 127.40, 127.30, 126.25, 125.88, 123.49, 122.64, 56.54, 53.17, 36.51, 21.54. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$ : 429.1115; found: 429.1119.

SFC Chiralpak<sup>®</sup> IC column (40% isopropanol, 2.0 mL/min)  $t_r$  = 3.70 min (major), 6.83 min (minor): 92:8 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




### Methyl (S)-4'-bromo-3'-(3-methoxy-2-((4-nitrophenyl)sulfonamido)-3-oxopropyl)-[1,1'-biphenyl]-2-carboxylate (**4z**)

Substrate **3l** was arylated following the general procedure by using methyl 2-bromobenzoate (21.2  $\mu\text{L}$ , 0.15 mmol, 1.5 equiv.) and TBME (1 mL) at 80  $^\circ\text{C}$  for 48 hours. After purification by preparative TLC chromatography (toluene/EtOAc = 5:1 v/v), compound **4z** (23.7 mg) was obtained in 41% yield as a white solid.

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.22 (d,  $J$  = 8.4 Hz, 2H), 7.96 (d,  $J$  = 7.8 Hz, 1H), 7.91 (d,  $J$  = 8.4 Hz, 2H), 7.58 (t,  $J$  = 7.6 Hz, 1H), 7.48 (t,  $J$  = 7.6 Hz, 1H), 7.42 (d,  $J$  = 8.1 Hz, 1H), 7.28 (d,  $J$  = 9.8 Hz, 1H), 7.15 (s, 1H), 7.06 (d,  $J$  = 8.2 Hz, 1H), 5.55 (d,  $J$  = 9.1 Hz, 1H), 4.42 (q,  $J$  = 8.6, 8.2 Hz, 1H), 3.81 (s, 3H), 3.69 (s, 3H), 3.29 (dd,  $J$  = 14.1, 5.3 Hz, 1H), 3.08 (dd,  $J$  = 14.1, 9.3 Hz, 1H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.42, 168.22, 150.05, 145.56, 141.32, 141.17, 134.08, 132.79, 132.32, 132.00, 130.86, 130.63, 129.84, 129.31, 128.57, 128.04, 124.24, 123.57, 55.53, 53.08, 52.51, 39.13. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{24}\text{H}_{22}\text{BrN}_2\text{O}_8\text{S}$   $[\text{M}+\text{H}]^+$ : 577.0275; found: 577.0277.

SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r$  = 6.16 min (major), 8.91 min (minor): 92:8 er. The absolute stereochemistry was assigned by analogy to compounds **4m** and **4n**.




### Methyl (S)-5-(2-(methoxycarbonyl)phenyl)-1-((4-nitrophenyl)sulfonyl)indoline-2-carboxylate (**5**)

Compound **4z** (17.3 mg, 30  $\mu\text{mol}$ , 1.0 equiv), CuI (2.9 mg, 15  $\mu\text{mol}$ , 50 mol%) and CsOAc (11.5 mg, 60  $\mu\text{mol}$ , 2.0 equiv.) were added into a flame-dried Schlenk tube. The Schlenk tube was evacuated and back-filled with nitrogen. DMSO (0.5 mL) was added to the reaction mixture. The Schlenk tube was immersed into a pre-heated oil bath at 80  $^\circ\text{C}$ . After 2.5 hours, the oil bath was removed, and the Schlenk tube was cooled to room temperature. Water was added into the reaction mixture, which was then extracted with EtOAc. The combined organic layers were dried with  $\text{Na}_2\text{SO}_4$ . The solvent was removed by evaporation under reduced pressure. Purification by preparative TLC chromatography (hexane/EtOAc = 2:1 v/v) afforded the 11.2 mg compound **5** as a yellow solid (75% yield).

$^1\text{H}$  NMR (600 MHz, Chloroform-*d*)  $\delta$  8.33 (d,  $J$  = 8.9 Hz, 2H), 8.05 (d,  $J$  = 8.9 Hz, 2H), 7.83 (dd,  $J$  = 7.8, 1.6 Hz, 1H), 7.55 (d,  $J$  = 8.3 Hz, 1H), 7.51 (td,  $J$  = 7.6, 1.5 Hz, 1H), 7.40 (td,  $J$  = 7.6, 1.5 Hz, 1H), 7.28 (dd,  $J$  =

7.6, 1.5 Hz, 1H), 7.17 (dd,  $J = 8.3, 2.1$  Hz, 1H), 7.05 (d,  $J = 1.7$  Hz, 1H), 4.90 (dd,  $J = 10.5, 4.9$  Hz, 1H), 3.82 (s, 3H), 3.68 (s, 3H), 3.27 (dd,  $J = 16.4, 10.5$  Hz, 1H), 3.18 (dd,  $J = 16.6, 4.8$  Hz, 1H);  $^{13}\text{C}$  NMR (150 MHz, Chloroform-*d*)  $\delta$  171.11, 168.61, 150.68, 143.49, 141.73, 139.91, 138.74, 131.58, 130.81, 130.60, 130.17, 129.63, 128.85, 128.79, 127.58, 125.40, 124.54, 114.94, 62.70, 53.23, 52.15, 33.03. HRMS (ESI-TOF)  $m/z$  calc'd for  $\text{C}_{24}\text{H}_{21}\text{N}_2\text{O}_8\text{S}$   $[\text{M}+\text{H}]^+$ : 497.1013; found: 497.1014.


SFC Chiralpak<sup>®</sup> IC column (30% isopropanol, 2.0 mL/min)  $t_r = 7.72$  min (major), 9.73 min (minor): 91:9 er.

**X-RAY CRYSTALLOGRAPHIC DATA**X-ray structure of **2ah**:Crystal data and structure refinement for **2ah**

Report date	2017-09-22
Identification code	IV-38-5
Empirical formula	C <sub>34</sub> H <sub>38</sub> N <sub>2</sub> O <sub>6</sub> S <sub>2</sub>
Molecular formula	C <sub>34</sub> H <sub>38</sub> N <sub>2</sub> O <sub>6</sub> S <sub>2</sub>
Formula weight	634.78
Temperature	100.0 K
Wavelength	1.54178 Å
Crystal system	Monoclinic
Space group	P 1 21 1

S58


Unit cell dimensions	a = 10.2520(4) Å b = 7.9470(3) Å c = 20.6363(9) Å	$\alpha = 90^\circ$ . $\beta = 104.098(2)^\circ$ . $\gamma = 90^\circ$ .
Volume	1630.65(11) Å <sup>3</sup>	
Z	2	
Density (calculated)	1.293 Mg/m <sup>3</sup>	
Absorption coefficient	1.863 mm <sup>-1</sup>	
F(000)	672	
Crystal size	0.075 x 0.011 x 0.004 mm <sup>3</sup>	
Crystal color, habit	Colorless Needle	
Theta range for data collection	2.207 to 54.261°.	
Index ranges	-10<=h<=10, -8<=k<=8, -20<=l<=21	
Reflections collected	14459	
Independent reflections	3998 [R(int) = 0.0954, R(sigma) = 0.0872]	
Completeness to theta = 54.261°	100.0 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.3017 and 0.2076	
Refinement method	Full-matrix least-squares on F <sup>2</sup>	
Data / restraints / parameters	3998 / 90 / 425	
Goodness-of-fit on F <sup>2</sup>	1.014	
Final R indices [I>2sigma(I)]	R1 = 0.0459, wR2 = 0.0838	
R indices (all data)	R1 = 0.0719, wR2 = 0.0929	
Absolute structure parameter	0.03(2)	
Extinction coefficient	n/a	
Largest diff. peak and hole	0.187 and -0.192 e.Å <sup>-3</sup>	

X-ray structure of **4m**:Crystal data and structure refinement for **4m**

Identification code	yu95_0m_a	
Empirical formula	C <sub>28</sub> H <sub>26</sub> Cl N <sub>3</sub> O <sub>4</sub> S	
Formula weight	536.03	
Temperature	100.0 K	
Wavelength	0.71073 Å	
Crystal system	Orthorhombic	
Space group	P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	
Unit cell dimensions	a = 7.5065(6) Å	α = 90°.
	b = 17.3919(13) Å	β = 90°.





	$c = 20.3819(11) \text{ \AA}$	$\gamma = 90^\circ$ .
Volume	$2660.9(3) \text{ \AA}^3$	
Z	4	
Density (calculated)	$1.338 \text{ Mg/m}^3$	
Absorption coefficient	$0.261 \text{ mm}^{-1}$	
F(000)	1120	
Crystal size	$0.28 \times 0.2 \times 0.14 \text{ mm}^3$	
Theta range for data collection	$2.892$ to $24.998^\circ$ .	
Index ranges	$-7 \leq h \leq 8$ , $-20 \leq k \leq 14$ , $-24 \leq l \leq 24$	
Reflections collected	7623	
Independent reflections	4527 [R(int) = 0.0247]	
Completeness to theta = $24.998^\circ$	99.1 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.8012 and 0.7059	
Refinement method	Full-matrix least-squares on $F^2$	
Data / restraints / parameters	4527 / 348 / 377	
Goodness-of-fit on $F^2$	1.037	
Final R indices [I > 2sigma(I)]	R1 = 0.0490, wR2 = 0.1009	
R indices (all data)	R1 = 0.0772, wR2 = 0.1147	
Absolute structure parameter	0.03(5) [abs stereochem determined]	
Extinction coefficient	n/a	
Largest diff. peak and hole	$0.214$ and $-0.231 \text{ e.\AA}^{-3}$	



X-ray structure of **4n**:Crystal data and structure refinement for **4n**



Identification code	III-152-3	
Empirical formula	C <sub>28</sub> H <sub>28</sub> N <sub>2</sub> O <sub>7</sub> S	
Formula weight	536.58	
Temperature	100.0 K	
Wavelength	0.71073 Å	
Crystal system	Monoclinic	
Space group	P 21	
Unit cell dimensions	a = 12.891(9) Å	α = 90°.
	b = 7.214(5) Å	β = 97.295(15)°.
	c = 28.37(2) Å	γ = 90°.
Volume	2617(3) Å <sup>3</sup>	
Z	4	



Density (calculated)	1.362 Mg/m <sup>3</sup>
Absorption coefficient	0.174 mm <sup>-1</sup>
F(000)	1128
Crystal size	0.28 x 0.2 x 0.1 mm <sup>3</sup>
Theta range for data collection	1.447 to 25.778°.
Index ranges	-15<=h<=15, -8<=k<=8, -34<=l<=31
Reflections collected	18746
Independent reflections	18746 [R(int) = ?]
Completeness to theta = 25.242°	91.2 %
Absorption correction	None
Max. and min. transmission	0.2589 and 0.2069
Refinement method	Full-matrix least-squares on F <sup>2</sup>
Data / restraints / parameters	18746 / 3 / 702
Goodness-of-fit on F <sup>2</sup>	1.000
Final R indices [I>2sigma(I)]	R1 = 0.0507, wR2 = 0.1279
R indices (all data)	R1 = 0.0618, wR2 = 0.1330
Absolute structure parameter	0.08(6)
Extinction coefficient	n/a
Largest diff. peak and hole	0.359 and -0.287 e.Å <sup>-3</sup>



## NMR SPECTRA















































-121.404  
-122.729




































































































































































































































































































8.070  
8.055  
7.603  
7.588  
7.260  
7.233  
7.220  
7.207  
7.058  
7.044  
6.985  
6.973  
6.868  
4.628  
4.614  
3.712  
3.703  
3.700  
3.690  
3.687  
3.681  
3.677  
3.667  
3.664  
3.654  
2.935  
2.925  
2.912  
2.902  
2.775  
2.762  
2.751  
2.739







149.810  
149.473  
149.463  
149.451  
149.440  
145.506  
139.062  
130.215  
127.838  
127.709  
123.023  
121.962  
121.317  
119.610  
119.568  
117.904  
77.371  
77.160  
76.948  
57.227  
41.423





— -58.046

































































-58.070  
-58.102


































































































## SFC TRACES






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.320	MM	0.1509	229.68727	25.37218	2.8077
2	4.829	MM	0.1797	7950.92139	737.59424	97.1923






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.121	MM	0.2614	529.16058	33.73596	4.2604
2	7.850	MM	0.3155	1.18912e4	628.12677	95.7396






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.415	MM	0.2476	2823.50439	190.06265	95.3276
2	6.910	MM	0.2723	138.39246	8.46927	4.6724





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.708	MM	0.1873	5077.84863	451.93127	90.2161
2	4.774	MM	0.2226	550.69342	41.22754	9.7839
Totals :				5628.54205	493.15881	



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.630	MM	0.1336	2358.35352	294.12524	91.7376
2	4.305	MM	0.1585	212.40570	22.33520	8.2624








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.348	MM	0.5418	2447.21826	75.27472	90.4425
2	12.330	MM	1.3038	258.60831	3.30577	9.5575






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.539	MM	0.4980	94.25928	3.15432	8.8241
2	13.873	MM	0.5678	973.94489	28.58943	91.1759






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.118	MM	0.7676	5609.67383	121.80787	92.8789
2	20.458	MM	0.8680	430.09839	8.25843	7.1211






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.091	MM	0.0985	2393.55249	404.92963	95.7118
2	2.573	MM	0.1089	107.23945	16.41767	4.2882






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.552	MM	0.4877	2488.58325	85.05038	93.6691
2	10.374	MM	0.5628	168.19827	4.98111	6.3309






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.134	MM	0.1341	4310.09961	535.67480	70.2700
2	5.243	MM	0.1816	1823.52490	167.33965	29.7300



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.847	MM	0.1168	106.01046	15.12457	2.5621
2	4.591	MM	0.1537	4031.58008	437.29309	97.4379



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.048	MM	0.3901	3.19785e4	1366.14307	92.2428
2	12.834	MM	0.3848	2689.26538	116.47205	7.7572








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.149	MM	0.2102	213.38335	16.92092	9.9286
2	5.891	MM	0.2604	1935.79797	123.88663	90.0714






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.683	MM	0.1574	1133.48279	120.01421	70.7728
2	4.179	MM	0.1775	468.09714	43.96405	29.2272






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.532	MM	0.2156	2789.01172	215.64548	97.7189
2	5.470	MM	0.4285	65.10661	2.53228	2.2811






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.056	MM	0.2007	73.97545	6.14264	3.5333
2	6.869	MM	0.2503	2019.68396	134.47147	96.4667






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.168	MM	0.1047	131.50948	20.93688	4.7070
2	3.680	MM	0.5499	2662.41602	80.69624	95.2930






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.611	MM	0.2971	2279.16431	127.85472	96.9621
2	9.368	MM	0.3410	71.40829	3.49040	3.0379



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.328	MM	0.0959	346.51639	60.22383	3.1992
2	4.128	MM	0.1368	1.04848e4	1277.26770	96.8008



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.992	MM	0.1538	257.49399	27.90685	4.5368
2	5.209	MM	0.1756	5418.17627	514.14496	95.4632








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.421	MM	0.1356	409.47339	50.32362	3.6671
2	5.759	MM	0.1956	1.07565e4	916.64673	96.3329






### Signal 2: DAD1 B, Sig=210,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.551	MM	0.0887	364.73767	68.51612	9.6449
2	4.113	MM	1.9086	3416.92749	29.83876	90.3551






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.659	MM	0.1497	1.96347e4	2185.73682	95.4041
2	4.705	MM	0.2225	945.85706	70.85395	4.5959






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.670	MM	0.1980	3.26040e4	2744.02490	97.4364
2	5.453	MM	0.1902	857.82245	75.18507	2.5636






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.260	MM	0.1165	1144.15857	163.68040	3.7403
2	3.924	MM	0.1576	2.94456e4	3114.60840	96.2597






Signal 2: DAD1 B, Sig=210,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	1.739	MM	0.0830	417.67682	83.85143	3.9971
2	2.508	MM	1.0507	1.00317e4	159.12238	96.0029



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.758	MM	0.2614	157.07967	10.01671	2.5838
2	9.384	MM	0.3292	5922.38379	299.85886	97.4162



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.684	MM	0.1455	476.44806	54.58828	8.2373
2	5.064	MM	1.5084	5307.59277	58.64465	91.7627








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.373	MM	0.1123	195.37979	28.99484	2.4422
2	3.694	MM	0.1328	7804.72314	979.33472	97.5578






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.841	MM	0.1717	648.81927	62.96412	4.1640
2	5.484	MM	0.2056	1.49329e4	1210.25586	95.8360






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.557	MM	0.1952	3.25701e4	2781.44775	95.1737
2	6.433	MM	0.3541	1651.65894	77.74711	4.8263






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.846	MM	0.3360	147.31938	7.30824	1.4370
2	7.713	MM	0.3329	1.01043e4	505.91608	98.5630






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.867	MM	0.2089	148.91724	11.88122	4.2822
2	5.645	MM	0.6124	3328.65210	90.58678	95.7178






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	20.030	BB	0.4498	244.98763	6.61937	3.6308
2	21.738	MM	0.7111	6502.47852	152.40547	96.3692



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.608	MM	0.2132	2.73691e4	2139.36987	96.6692
2	8.667	MM	0.2222	943.02783	70.74281	3.3308



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.790	MM	0.1805	304.03473	28.07036	4.0266
2	5.349	MM	0.2411	7246.68115	500.97849	95.9734








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.100	MM	0.1552	142.12622	15.26688	4.5980
2	5.023	MM	0.1878	2948.95020	261.68994	95.4020






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.671	MM	0.0920	964.15527	174.58240	10.7582
2	3.179	MM	0.1155	7997.92480	1154.24976	89.2418






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.759	MM	0.2990	2056.45923	114.62666	9.8817
2	8.792	MM	0.3583	1.87543e4	872.31128	90.1183






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.866	MM	0.3384	198.52547	9.77880	15.6810
2	9.292	MM	0.4059	1067.50208	43.83463	84.3190






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.012	MM	0.1902	3426.08545	300.28397	97.1766
2	6.477	MM	0.2112	99.54285	7.85430	2.8234






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.608	MM	0.1523	366.60370	40.11977	3.6138
2	5.441	MM	0.1896	9777.97461	859.60364	96.3862



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.263	MM	0.2169	129.60992	9.95831	11.2106
2	7.288	MM	0.2665	1026.52490	64.20895	88.7894



Signal 2: DAD1 B, Sig=210,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.555	MM	0.0719	40.35028	9.35781	0.1726
2	2.985	MM	0.5451	2.33382e4	713.63544	99.8274








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	23.563	MM	0.7665	1820.70520	39.58834	7.7051
2	25.765	MM	1.6020	2.18090e4	226.88873	92.2949






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.700	MM	0.1525	3.09492e4	3382.94434	94.1698
2	3.322	MM	0.1762	1916.10339	181.27367	5.8302






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.118	MM	0.1984	2695.29712	226.42526	6.2509
2	9.743	MM	0.3780	4.04233e4	1782.31323	93.7491






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.088	MM	0.1385	241.31932	29.04813	3.0469
2	4.570	MM	0.1587	7678.76660	806.38159	96.9531






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.844	MM	0.1658	132.40337	13.30708	13.2096
2	4.411	MM	0.2586	869.92133	56.06168	86.7904






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.274	MM	0.0816	204.21960	41.70602	14.0092
2	3.535	MM	0.1014	1253.53442	206.02576	85.9908



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.337	MM	0.1902	367.13989	32.17627	4.7708
2	5.648	MM	0.3832	7328.36084	318.74097	95.2292



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.455	MM	0.1695	1.17368e4	1153.87244	87.6585
2	5.781	MM	0.2540	1652.43713	108.42530	12.3415








Signal 2: DAD1 B, Sig=210,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.836	MM	0.1526	837.90576	91.53378	9.7702
2	6.023	MM	0.1971	7738.27490	654.50769	90.2298






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.367	MM	0.2039	152.35146	12.45088	2.3778
2	8.260	MM	0.3247	6254.95654	321.03714	97.6222






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.962	MM	0.1099	539.17792	81.76174	8.0316
2	4.400	MM	0.1569	6174.00928	656.01202	91.9684






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	23.643	MM	0.5091	103.70914	3.39537	1.2808
2	24.811	MM	0.5724	7993.39209	232.74353	98.7192






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.505	MM	0.2401	2310.84912	160.43649	96.0311
2	8.575	MM	1.1314	95.50554	1.40690	3.9689






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.009	MM	0.3380	186.65569	9.20326	8.6562
2	7.355	MM	0.3139	1969.67542	104.57546	91.3438



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.166	MM	0.1885	148.88176	13.16310	4.5311
2	4.376	MM	0.2433	3136.87891	214.88333	95.4689



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.678	MM	0.1465	2649.63574	301.41370	92.2399
2	10.335	MM	1.1082	222.91309	3.35239	7.7601








Signal 2: DAD1 B, Sig=210,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.741	MM	0.2292	1825.73450	132.75627	96.0763
2	4.414	MM	0.3333	74.56106	3.72887	3.9237






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.079	MM	0.1616	1493.21191	153.99384	88.1214
2	5.818	MM	0.1849	201.28221	18.13864	11.8786





Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.869	MM	0.1042	355.07101	56.79617	8.4395
2	4.181	MM	0.1187	3852.19800	541.02374	91.5605






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.309	MM	0.1973	865.05347	73.09028	12.2446
2	6.639	MM	0.3105	6199.71631	332.83386	87.7554






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.700	MM	0.1579	1998.88965	211.03954	87.8949
2	4.512	MM	0.1776	275.29227	25.83036	12.1051






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.855	MM	0.2266	6444.08398	473.91415	92.9796
2	8.899	MM	0.3658	486.55807	22.16995	7.0204



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.432	MM	0.1920	109.96355	9.54492	7.4788
2	8.493	MM	0.3289	1360.38098	68.94481	92.5212



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.047	MM	0.1041	6500.20361	1040.88354	92.4072
2	3.964	MM	0.1421	534.09979	62.65053	7.5928








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.184	MM	0.3906	88.21686	3.76424	6.6085
2	9.912	MM	0.5032	1246.67957	41.29092	93.3915






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.088	MM	0.1528	4179.16943	455.88596	92.9598
2	6.499	MM	0.2030	316.50284	25.98948	7.0402




Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.084	MM	0.1267	622.26953	81.83183	23.2962
2	5.606	MM	0.1432	2048.85010	238.52176	76.7038





Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.181	MM	0.1861	3813.48438	341.60596	89.6020
2	5.901	MM	0.2166	442.54083	34.05733	10.3980






3n






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	22.841	MM	0.9240	1680.05347	30.30535	94.2165
2	25.244	MM	0.9805	103.13062	1.75308	5.7835






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.173	MM	0.1155	1.03383e4	1491.61975	91.5744
2	4.200	MM	0.1581	951.21368	100.26136	8.4256



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.439	BB	0.1743	327.99240	28.92523	15.3240
2	8.489	MM	0.3077	1812.38513	98.16897	84.6760



Signal 1: DAD1 A, Sig=250,4 Ref=360,100




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.352	MM	0.3749	1351.17456	60.07418	90.4829
2	10.687	MM	0.4269	142.11836	5.54905	9.5171








Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.810	MM	0.2600	238.98119	15.32124	5.1286
2	9.429	MM	0.4416	4420.81201	166.84232	94.8714






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.099	MM	0.2380	1550.60046	108.56999	90.0303
2	17.174	BB	0.4969	171.70859	4.27254	9.9697






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.434	MM	0.1939	136.63313	11.74363	8.9432
2	8.490	MM	0.3110	1391.15540	74.56083	91.0568






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.699	MM	0.1366	1884.99915	230.05949	92.0766
2	6.825	MM	0.2376	162.20778	11.37620	7.9234






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.444	BB	0.1743	619.92261	54.67658	26.2467
2	8.492	MM	0.3125	1741.98792	92.92081	73.7533






Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.163	MM	0.2145	2380.57056	184.94643	92.3810
2	8.908	BB	0.3025	196.33482	10.20089	7.6190



Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.352	MM	0.1299	343.09421	44.03119	18.0759
2	5.452	MM	0.1697	1554.98279	152.74278	81.9241



Signal 1: DAD1 A, Sig=250,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.717	MM	0.2747	1.12536e4	682.73999	90.6493
2	9.726	MM	0.3379	1160.83484	57.26508	9.3507



**REFERENCES**

34. Bolm, C., Schiffrers, I., Dinter, C. L. & Gerlach, A. Practical and highly enantioselective ring opening of cyclic *meso*-anhydrides mediated by cinchona alkaloids. *J. Org. Chem.* **65**, 6984–6991 (2000).
35. Youk, S. H., Oh, S. H., Rho, Ho S., Lee, J. E., Lee, J. W. & Song, C. E. A polymer-supported *Cinchona*-based bifunctional sulfonamide catalyst: a highly enantioselective, recyclable heterogeneous organocatalyst. *Chem. Commun.* 2220–2222 (2009).
36. Wang, P., Li, G.-C., Jain, P., Farmer, M. E., He, J., Shen, P.-X. & Yu, J.-Q. Ligand-promoted *meta*-C–H amination and alkynylation. *J. Am. Chem. Soc.* **138**, 14092–14099 (2016).
37. Chu, L., Wang, X.-C., Moore, C. E., Rheingold, A. L. & Yu, J.-Q. Pd-catalyzed enantioselective C–H iodination: asymmetric synthesis of chiral diarylmethylamines. *J. Am. Chem. Soc.* **135**, 16344–16347 (2013).
38. Dastbaravardeh, N., Schngrch, M. & Mihovilovic, M. D. Ruthenium(0)-catalyzed  $sp^3$  C–H bond arylation of benzylic amines using arylboronates. *Org. Lett.* **14**, 1930–1933 (2012).
39. Resendiz, M. J. E. & Garcia-Garibay, M. A. Hammett analysis of photodecarbonylation in crystalline 1,3-diarylacetonates. *Org. Lett.* **7**, 371–374 (2005).